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Abstract 
Telomerase, a RNA-dependent DNA polymerase that adds telomeric DNA at 
the ends of eukaryotic chromosomes, is essential for the lifelong 
preservation of the proliferative potential of antigen specific T lymphocytes. 
However, senescent T cells that have low telomerase activity, short 
telomeres and lack of replicative capacity accumulate in old humans, 
patients with chronic viral infections and cancer. The mechanisms inhibiting 
telomerase in these cells are poorly understood. Here I investigated the 
molecular pathways causing telomerase dysfunction and defined an 
unrecognized mode of p38 MAPK activation in T cells. To identify 
mechanisms involved in telomerase down-regulation, I activated T cells in 
the presence of IFN-α, an inflammatory cytokine that inhibits telomerase. 
Telomerase down-regulation was mediated in part by p38 activation. I 
further investigated the upstream regulatory network of p38 MAPK in 
senescent T cells. Unexpectedly,  spontaneous p38 activation in these cells 
was not regulated by either the ‘canonical’ MAPK cascade or the 
‘alternative’ pathway downstream of the T cell receptor, in contrast to the 
current paradigm of how this pathway is activated in T cells. Instead, the 
senescence-related DNA damage response pathway activates the low 
nutrient sensor AMPK, which in turn induces p38 auto-phosphorylation 
through the scaffold molecule TAB1.  These findings establish a third, ‘intra-
sensory’ pathway for p38 activation in T cells in which low nutrient and 
genotoxic signalling converge to inhibit proliferative responses. This can be 
reversed by blocking AMPK/TAB1 mediated activation of p38, which may 
represent a selective way for boosting T cell activity during ageing. 
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Chapter I: Introduction 
 
 
1.1 The immune response: general premises 
An immune system is essential for the lifelong preservation of human health. 
Immunity is characterized by both innate and adaptive components, which have 
evolved to either preserve endogenous (self) or disrupt exogenous (non-self) 
structures. While innate immunity comprises non-specific mechanisms of immune-
protection, adaptive responses are antigen-specific and rely on T and B-
lymphocyte activation. The process is generally triggered by an immunogen, a 
non-self substance capable of eliciting an inflammatory response, which 
culminates in lymphocyte activation by antigen presenting cells (APCs) at the level 
of the secondary lymphoid organs.  
The ability of the immune system to elicit an immune response progressively 
declines during ageing (Akbar and Henson, 2011), a process known as immune-
senescence, and changes in both inflammatory and antigen related signals are 
involved in this decline (Boraschi et al., 2013). Recent studies froum our group 
highlighted that some key aspects of immune senescence may be reversible 
(Henson et al., 2014, 2015; Di Mitri et al., 2011). This is the case for T cells, an 
essential componenent of adaptive immunity, whose function is severely impaired 
during ageing (Boraschi et al., 2013; Weng et al., 2009). Understanding how 
senescent T cells function may reveal unrecognized strategies to restore immune 
protection in old humans, or in patients with chronic viral infections and cancer, 
who often exhibit features of premature immune-senescence (Chou et al., 2013; 
Crespo et al., 2013). The aim of the present study was to delineate strategies to 
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restore human senescent T cell function. Below, I introduce T cells, and dissuss 
properties of their development, function and end-stage differentiation.  
 
1.2 T cells: development and function 
T lymphocytes can either orchestrate an immune response, which defines T helper 
(Th) cells, or target non-self cells to destruction, which identifies cytotoxic T cells. 
Most T cells (above 95% in healthy individuals) possess an antigenic surface 
receptor, the T cell receptor, which is a heterodimer of α and β-chains that 
recognises antigens presented by major histocompatibility complex (MHC) 
molecules (Brownlie and Zamoyska, 2013). In addition, mature T cells possess 
either a CD8 or CD4 co-receptor that is important, together with α/β TCR 
molecules, for recognition of MHC class I and class II bound antigens, respectively 
(Germain, 2002).  
Conversely, about 5% of unconventional T cells express a TCR of γ and δ−chains 
that recognises antigens, especially lipids, independently of MHC molecules. 
These cells are mostly located in peripheral tissues where they have been 
proposed to control local responses, providing a bridge between innate and 
adaptive immunity (Hayday and Tigelaar, 2003). In both rodents and humans, T 
helper cells are generally CD4+ while cytotoxic cells are CD8+; however cytotoxic 
CD4+ T cells (especially when becoming senescent) have also been reported 
(Appay, 2004; Libri et al., 2011; Quezada et al., 2010).  
 
T cells develop in the thymus, a lobulated lymphoid and retro-sternal organ, in a 
multi-step process. First, hematopoietic stem cells (HSC) enter the thymus, giving 
rise to a heterogeneous population of CD4- CD8- (double negative, DN1) CD25- 
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CD44+ thymocytes. Next, T cell precursors expressing either α/β or 
γ/δ TCR molecule diverge during the T cell lineage commitment. Thirdly, CD4+ 
CD8+ double positives (DP) thymocytes stem from late T cell precursors, namely 
DN4 thymocytes, following an intra-thymic beta-selection reaction. Finally, allo-
reactive single positive CD4+ or CD8+ mature T cells, that only express α/β TCR 
molecules, are selected (in a 2:1 ratio) and allowed to exit the thymus (Germain, 
2002). Importantly, because mechanisms of central tolerance exist to avoid auto-
immunity, self-reactive mature T cells undergo intra-thymic apoptosis (Germain, 
2002). 
 
1.3 Human T cell differentiation  
An important feature of human T lymphocytes is that the expression of various cell 
surface markers can be used to distinguish cells at different relative stages of 
differentiation (Akbar and Henson, 2011). Changes in phenotipic marker 
expression and T cell function are thus directly linked. Naïve (NA) T cells which 
express both the co-stimulatory receptors CD27 and CD28 along with the 
membrane-bound intracellular phosphatase CD45RA and high levels of CC-
chemokine receptor 7 (CCR7) possess the longest telomeres and exhibit the 
highest proliferative and telomerase activity upon activation (Akbar and Fletcher, 
2005). In contrast, human memory T lymphocytes represent a heterogenous cell 
compartment. This comprises central memory (CM) T cells that have lost either 
CD27 (in CD4+ T cells) or CD28 (in CD8+ T cells) expression and that have 
switched to a shorter variant of the phosphatase receptor CD45, namely CD45RO, 
exhibit elevated proliferative potential (Akbar and Fletcher, 2005; Weng et al., 
2009). Effector memory (EM) T cells are CD27- CD28- CCR7- CD45RO 
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lymphocytes in both the human CD4+ and CD8+ pools. These cells exhibit features 
of end-stage differentiation including very short telomeres, low proliferative 
potential, decreased telomerase activity (Weng et al., 2009), as well senescence-
associated DNA damage foci (Henson et al., 2014; Di Mitri et al., 2011). Thus, EM 
T cells are approaching replicative senescence (Weng et al., 2009). Finally, 
effector memory CD27- CD28- T lymphocytes that re-express CD45RA (EMRA) 
have the lowest telomerase and proliferative potential and highest expression of 
senescence associated markers yet not the shortest telomeres (Henson et al., 
2014; Di Mitri et al., 2011). These cells accumulate in old humans especially within 
the CD8+ T cell pool (Akbar et al., 2004). Although the reason why these cells re-
express CD45RA is not clear, it has been proposed that EMRAs may exhibit 
features of telomere-independent senescence (Akbar and Henson, 2011; Di Mitri 
et al., 2011). However, despite the loss of proliferative potential in vivo, both EM 
and EMRA cells retain high functionality. These cells (especially EMRAs) can 
release high levels of pro-inflammatory cytokines (e.g. TNF-a, IL-6), metallo-
proteins, granzymes and perforins indicating that they may be senescent yet not 
functionally exhausted cells (Akbar and Henson, 2011). Whether this inflammatory 
signature resembles in toto the senescence-associated secretory phenotype 
(SASP) displayed by senescent fibroblasts (Campisi and d’Adda di Fagagna, 
2007) is currently under investigation in our laboratory. Interestingly, human end-
stage T cell sub-populations also acquire expression of surface inhibitory/cytotoxic 
natural killer receptors such as CD57 and KLRG1 (Akbar and Henson, 2011; 
Henson et al., 2009). Signalling via these receptors (e.g. KLRG1) has been 
recently proved to actively inhibit proliferation in primary human highly 
differentiated CD27- CD28- CD8+ T lymphocytes (Henson et al., 2009), indicating 
	 20	
that the phenotypic switches characterizing human T cell differentiation are strictly 
linked with the regulation of T cell functions. The relative expression of CD27 and 
CD28 receptors identifies 3 discrete populations within the primary human T cell 
compartment at different stages of progressive differentiation. As discussed, 
undifferentiated populations of these cells express both CD27 and CD28, cells at 
an intermediate stage of differentiation express CD28 but not CD27 while 
senescent populations express neither molecule (Weng et al., 2009). Profound 
changes in T cell signalling are therefore likely due to the loss of key co-
stimulatory receptors, during human T cell differentiation. However at present little 
is known about the regulation of signalling pathways in primary human highly 
differentiated T cells. So far defective AKT and mTOR activity (unlike other 
senescent cells such as fibroblasts), reduced telomerase activity and a 
spontaneous but unexplained increase of p38 MAPK phosphorylation inhibiting 
their mitogen capacity have been reported (Henson et al., 2009, 2014; Di Mitri et 
al., 2011; Plunkett et al., 2007). In table 1, the main phenotypic and functional 
features of T cells at the different stage of differentiation are summarized. Below, 
an overview on T cell signalling is provided. 
 
	 21	
 Markers
CD27
CD28
CD45RA
 CCR7
CD57
+++
+++
+++
+++
+
+/-
+/-
+/-
++
++
+/-
-
-
-
+++
Functions
p-p38 ++++++
Cytotox. + ++ +++
IFN- + ++ +++
IL-2 +++ + -
TNF + ++ +++
Senescence
Telomerase +++ ++ -
Telomeres +++ ++ +
+++++
Differentiation
-Proliferation
	
Table 1. Characteristics of functional changes of human T cell 
differentiation. The main known characteristics of human T cell differentiation are shown. The 
role of p38 signalling will be extensively discussed in the text. Adapted from (Akbar & Henson, 
2011). 
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1.4 T cell activation: biochemical and functional considerations 
Optimal T cell activation requires both TCR and co-stimulatory receptor 
engagement. The α and β chains of the TCR possess both variable (extracellular) 
and constant (trans-membrane) domains that are non-covalently bound to an 
invariant CD3 chain complex, coupling antigenic recognition to intracellular 
biochemical events (T cell signalling) (Chakraborty and Weiss, 2014). There are 
two important factors that modulate early TCR signalling: antigen specificity of the 
receptor and binding-avidity of the TCR (Alarcon et al., 2003; Schamel and 
Alarcón, 2013). While the former is regulated through the interaction between 
MHC-peptides on APC and complementary determining regions within the variable 
domains of both TCR α and β chains (Dustin, 2014), the latter is thought to 
distinguish between productive (agonist) and non-productive (or antagonist) MHC-
TCR interactions (Stone et al., 2009). However, the exact determinants which 
regulate binding avidity of the TCR are presently unknown. Individual TCR 
molecules can oligomerize within cholesterol-enriched portions of the T cell 
membrane (Molnár et al., 2012), a process known as TCR nanoclustering, thereby 
enchancing TCR sensitivity (Alarcón et al., 2011; Schamel and Alarcón, 2013). 
Importantly, despite elevated antigen specificity, naïve T cells have generally low 
binding avidity/sensitivity for antigens, which increase upon activation and 
differentiation. Therefore, memory T cells are more prone to trigger an immune 
response than their naïve counterparts (Corse et al., 2011). Down-stream of TCR 
activation, important biochemical events are regulated in concert to co-ordinate T 
cell responses. Excellent comprehensive reviews on T cell signalling are available 
(Acuto et al., 2008; Chakraborty and Weiss, 2014; Navarro and Cantrell, 2014). 
Because the TCR does not possess intrinsic enzymatic activity, signal 
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transduction downstream of the receptor relies on a series of trans-
phosphorylation cascades. Precisely, the cytoplasmic domains of the CD4 and 
CD8 co-receptors are bound by the lymphocyte specific signalling kinase LCK 
which in turn phosphorylates immune-receptor tyrosine-based activation motives 
(ITAMs) within the CD3 cytoplasmic tails of the receptor. Upon activation, the 
phosphorylated ITAMs in turn recruit the signalling kinase ZAP70 through SH2 
domains. Next, ITAM-bound ZAP70 is further phosphorylated by LCK and this 
leads to conformational changes within ZAP70 that are important for downstream 
signal propagation. The most characterized (but not sole) biological target of 
activated ZAP70 is the linker for T cell activation (LAT), which serves to recruit a 
multimeric platform that orchestrates a variety of biochemical and functional 
processes important for T cell transcription, growth, activation and ultimately 
differentiation into effector populations. Crucial components of this complex (also 
known as ‘LAT-signalosome’) includes the distal T cell-signalling adaptors SLP76 
and VAV1, the phospholipase PLCγ1, the growth factor receptor-bound protein 
GRB2, its adaptor protein GADS, and the kinase ITK. Three main biochemical 
cascades are activated in turn by this ‘LAT signalosome’: calcium, mitogen-
activated protein kinase (MAPK) and nuclear factor-κB (NF-κB) signalling 
pathways. In order, rapid calcium influx is regulated by the ITK-dependent 
activation of PLC-γ 1 that is essential to trigger activation of the inositol cascade. 
This generates second lipid-derived messengers (diacyl-glycerol and inositol-
triphosphates) to activate protein kinase C (PKC) isoforms and the calcineurin-
nuclear factor of activated T cells (NFAT) signalling pathways, respectively. Thus, 
ITK is essential for T cell activation. The MAPK cascade is also triggered by 
diacyl-glycerol generation through the PKC-dependent activation of the guanine 
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nucleotide-binding protein Ras. Upon activation, Ras interacts with Raf1, a MAPK 
kinase kinase, which in turn activates a signaling cascade where the MAPK 
kinases 1/2 (MEK1/2) downstream activate the extracellular-regulated protein 
kinases 1/2 (ERK1/2), prototype member of the MAPK pathway. Activated ERKs 
orchestrate a variety of downstream biological substrates (i.e. ELK1, stathmin) that 
regulate cell-cycle progression, cytokine production, T cell metabolism, protein 
expression and cytoskeleton remodelling. Other two prototype MAPK pathways, 
involved in diverse aspects of T cell biology, are the JNK and p38 signaling 
cascades. Both pathways share with ERK the same structure of the activation 
module, but they are regulated through separate upstream cascades. JNK, which 
is important for T cell differentiation but seems to be dispensable fo T cell 
activation (Dong et al., 2000), is directly activated by the kinases MEKK4 and 
MEKK7 which are in turn activated by a plethora of upstream MKKKs. While 
expression of JNK proteins can be induced by TCR triggering alone, co-stimulatory 
signals (i.e. CD28 engagement) seem to be important to induce JNK activation in 
T cells (Su, 1994). This is different from the activation of ERK (and p38) that can 
occur even in the absence of costimulation (Ashwell, 2006). As per ERK, JNK 
function is mediated by various biological substrates, mostly transcription factors 
(for instance, c-JUN), that are activated by direct JNK phosphorylation. The role 
and activation of the p38 MAPK pathway is discussed in detail in a dedicated 
session. The NF-κB pathway is another pivotal regulator of T cell function and is 
linked to the ‘LAT signalosome’ through PKC theta activation . PKC theta collects 
upstream activation signals from both the TCR and co-stimulatroy receptors to 
orchestrate in turn formation of a signaling complex with the proteins CARMA1, 
BCL10 and MALT1 (‘CBM complex’). Formation of this CBM complex is essential 
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for NF-κB activation in response to TCR triggering, however how the CMB 
complex is itself regulated is not fully understood. Conversely, the downstream 
activation of NF-κB is more established. In unstimulated T cells, NF-κB is kept in 
the cytosol by its inhibitor, IκBα. Upon TCR activation, IκBα is degraded through 
poly-ubiquitination by its upstream regulatory complex, the IKK. Therefore, the IKK 
complex links NF-κB  activation to the CBM complex and (further upstream) to the 
LAT signalosome. NF-κB  signaling plays a crucial role in the inflammatory 
response, as well T cell development and can promote either Th1 or Th2 
differentiation directing distinct transcriptional programs (Oh and Ghosh, 2013).  
 
A well-defined property of T cell signaling networks, important to ensure functional 
plasticity, is downstream signaling divergence. Thus, a multitude of transcription 
factors have to be activated to dictate immune-related gene expression, in a T cell-
subset specific way. For instance, CD4+ T helper 1 and 2 cells express, 
respectively, either T–bet or GATA-3, transcription factors essential for their 
functions (Ho et al., 2009; Kanhere et al., 2012; Lazarevic et al., 2013); conversely 
the transcription factor Eomes is required for CD8+ T cell function (Pearce et al., 
2003). In addition to TCR signalling, co-stimulatory receptor (e.g. CD28 
engagement) and environmental signals (e.g. cytokines) are also important to 
drive the activation, differentiation and function of T lymphocytes. Indeed, CD28 
co-stimulation is required to avoid T cell anergy (that is, the inability of T cell 
clones to respond to antigens in the absence of appropriate co-stimulation) (Abbas 
et al., 2004; Parijs et al., 1997). Upon activation, the cytoplasmic domain of CD28 
binds to the phosphatidylinositol 3-kinase (PI3K) to generate inositol-
triphosphates, which recruit the signalling kinases phosphoinositide-dependent 
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kinase 1 (PDK1) and AKT at the cell membrane. Activated PDK1 also contributes 
to NF-κB activation and convege at the point of PKC theta. This in turn leads to 
AKT phosphorylation (on Thr308) by PDK1. To become fully activated, AKT has to 
be further phosphorylated (on Ser473) by another kinase, namely mTOR complex 
2 (that consists of mTOR, mLST8, SIN1 and Rictor) (Rudd and Schneider, 2003). 
In turn, activated AKT is thought to control the activation of pleiotropic anabolic 
pathways via activation of the anabolic signaling kinase mTOR (further details on 
mTOR are discussed in the next session). This concept has recently been 
challenged, however, when AKT was shown to be nonessential for T cell 
metabolism but required for cytotoxic T cell fate (Finlay et al., 2012; Macintyre et 
al., 2011). Cytokine signalling is also involved in tuning signal transduction in T 
cells. In general, cytokines signalling acts via the STAT transcription factor family 
that is well recognised to polarize T cell function. For instance, if IFN-γ and/or IL12 
are present in the activation milieu of the immunological synapse, STAT1 and 
STAT4 activation promotes T-bet expression (Moriggl et al., 1998), required for T 
helper 1 induction which in turn boosts the activity of phagocytes to eradicate 
pathogens (mostly bacteria and protozoa); conversely IL-4 and IL-6 trigger STAT6 
activity to induce GATA3 expression and related shift toward T helper 2 functions 
that is essential to induce B cell mediated humoral (antibody-mediated) immune-
responses (Wurster et al., 2000). Thus, cytokine signalling regulates CD4+ T cell 
activity in a non-reduntant manner. Of note, because positive feedback 
mechanisms exist, the same pool of cytokines that induce specific T cell 
polarization are also produced by the specific T cell subsets, upon induction. 
Figure 1 illustrates the main biochemical pathways that regulate T cell activation, 
proliferation and functional activities. 
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Figure 1: T cell signalling.  
An overview of T cell signalling is provided. Activation cascades are discussed in details in the text, 
and are important to drive T cell differentiation, proliferation and effector functions. Briefly, antigen 
presentation triggers TCR signalosome activation by phosphorylation of Src kinases (e.g. LCK) and 
Syk kinases (e.g. ZAP70) that in turn phosphorylate various tyrosine sites within the CD3-ζ chain 
(ITAMs, not shown). LAT and SLP76 are downstream components of the TCR signalosome which 
in turn activate PLC-γ1 to trigger inositol triphosphate leading to the calcium dependent activation 
of NFAT. PLC activation also leads to release of diacylglycerol (DAG) important for the PKC-
dependent activation of the NF-κ-B (via the CMB and IKK complexes) and the MAPK cascade via 
RAS. NF-κ-B activation relies on IkB degradation and is linked to LAT signalosome via the IKK and 
CMB complexes. The MAPK cascade is a three-tier module where an upstream kinase 
phosphorylates another. Activated MAPK substrates, NF-κ-B and NFAT undergo nucleus shuttling 
and activate various transcription factors (T-BET, GATA-3, Eomes) to establish different functional 
programs within the T cells. Protein translation is supported by mTORC1 activation downstream of 
PI3K/AKT, in response to CD28 engagement. Co-stimulatory signaling can converge on NF-κ-B via 
PKC and also on the MAPK JNK (not shown). mTOR activation also triggers mTORC2 dependent 
signalling that reinforces AKT activation (not shown). The upstream regulatory network of mTORC2 
is presently unknown.  
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1.5 T cell metabolism: signal integration by mTOR and AMPK. 
The intertwining of T cell activation and metabolic pathways has received recently 
renewed interest as an attractive way to modulate T cell responses (Wellen and 
Thompson, 2012). There are two important metabolic-checkpoint kinases that 
orchestrate either T cell anabolic or catabolic pathways: the mTOR and AMP-
responsive protein kinase, respectively. The former is a member of the PI3K family 
that integrates both TCR and co-stimulatory signals to orchestrate T cell activation, 
clonal expansion and functional differentiation in response to upstream activation 
by the AKT pathway (Laplante and Sabatini, 2012; Pollizzi and Powell, 2014), or 
(at least in cytotoxic CD8 T cells), by PDK1 independently of AKT (Finlay et al., 
2012). mTOR is a serine-threonine kinase whose activity is regulated through the 
assembling of two distinct super-molecular complexes: mTORC1 and mTORC2 
(Delgoffe et al., 2011). Characteristic of either mTORC1 or mTORC2 are the 
regulatory-associated protein of mTOR (RAPTOR) and the scaffolding protein 
RAPTOR-independent companion of TOR (RICTOR), respectively. This dictates 
that mTORC1 yet not mTORC2 activity can be pharmacological inhibited by 
rapamycin, an immunosuppressive drug that prevents RAPTOR recruitment to the 
mTOR (Sabatini et al., 1994). However, it has been reported that T cell mTORC2 
can be inhibited by modest rapamycin concentration as well, perhaps through 
unrecognized off-target effects (Pollizzi and Powell, 2014). Both mTOR complexes 
are important for inducing T cell activation, proliferation and polarization although 
the mechanisms by which mTORC2 act are much less characterized. The control 
of T cell metabolism by mTOR is essential for the regulation of T cell function. 
Importantly, the so-called Warburg effect dictates that proliferating cells- including 
T cells- rely on aerobic glycolysis (that is, the cytoplasmic oxidation of glucose into 
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pyruvate) rather than the more efficient oxidative phosphorylation (that is, the 
mitochondrial break up of nutrients) to generate their energy, possibly through the 
generation of important glycolytic by-products. Indeed, mTOR activity promotes 
the Warburg effect in T cells by up-regulating the glycolytic-machinery and 
activating various biosynthetic pathways that are important for the incorporation of 
molecules into daughter cells (Finlay and Cantrell, 2011; Finlay et al., 2012; 
Sinclair et al., 2013). This is essential during an immune response when naïve T 
lymphocytes that are metabolically quiescent and rely on basal oxidative 
metabolism, become effector T cells and switch to aerobic glycolysis (Pearce et 
al., 2013). Furthermore, aerobic glycolysis is required for effector functions in T 
cells (Chang et al., 2013b). Figure 2 resumes the metabolic switches that 
characterize T cell function. 
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Figure 2: The metabolic changes that dictate T cell function.  
The different metabolic switches characterizing naïve T cells (TN), effector T cells (TEFF) and 
memory T cells (TM) are shown. Naïve T cells are metabolically quiescent, have minimal 
biosynthetic requirements and maintain a basal oxidative profile; upon activation effector T cells 
undergo clonal expansion that is sustained by elevated glycolytic rates and increased biomass (cell 
growth) resulting in cell proliferation and robust effector functions; memory T cells switch back to 
oxidative metabolism for long-term survival but show significantly larger spare-respiratory capacity 
(SRC) and increased mitochondrial mass than naïve T cells indicating that these cells have been 
metabolically primed. Adapted from (Pearce EP et al, 2013). 
 
 
 
 
 
	 31	
Conversely, the AMP-responsive protein kinase (AMPK) is a heterotrimer of α-β-γ 
subunits that is a low-energy sensor that is activated by the up-regulation of 
intracellular AMP: ATP ratios (Hardie et al., 2012). There are two catalytic 
AMPKα sub-units (α1 ubiquitously expressed and α2 restricted to muscles cells) 
that are activated by phosphorylation on Thr172 by either the upstream kinases 
LKB1 or CAMKK2 in response to either glucose-starvation or cytoplasmic calcium-
influx, respectively (Shaw et al., 2004; Woods et al., 2005). The latter may be 
important in activated T cells in which AMPK activation is thought to cope with the 
increased energetic demand of TCR mediated cell proliferation (Tamás et al., 
2006). In addition, the MAPKKK TAK1 activates AMPK but the biological 
relevance is not well defined (Herrero-Martín et al., 2009). In order to become 
activated, AMPK has to undergo conformational changes that are dependent on its 
γ and β regulatory subunits (Figure 3). There are 3 different AMPK γ-subunits (γ1, 
γ2 and γ3) that are differentially expressed in tissues, with AMPK-γ1 ubiquitously 
distributed, AMPK-γ2 mostly expressed in muscle cells while AMPK-γ3 expression 
is restricted to neurons. Each γ−subunit contains four nucleotide-binding sites, one 
of which constantly occupied by AMP, another of unknown function and the 
remaining two that can bind either AMP or ATP and possibly also ADP (Cardaci et 
al., 2012; Hardie et al., 2012). Upon AMP binding, a myristoyl modification of the 
AMPK-β regulatory subunit allows AMPK to become activated and promote the 
switch toward catabolic, ATP-producing pathways, especially through the 
activation of oxidative metabolism. At the same time, AMPK activity inhibits 
biosynthetic pathways that are ATP-consuming. In T cells, AMPK in part executes 
this task by mTOR inhibition (Navarro and Cantrell, 2014), which regulates the 
‘primed’ oxidative metabolism characteristic of memory T cells (O’Sullivan and 
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Pearce, 2015), upon clearance of an antigenic challenge. Indeed both 
pharmacological AMPK activation or mTOR inhibition promote T cell memory 
generation in mice (Araki et al., 2009; Pearce et al., 2009). However, mTOR 
inhibition is not the only way by which AMPK regulates T cell function. In this 
thesis, I will show that AMPK activation negatively regulates both T cell 
proliferation and telomerase activity through activation of p38 MAP kinase. Below, 
I discuss the current, by-phasic model for p38 activation in T cells.  
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Figure 3: Tuning of a tuner: the metabolic master regulator AMPK.  
The structure and biochemical consequences of AMPK activation are shown. AMPK is a      
heterotrimer of α, β and γ chains activated in response to nutrient deprivation, when energy 
imbalance elevates AMP over ATP. AMPK is allosterically activated by AMP binding to 3 specific 
sites within its regulatory γ-subunit; upon AMP binding AMPK undergoes conformational changes 
that result in AMPK-β myristoylation and robust AMPK-α (Thr-172) phosphorylation by AMPK 
upstream kinases, LKB1 and CaMKKβ. ATP is an allosteric inhibitor of AMPK and competes with 
AMP for regulatory binding to AMPK-γ subunit. Activated AMPK re-directs metabolism towards 
catabolic pathways and activates oxidative phosphorylation. When energy is restored, ATP 
displaces AMP (or ADP) from AMPK-γ, which renders the molecule targetable by inactivating PP2C 
dependent de-phosphorylation. 
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1.6 P38 MAPK signalling in T cells: current understanding 
There are three main groups of MAPKs: p38, ERK and JNK (Chang and Karin, 
2001). There are four distinct p38 MAPK isoforms: α, β, γ, δ (Ashwell, 2006). T 
cells mainly express the α and to a lesser extent the β and δ isoforms of p38 
(Ashwell, 2006). Like all other MAPKs, p38 is phosphorylated within its activation 
Thr-x-Tyr loop in response to activatory signals by the canonical MAPK cascade, 
in which various upstream enzymes (such as MTK1, ASK1 and TAK1), that act as 
MAPKKK, downstream activates MKK3 or MKK6 that in turn activate p38 (Rincón 
and Davis, 2007).  
MKK4, which normally phosphorylates JNK, can also activate p38 in some cases 
(Brancho et al., 2003). Many different signals can converge on the canonical 
MAPK cascade, including environmental stress, DNA damage, inflammatory 
cytokines and also co-stimulatory receptor engagement, possibly through the 
activation of the small GTPase Rac1 (Figure 4, left side) (Ashwell, 2006). In turn, 
p38 can activate a tremendous number of transcription factors and other effector 
molecules, such as ATF2, p53 and MAPKAPK2 therefore regulating complex 
biochemical and functional responses (Zarubin and Han, 2005). Importantly, it is 
also possible that different MAPKs (especially JNK) converge with p38 on the 
activation of the same subset of biochemical targets (Wagner and Nebreda, 2009), 
perhaps to strengthen the functional outcome. Given the involvement of active p38 
signalling in both stress and inflammatory responses, p38 structure has been 
determined to allow the development of various p38 inhibitors. Among these 
compounds, the ATP competitor SB-203580 and lorapemid (BIRB796) that act by 
both ATP competition (that is, direct inhibition of kinase activity) and targeting of 
upstream components within the MAPK cascade (Lee et al., 2000). However the 
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consideration of p38 as a pharmacological target was reduced following 
disappointing clinical trials in which p38 inhibitors failed (for instance, for the 
treatment of rheumatoid arthritis and other auto-immune inflammatory conditions) 
because of toxicity issues. This was possibly due to the ubiquitous expression of 
p38, which also significantly lowered the therapeutic index (that is, the ratio 
between therapeutic and adverse effects of a drug). At present there is no p38 
inhibitor approved for treating human disease, and it has been proposed that 
targeting the (complex) upstream regulatory network of p38 may provide a more 
selective pharmacological intervention (Hammaker and Firestein, 2010).  
The role of p38 in immune cells and more specifically in T cells has been 
extensively studied. For instance in non-senescent T cells, p38 inhibition by SB-
203580 dampens T cell proliferation, T helper 1 polarization and related cytokine 
production in response to TCR activation (Rincón et al., 1998; Zhang et al., 1999). 
Although it was generally assumed that the MAPK cascade would be the sole 
regulatory mechanism for p38 activation, Salvador et al identified an alternative 
pathway, in which activated T cells but not B cells, phosphorylate p38 on a 
previously unrecognized site of Tyr 323 through the upstream activation of the 
TCR signalling molecules LCK and Zap70, therefore bypassing the canonical 
MAPK cascade (Figure 4, right side) (Salvador et al., 2005). Subsequently, this 
leads to p38 auto-phosphorylation on Thr180-Tyr182 within its own activation loop 
(Salvador et al., 2005). However, recent studies suggested that also B cells can 
alternatively activate p38 in response to BCR engagement (Liu et al., 2012). The 
reason for the existence of different modes for the activation of p38 remains 
elusive, however it has been recently shown that alternative and canonical 
activated p38 counter-regulate each other in the induction of T cell proliferation 
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and effector functions by differentially tuning NFAT activity and nuclear import 
(Alam et al., 2014).  
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Figure 4: The bi-phasic model for p38 activation in T cells.  
The current understanding for p38 activation in T cells is shown. As the JNKs and ERKs do, p38 is 
also activated through a canonical MAPK cascade in response to CD28 engagement, pro-
inflammatory cytokines and stress signals. The canonical MAPK cascade activates p38 by 
phosphorylation on Thr180/Tyr182 within its activation loop through a series of phosphorylation 
events in which the most upstream enzyme, a MAPKKK (not shown), downstream activates a 
MAPKK (either MKK3 or MKK6) that in turn directly phosphorylates p38. Salvador et al. identified 
an alternative pathway in which TCR activation in the absence of co-stimulation triggers p38 
activity downstream of TCR signalling machinery. In the alternative pathway, activated LCK in turn 
activates ZAP70 that then phosphorylates p38 on a previously unrecognized site of Y323 followed 
by p38 auto-phosphorylation on T180/Y182. Unlike canonical activated p38, alternative activation 
of p38 downstream of TCR signalosome has been shown to be important for T cell proliferation and 
Th1 differentiation.  
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Another MKK-independent mechanism for p38 activation was described in 
HEK293 cell line in which the scaffold molecule TAB1 can bind to p38α inducing 
its auto-phosphorylation (Ge et al., 2002). This pathway requires upstream 
activation by the ubiquitin ligase TRAF6, and operates in response to inflammatory 
and stress signals (Ge et al., 2002). Because these signals also activate p38 by 
the canonical MAPK cascade, the need for TRAF6-TAB1 dependent activation of 
p38 is unexplained. Importantly, TAB1 was also reported to induce p38 auto-
phosphorylation in response to AMPK activation in mouse ischemic 
cardiomyocytes (Li et al., 2005), but two subsequent studies in the same 
experimental system challenged the former report (Jacquet et al., 2007; Jaswal et 
al., 2007). Whether TRAF6, which was shown to be important for optimal AMPK 
activation in mouse T cells (Pearce et al., 2009), may also be involved in this latter 
mechanism is not known. In this regard, I will describe in this thesis a third 
pathway for the activation of p38 in T cells that relies on AMPK/TAB1 and 
spontaneously maintains human T cell senescence. 
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1.7 Human T Cell Senescence  
Because thymic involution occurs in early adulthood, when the thymus is 
progressively replaced by non-functional adipose tissue, the extra-thymic output of 
naïve (that is, before antigen-presentation) allo-reactive mature T cells severely 
constraines during ageing (Boraschi et al., 2013a; Goronzy and Weyand, 2013). 
However, the human naïve T cell repertoire is maintained throughout life, possibly 
through mechanisms of homeostatic proliferation and/or long-term survival 
(Goronzy et al., 2015). Importantly, the cytokine IL-15 and IL-7 have been 
identified as important factors which regulate the maintance of the overall CD8+ 
and CD4+ T cell pool in vivo (Ku, 2000; Seddon et al., 2003). IL-15 can also induce 
re-expression of CD45-RA within the human memory CD8+ T cell comportament 
and has been proposed to act as a quiescence inducing signal (Libri et al., 2011). 
However, the concept that homestatic proliferation and long-term survival are 
mediated by the same signaling pathways has been challenged (Seddon et al., 
2000). Mice with genetic disruption of the key proximal TCR signaling kinase LCK 
retain long-term survival but show defective homeostatic proliferation in vivo 
(Seddon et al., 2000).  
 
In humans, the function of elderly naïve T cells, for example their capacity for TCR 
activation and IL-2 release, is dampened because of a variety of mechanisms 
including reduced TCR responsiveness and calcium influx due to a decrease in 
both ERK and JNK signalling (Li et al., 2012; Linton et al., 1996). Importantly, 
thymic involution also dictates that effector (that is, after antigen-presentation) 
human T cell populations have to be maintained by repeated episodes of 
expansion of antigen specific T cells followed by their clearance when the immune 
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challenge subsides (Akbar et al., 2004). Unlike most adult somatic cells, human T 
lymphocytes are able to re-activate telomerase (a RNA-dependent DNA 
polymerase which extends the telomeres; described in section 1.9) upon antigenic 
challenges and this is essential for the life-long preservation of their proliferative 
potential in vivo (Hodes et al., 2002). However after repeated episodes of 
activation, T cells progressively differentiate and lose the capacity to up-regulate 
the enzyme telomerase, which leads to telomere erosion, loss of proliferative 
capacity and ultimately telomere-dependent senescence (Figure 5) (Akbar and 
Vukmanovic-Stejic, 2007). The proof of principle of the importance of telomerase 
in T cell differentiation comes from studies in which enforced telomerase 
expression in human CD8+ T cells significantly delayed the onset of replicative 
senescence without introducing genetic abnormalities or loss of functional activity 
(Plunkett et al., 2005).  
Highly differentiated, senescent T lymphocytes that have lost expression of both 
CD27 and CD28 co-stimulatory receptors accumulate in old humans, in patients 
with chronic viral infections, autoimmune disorders and in those with malignancy 
(Crespo et al., 2013; Weng et al., 2009). The loss of CD28 expression 
characterizes about 10% of memory CD4+ T cells and up to 50% CD8+ T cells in 
humans and other primates, but not in rodents in which T cells stably maintain 
CD28 expression (Weng et al., 2009). Because CD28 is important for T cell 
interaction with antigen presenting cells (through CD80-CD86 binding), it is 
anticipated that loss of CD28 signalling during ageing impairs the formation of an 
active, functional immunological synapsis (Miller et al 2001; Henson, personal 
communications). The importance of both chronic T cell activation and CD28 loss 
in driving the senescence of human T lymphocytes, was highlighted by recent 
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studies from Plunkett et al investigating a group of young individuals (median age 
of 15 years) affected by an X-linked lymphoproliferative syndrome (XLP), due to a 
defect in the SH2D1A gene encoding for the SLAM-associated protein. These 
young patients showed accumulation of CD28- lymphocytes and very short 
telomeres, similarly to those of healthy old individuals, indicating that abnormal T 
cell proliferation may accelerate human T cell differentiation, leading to premature 
immune-senescence independently of the ageing process per se (Plunkett et al., 
2007). 
Besides prolonged antigen presentation, T cell differentiation in vivo is also 
accelerated by an inflammatory microenvironment, which in part contributes to the 
accumulation of highly differentiated senescent T cells in chronic viral infections 
and autoimmune disorders (Fujii et al., 2009). Also, it has been recently reported 
that chronic stimulation by the anti-proliferative cytokine Interferon-β can trigger 
p53-dependent DNA Damage Response (DDR) signalling and related senescence 
in human fibroblasts (Moiseeva et al., 2006), offering an interesting parallel with 
human T lymphocytes in which another Interferon, namely IFN-α, promotes 
terminal differentiation (Reed et al., 2004), inhibits telomerase activity (Akbar and 
Fletcher, 2005) and possibly activates senescence via an unknown mechanism.  
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Figure 5: A model for the induction of human T cell senescence.  
Naïve T cells potently induce telomerase upon activation that is important for their antigen specific 
expansion. When the immune challenge is resolved, effector populations contract becoming 
memory T cells. Memory T cells are long-term surviving cells and undergo repeated episodes of 
activation upon re-encountering a specific antigen. However following repeated episodes of 
activation, memory T cells progressively differentiate losing the ability to re-induce telomerase, until 
a maximum extent at which they become highly differentiated (senescent) T cells that cannot 
reactivate telomerase even if challenged. As a result, highly differentiated T cells have very short 
telomeres, activate DNA damage responses and approach replicative senescence in vivo. These 
cells accumulate in the elderly however their role in immunity is not clear. Permission to reproduce 
this image has been granted by (Akbar et Vukmanovic-Stejic, 2007). 
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1.8 IFNα: a bridge between immune modulation and senescence? 
In response to viral infections, eukaryotic cells release anti-inflammatory and 
immune-modulatory cytokines known as interferons (IFNs). There are two main 
groups of IFNs: type I and type II IFNs (Platanias, 2005). There are six different 
type I IFN genes: IFN-α, IFN-β, IFN-γ, IFN-δ, IFN-ε and IFN-ω (Platanias, 2005). 
There is only one type II IFN gene that is IFN-γ (Platanias, 2005). In immune cells, 
IFN synthesis is mainly orchestrated through the Toll-like receptors (TLR) that are 
part of innate immunity and react toward highly conserved and redundant 
components of pathogens by activating different transcription factors and effector 
molecules, such as NF-κ-B and MyD88 (Borden et al., 2007).  
The IFN receptor transduces signals from all IFN gene products and consists of 
two sub-units (IFNAR1 and IFNAR2) that are coupled to the cytosolic tyrosine 
kinases TYK2 and JAK1 (Borden et al., 2007). As anticipated from other immune-
modulatory cytokines, IFNα also acts via the STAT transcription factor family, in 
particular STAT1 and STAT2 (Meyer, 2009). However, STAT-independent 
mechanisms are also involved in mediating IFN-α activity, especially through the 
activation of p38 MAPK. Indeed, blocking p38 signalling by either enforced 
negative-dominant expression or chemical inhibitors prevent the induction of IFN-
α responsive genes (that are, gene-clusters controlled by interferon responsive 
elements or IRE sequences) (Platanias, 2005). Importantly, p38 blockade does not 
interfere with IFN-α driven modulation of STAT1/2 activity and related functional 
outcome, indicating that MAPK and STAT activation cascades by IFN-α are 
independent.  
In humans, IFN-α is produced by plasmacytoid dendritic cells and modulates both 
innate and adaptive antiviral immunity (Ferrantini et al., 2007; Meyer, 2009). In 
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both human CD4+ and CD8+ T cells, IFN-α drives important immune-modulatory 
effects. Firstly, it  induces the down-modulation of CD27 and CD28 co-stimulatory 
receptor expression (Fletcher et al., 2005). Secondly, it accelerates telomere 
shortening and inhibits telomerase activity (Fletcher et al., 2005; Xu et al., 2000). 
Thirdly, it potentiates cytotoxic CD8+ T cell killing activity (Brassard et al., 2002). 
Reed et al recently showed that IFN-α down-regulates telomerase activity of skin 
antigen-specific CD4+ T cells, which may constrain memory T cell expansion that 
is important for life-long immune protection (Reed et al., 2004).  
Among various chronic viral infections, that caused by cytomegalovirus (CMV) is 
particularly efficient at inducing IFN-α production, which accelerates human T cell 
differentiation, inhibits telomerase activity and leads to the accumulation of 
antigen-specific yet hypo-responsive T lymphocytes (Fletcher et al., 2005). 
Understanding the molecular bases of IFN-α  mediated telomerase down-
modulation may thus uncover novel interventional targets to boost immune 
responses during ageing and mitigate immune-senescence. Below, I introduce the 
enzyme telomerase and discuss its importance, mechanism of action and 
regulation. 
 
 
1.9 Telomeres and telomerase 
The ends of the eukaryotic chromosomes are characterized by repeated 
hexameric sequences of GT-rich nucleotides known as telomeres that provide 
genomic protection and stability (Blackburn, 2000). Functional telomeres require 
minimal telomere length (above 4-kilo bases (kb)), an intact G-rich 3’ DNA 
overhang and the interaction with specific telomere-binding proteins, the shelterin 
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(Blasco, 2005). This complex consists of six different proteins (TRF1, TRF2, 
hRAP1, TIN2, TPP1 and POT1) that negatively regulate the access of the enzyme 
telomerase at the telomere by both T and D loop formations, structures that 
impede telomerase-telomere interaction (de Lange, 2009). Although telomeres 
also interact with the DNA-damage repair machinery of the cell, it has been 
recently shown that any DNA damage that occurs at the site of the telomere is 
irreversible and triggers DNA damage responses leading to proliferative arrest, 
characteristic of replicative senescence (Fumagalli et al., 2012). Importantly, when 
telomeres become critically short after repeated cell divisions, senescent cells 
spontaneously activate DNA damage response (DDR) cascades and the 
replicative capacity ceases (Campisi and d’Adda di Fagagna, 2007). This can be 
delayed by the up-regulation of the enzyme telomerase, a RNA-dependent DNA 
polymerase firstly identified in 1985 in the protozoa Tetrahymena Thermophila 
(Greider and Blackburn, 1985). The holo-enzyme, which consists of a catalytic 
core (hTERT) and a RNA template (hTR or hTERC), acts by physically binding to 
and extending the G-rich 3’ DNA overhang of the telomere, to replenish the loss of 
genetic material that is due to the semiconservative mechanism of DNA replication 
(Verdun and Karlseder, 2007). Figure 6 illustrates a schematic representation of 
telomerase function.  
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Figure 6: Telomerase function.  
The telomere-telomerase complex is shown. Telomerase is a RNA dependent DNA polymerase 
that extends telomeric DNA at each cell division, preventing telomere shortening. Telomerase 
function requires both a catalytic subunit (hTERT) and a RNA component (TERC) that directly 
binds to the single strand 3’ overhangs at the end of eukaryotic chromosomes. Details of 
telomerase function are provided in the text.  
 
 
Briefly, because DNA synthesis is unidirectional (5’-3’) (Watson, 1971), each DNA 
duplex is characterized by one strand that is processed in toto (leading strand) 
while the synthesis of the complementary strand is delayed (lagging strand), giving 
rise to the Okazaki fragments (which are DNA sequences of 50-100 nucleotides 
bound to a RNA primer; Figure 7). Telomere shortening can be therefore defined 
as the biochemical reaction occurring at each lagging strand, due to the 
degradation of the terminal Okazaki fragment, and accounts for the loss of about 
50-100 bp of DNA at each cell division. Hayflick was the first to identify the 
existence of a limit, imposed by mechanisms of telomere erosion, to the extent at 
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which mammalian cells can proliferate (Hayflick limit) (HAYFLICK and 
MOORHEAD, 1961). This dictates that adult somatic cells in which telomerase 
activity is generally very low or undetectable, reach replicative senescence after 
about 50 cell passages in vitro (HAYFLICK and MOORHEAD, 1961). Conversely, 
elevated telomerase activity in cancer cells confers virtually unlimited proliferative 
potential (Cong et al., 2002). Fine-molecular tuning of telomerase is therefore 
needed to control mammalian cell proliferation and ensure a balance between the 
delaying of cellular senescence and the risk of developing malignancy. Below, I 
briefly discuss the current understanding of the main mechanisms controlling 
telomerase expression, nuclear import and activation. 
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Figure 7: The semi-conservative mechanism of eukaryotic DNA replication. 
The mechanism of DNA replication is shown. Helicase activity (not shown) renders parental DNA 
available to binding by the DNA polymerase within the replication fork to extend 3’-OH of RNA 
primers on both leading and lagging strands; topoisomerase activity assists this process removing 
eventual positive or negative super-loops that would impede DNA replication (not shown). Note that 
while the DNA lagging strand is synthesized from a single RNA primer (bottom), multiple RNA 
primers are required on the complementary DNA leading strand instead (top), since the activity of 
the DNA replication fork possesses opposite polarity to the synthesis of this strand. Thus, multiple 
RNA-DNA hybrid Okazaki fragments originate during lagging strand synthesis. The degradation of 
the terminal Okazaki fragment is responsible for telomere shortening at each cell division 
(discussed in the text). 
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1.10 Complexity of telomerase regulation: transcriptional and post-
translational mechanisms. 
The biological importance of telomerase is highlighted by the complexity of both 
transcriptional and post-translational mechanisms tuning the expression of its 
catalytic sub-unit, hTERT (Tesmer et al., 1999). The hTERT promoter is well 
characterized and comprises binding sites for both inhibitory and activatory 
transcription factors (Figure 8) (Kyo et al., 2008). For instance, the transcription 
factor c-MYC binds to the hTERT promoter at regulatory sites known as ‘E-boxes’, 
hence inducing hTERT transcription (DePinho et al., 1991). This has been well 
documented in studies where elevated hTERT expression was directly induced by 
increased c-MYC activity, in cancer cells (Kyo et al., 2008). Between the E-boxes, 
the hTERT promoter possesses at least five distinct GC-rich DNA sequences 
(CpG islands) that are important for Sp1-mediated hTERT up-regulation. Similarly, 
the p65 sub-unit of the transcription factor NF-KB has been reported to up-regulate 
hTERT expression (Akiyama et al., 2003), however the precise binding regulatory 
site has not been identified. Conversely, E2F1 is an inhibitor of hTERT 
transcription, and four related binding sites have been identified, in which its action 
is coordinated by the histone deacetylase HDAC (Crowe, 2001). It is also well 
recognized that the tumour suppressor p53 inhibits hTERT expression, possibly 
preventing the binding of Sp1 to the hTERT promoter (Xu et al., 2000).  
Although the transcriptional regulation of hTERT has been initially considered the 
sole regulatory mechanism, it has recently arisen that post-translational 
mechanisms are also involved in telomerase regulation (see also Figure 8). In 
accordance with this, Liu and colleagues firstly reported the existence of notable 
differences between the levels of hTERT transcripts and telomerase activity in 
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human lymphocytes (Liu et al., 2001). In an extension of this work, the kinase AKT 
has been shown to phosphorylate hTERT (at 220-GARRRGGSAS-229 and 817-
AVRIRGKSYV-826 sites), a process required for its nuclear import and activity 
(Kang et al., 1999). Indeed, defective AKT signalling is a molecular feature of 
human highly differentiated T cells that have low telomerase activity (Henson et 
al., 2009; Plunkett et al., 2007). In addition to AKT, hTERT also binds to mTOR; 
this interaction can be disrupted by PP2A activity, a tumour suppressor 
phosphatase that dephosphorylates AKT and possibly also hTERT (Li et al., 
1997). More recently, reports on the existence of AKT-independent mechanisms in 
controlling telomerase activity in human highly differentiated T cells that in part 
involve spontaneous activation of p38 MAP kinase through an unknown 
mechanism (Di Mitri et al., 2011). Intervention at the point of telomerase regulating 
pathways may be important to restore immune cell function during ageing. Below, I 
describe the senescence response and highlight the many knowns and unknowns 
that characterize it.  
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Figure 8: Molecular tuning of telomerase. 
An overview of both transcriptional (left) and post-translational mechanisms (right) regulating the 
catalytic subunit of telomerase hTERT is shown. An extract (sites comprised between -200 and 
+78) of the telomerase catalytic sub-unit hTERT gene is reproduced, depicting the main 
transcriptional activators (c-MYC, Sp1, NFkB, and ERK) and repressors of hTERT expression (p53, 
E2F1, phosphorylated Rb and HDAC). Various regulatory elements have been identified within the 
hTERT promoter that directly or indirectly interacts with transcriptional regulators; the role of both 
E-box sites binding to c-MYC and Sp1-binding sites between the E-boxes is described in the text. 
NFkB promotes hTERT transcription but the precise binding on the hTERT promoter has not been 
identified. ATG in bold indicates gene hTERT start. The post-translational tuning of telomerase is 
less well characterized; AKT can directly phosphorylate hTERT promoting its nuclear import; 
mTOR binds to hTERT and promotes its activity through an unknown mechanism; NfKB promotes 
hTERT nuclear import; PP2A inhibits telomerase activity by de-phosphorylating both AKT and 
hTERT; and p38 has been proposed to inhibit telomerase but bot upstream and downstream 
signals regulating this process have not been identified.  
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1.11 Ageing and Cellular Senescence 
The reasons for ageing, the progressive detrimental decay of cellular and tissue 
homeostasis, are presently unknown. However various types of non-dividing, 
senescent cells significantly accumulate during ageing (van Deursen, 2014). 
Ageing and senescence are evolutionary regarded as an important example of 
antagonistic pleiotropy, which characterizes a mechanism (senescence) that 
protects young organisms from cancer at the expenses of their own ageing 
(Campisi and d’Adda di Fagagna, 2007). Three progressive phases characterize 
the senescence response (Figure 9). In order, senescence is caused by the 
accumulation of persistent DNA damage (phase 1), related activation of the DDR 
pathway in cell (phase 2), eventually leading to growth arrest (phase 3) (Akbar and 
Henson, 2011). DNA damage can originate at the telomere (e.g. due to the 
progress towards the Hayflick limit), and this is defined as telomere-dependent 
senescence (d’Adda di Fagagna et al., 2003). Conversely, when the source of 
DNA damage is not due to telomere shortening, the process is known as telomere-
independent senescence. In such cases, DDR signalling can be induced by 
ionizing radiations, oxidative stress, growth factor deprivation and aberrant 
oncogene activation. Of note, there are also important differences in the 
senescence manifestations in both humans and rodents, in that rodents maintain 
significantly longer telomeres than humans, suggesting that telomere-independent 
mechanisms of senescence may be an important regulator of the short mouse life 
span (Kipling, 2001). Whether telomere-dependent and independent senescence 
rely on the same signalling pathways remains elusive, although it appears that p53 
activation may be an essential downstream component of an effective DDR. 
Mechanistically, DDR signalling occurs at active DDR foci which comprise a 
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complex of DDR-sensors (such as: RPA, RPC, the 911 and MRN complexes), 
activation of the apical kinases ataxia telangiectasia mutated (ATM) and ATM and 
RAD-3 related (ATR) and downstream phosphorylation of chromatin re-modellers 
(e.g. H2AX) and other kinases (CHK1/2) (Fumagalli and d’Adda di Fagagna, 
2009). Although there is now ample evidence that senescence is an anti-cancer 
mechanism, elevated secretory activity in senescent cells can in turn alter the 
tissue microenvironment through paracrine signalling (e.g. stimulating 
angiogenesis), which may paradoxically lead to neoplastic transformation of the 
surrounding cells (Campisi and d’Adda di Fagagna, 2007). The set of inflammatory 
factors that are secreted by senescent cells (e.g. IL-6, IL-8, TNF, metallo-proteins) 
is known as ‘senescence-associated secretory phenotype’ (SASP), and at least in 
fibroblasts, is controlled by active p38 MAPK signaling (Freund et al., 2011). 
Notably, SASP does not only contribute to tissue remodelling yet also reinforces 
senescence itself, in an autocrinous manner (Acosta et al., 2008). Importantly, the 
current understanding on the biochemical processes regulating senescence is 
mainly based on studies of senescent fibroblasts; it is presently unknown whether 
the DDR and/or the SASP may be regulated by identical mechanisms in different 
cell types. If so, this may lead to setting up a common strategy for reversal of 
senescence in different tissues. 	
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Figure 9: The three-phase model for the induction of cell senescence. 
Induction of cellular senescence. In phase 1, persistent (telomeric or non telomeric) DNA damage 
occurs and triggers the activity of the apical kinases ATM and ATR that in turn activate and recruit 
a plethora of DNA damage sensors at the level of DDR foci (phase 2). Various biochemical 
effectors downstream of ATM/ATR mediate the DNA damage response; and on the basis of the 
extent, nature, and localization of the damage, DDR signalling triggers different physiological 
outcomes, leading to apoptosis, transient cell cycle arrest or senescence (irreversible growth 
arrest, phase 3). The exact mechanism determining the specific activation of any of these 
programs remains elusive. The most important components of the figure are discussed in more 
detail in the text. p38 MAPK activation may be involved in the senescence response, possibly 
upstream of p53-p21, but its role is not firmly established. Activation of the transcription factor p53 
seems to be a foundamental biochemical requirement for generation of the robust, persistent DNA 
Damage response characterizing senescence. Permission for reproducing this picture has been 
granted by (Akbar & Henson, 2011) 
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1.12 Cell cycle regulation: implications for cellular senescence. 
The study of cellular senescence is directly linked with the modulation of the cell 
cycle machinery. Proliferating cells distribute within four distinct, highly regulated 
phases: the G1 (for anabolic growth), S (for DNA synthesis), G2 (in preparation to 
mitosis) and M phase (during which mitosis (or cell division) occurs) (Chandler and 
Peters, 2013). The transitions from each of these phases, especially the G1/S and 
G2/M transitions, are tightly regulated in cell. However because senescent cells 
accumulate DNA damage, they are mostly retained within the G1 part of the 
interphase (that is, the time spent by proliferating cells between two consecutive M 
phases) to avoid synthesis of irreversibly damaged DNA (d’Adda di Fagagna et al., 
2003). Because G1 cycling-cells engage anabolic reactions, it is well recognized 
that senescent cells retain high metabolic activity and significantly enlarge 
(Campisi and d’Adda di Fagagna, 2007). In fribroblasts, senescence appears to be 
regulated by active mTOR signalling (Laberge et al., 2015). Downstream of the 
DDR and in addition to p53 activation, there are important events to induce (or 
maintain) senescence. This includes changes in the phosphorylation and/or 
expression of the retinoblastoma protein (pRB), as well as the coordinated down-
modulation of cyclins (e.g. D, E) and up-regulation of cell-cycle inhibitors (e.g. p21, 
p27), that dictate the proliferative arrest of senescent cells at the G1 phase 
(Giacinti and Giordano, 2006). In particular, the abundance of under-
phosphorylated pRb levels is perhaps the most recognized regulator of cell-cycle 
progression. In dividing cells, pRb is phosphorylated by various cyclin dependent 
kinases (CDKs), therefore losing the ability to bind and inhibit E2F1, which leads to 
the G1/S transition (Giacinti and Giordano, 2006). In senescent cells, persistent 
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p53 activation antagonizes this mechanism through the transcription of p21, an 
inhibitor of CDKs, resulting in lower pRb phosphorylation and cell cycle termination 
(Riley et al., 2008). Despite the well-recognized role of p53 in the senescence 
response, the exact mechanism linking DDR and p53 signalling is not clear. Also, 
how cells decide to undergo either apoptosis (that is, the programmed cell death 
on genetic bases) or senescence that are both controlled by p53 activation in 
response to irreversible DNA damage remains elusive. Inactivating mutations in 
any cell cycle related mechanism favour neoplastic transformation, indicating that 
cell cycle regulators act as tumour suppressor genes (Fumagalli and d’Adda di 
Fagagna, 2009). The relationship itself between senescence and apoptosis 
appears to be cell type dependent, in that senescent fibroblasts yet not leukocytes 
are apoptosis-resistant (Akbar and Henson, 2011). However the mechanisms 
regulating senescence in leukocytes remain poorly defined. In this study, 
unrecognized mechanisms of senescence in primary human CD4+ T cells have 
been identified. 
 
1.13  AIM OF THE WORK 
The worldwide demographic shift towards an older age is associated with an 
increase in the incidence and severity of many infectious diseases (Pawelec et al., 
2005; Wikby et al., 2002). This is attributed to the decline of immunity during 
ageing (Akbar et al., 2004; Weng, 2006). A global challenge therefore is to identify 
mechanisms involved with immune dysfunction and to identify ways to restore 
immunity during ageing. The loss of telomerase and proliferative potential are well-
recognized yet mechanistically poorly defined hallmarks of human senescent T 
cells. The aim of this PhD was to identify mechanisms involved in human T cell 
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senescence and whether intervention is possible to restore telomerase and 
proliferative activity in these cells.  
 
To achieve this goal, three related strategies were conceived:  
1) Identifying mechanisms of telomerase down-regulation by an inflammatory 
signal, IFNα, which is known to accelerate human T cell differentiation both in 
vitro and in vivo. 
2) Understanding in parallel the upstream regulatory network of a signalling 
molecule, p38 MAPK, which is shown to be required for telomerase down 
regulation in both IFN-treated T cells and natural occurring senescent T cells. 
3) Restoring telomerase and proliferation in human senescent T cells by both 
genetic and pharmacological modulation of a novel T cell p38 MAPK activation 
pathway. 
 
 
Here I found evidence to challenge the current paradigm for activation of p38 in 
human T cell populations and I present a previously unrecognized mode of MAPK 
activation in T cells. This, a prototype mechanism linking immune-modulation, 
senescence, metabolism and cancer. Thus, the present study contributes to 
enhance our understading on both human ageing and senescence, with the 
potential to reverse it. 
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CHAPTER II: Materials and Methods 
 
2.1 Cellular Biology 
2.1.1 Isolation of Peripheral Blood Mononuclear Cells (PBMC) 
Heparinized peripheral blood samples were taken from healthy volunteers (aged 
25-65, median 52, male 55% and female 45%; n=85). All samples were obtained 
with the approval of the Ethical Committee of Royal Free and University College 
Medical School and voluntary informed consent was obtained in accordance with 
the Declaration of Helsinki. Donors did not have any co-morbidity, were not on any 
immunosuppressive drugs, and retained physical mobility and lifestyle 
independence. Peripheral blood mononuclear cells (PBMC) were isolated by 
gradient separation based on the addition of Lymphoprep™ (Axis-Shield) to fresh 
blood. Blood was diluted 1:4 using Dulbecco’s Phosphate Buffered Saline solution 
(D-PBS) and carefully layered on 20 mL Lymphoprep gradient in 50-mL Falcon 
tubes. Samples were then centrifuged at 2000 rpm for 20’, brake-off, which 
resulted in erythrocytes sedimentation and mononuclear cell-ring layering at the 
interface between (enucleated) erythrocytes on the bottom and plasma on the top 
of the tubes. Next the mononuclear cell-ring was aspired. PBMC were then 
washed 3 times in D-PBS for 30’, 20’ and 15’ respectively, to remove Lymphoprep 
contamination. Cells were then resuspended in 10 mL of either Magnetic Activated 
Cell Sorting buffer if further isolated (MACS buffer, filtered and ready to use, 
Miltenyi Biotec) or D-PBS, counted and used for downstream applications.  
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2.1.2 Cell counting  
Cells were diluted using Trypan-blue dye (Life Technologies 15250-061), to which 
only dead cells are permeable, loaded onto on a Haemocytometer and counted on 
a light microscope. Cells within 2 large grids were enumerated and total cell 
number was assessed using the formula: 
N = n * D/ 104  
where N is cell concentration per mL, n is the number of cells counted in the grids 
and D is the cell dilution factor.   
 
2.1.3 Isolation of human CD8+ or CD4+ T cells  
Primary human CD4+ and CD8+ T lymphocytes were isolated from PBMC 
preparations by immunomagnetic separation. Cells were isolated by either 
‘positive’ or ‘negative’ selection. In the former procedure, PBMC were pelleted by 
centrifuging at 1600 rpm for 7’ and, after supernatants were discarded, 
resuspended in 80 µl of MACS buffer per 107 cells followed by addition of 20 µl of 
magnetic microbeads bound to monoclonal antibody to either CD4 or CD8 
receptor (CD4 or CD8 Microbeads, Miltenyi Biotec). Receptor labelling was then 
allowed by incubating cells 15’ in the fridge (between 4-8° C).  Next, cells were 
washed by adding 1-2 mL of MACS buffer per 107 cells and centrifuged at 1200 
rpm for 10’; and after supernatants being discarded, resuspended in 500 µl of 
MACS buffer per 108 cells. Meanwhile, LS-magnetic separation columns (130-042-
401, Miltenyi Biotec) were allocated in a magnetic MACS Separator (Miltenyi 
Biotec) and equilibrated by 3 consecutive washes using 3 mL of MACS buffer. At 
this stage, cell suspensions were loaded through the equilibrated columns, 
followed by 3 consecutive washes using 3 mL of MACS buffer. The unlabelled 
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fraction containing CD4- or CD8- cells was then discarded and columns were 
displaced from the magnetic separator and the labelled cell fraction was instead 
flushed off the column into a falcon tube with 5 mL of MACS buffer. Cell purity 
(above 95%) of either CD4+ or CD8+ T cell populations was assessed by flow-
cytometry. 
 
For CD4+ T cell isolation followed by further purification into the CD27/CD28 
relative sub-populations, ‘negative selection’ was used. PBMC pellets were 
resuspended in 40 µl of MACS buffer per 107 cells and incubated with 10 µl of 
biotin-conjugated antibody cocktail (130-096-533, Miltenyi Biotec) against CD8, 
CD14, CD15, CD16, CD19, CD36, CD56, CD123, TCRγ/δ, and CD235a 
(Glycophorin A) per 107 cells (that is, to magnetically label all mononuclear 
immune cell types, except CD4+ T cells). Receptor labelling was then allowed for 
5’ in the fridge. Next, 30 µl of MACS buffer per 107 cells were added to cell 
suspensions along with 20 µl/107 cells of MicroBead cocktail bound to monoclonal 
antibody to biotin and CD61 (130-096-533, Miltenyi Biotec). Cells were incubated 
for additional 10’ in the fridge. Subsequently, cells were washed by centrifuging at 
1200 rpm for 10’, resuspended in 500 µl MACS buffer and loaded on equilibrated 
LS-magnetic columns as above described. The columns were eluted by 3 
consecutive washes using 3 mL of MACS buffer and, at this time, elutes containing 
‘untouched’ CD4+ T cells were collected. Cell purity (above 95%) was verified by 
flow-cytometry. 
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2.1.4 Isolation of CD27/CD28 related subsets of human CD4+ T cells 
The relative expression of CD27 and CD28 receptors identifies three separate 
populations of human CD4+ T cells directly ex vivo. To begin to isolate relatively 
undifferentiated CD27+ CD28+ CD4+ T cells, the above-purified ‘untouched’ CD4+ T 
cell population was pelleted by centrifugation and resuspended in 80 µl of MACS 
buffer per 107 cells followed by the addition of 20 µl/107 cells of MicroBeads 
conjugated to monoclonal antibody to CD27 receptor. Receptor labelling was then 
allowed for 15’ in the fridge. Cells were washed in 2 mL MACS buffer per 107 cells 
by centrifugation and then resuspended in 500 µl MACS buffer. Cell suspensions 
were loaded into LS columns, equilibrated as above described, and eluted were 
downstream collected in a falcon tube by 3 consecutive washes using 3 mL MACS 
buffer each time. The unlabelled cell fraction contained both intermediate 
differentiated CD27- CD28+ and highly differentiated (senescent) CD27- CD28- 
CD4+ T cells (that is, because human CD4+ T cells first lose CD27 followed by 
CD28 expression during their differentiation). Instead, positively labelled cells 
retained by the column were flushed off the columns into a falcon tube. These cells 
were relatively undifferentiated (non-senescent) CD27+ CD28+ CD4+ T cells. 
 
To continue to isolate intermediate differentiated CD27- CD28+ and highly 
differentiated (senescent) CD27- CD28- CD4+ T cells, elutes were counted, 
pelleted by centrifugation and resuspended in 100 µl of MACS buffer per 107 cells 
followed by addition of 10 µl/107 cells of magnetic, PE-conjugated monoclonal 
antibody to CD28 receptor. Receptor labelling was then allowed for 15’ in the 
fridge. Next, cells were washed by centrifugation in 2 mL of MACS buffer per 107 
cells, and again resuspended in 80 µl of MACS along with 20 µl of anti-PE beads, 
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per 107 cells. Cells were incubated in the fridge for additional 15’, followed by 
washing and re-suspension in 500 µl MACS buffer. Cell suspensions were loaded 
into MS-columns (130-042-201, Miltenyi Biotec) equilibrated by rinsing with 500 µl 
of MACS buffer. Columns were eluted into a falcon tube by 3 consecutive washes 
using 500 µl of MACS buffer each time. Elutes were CD27- CD28- CD4+ T cells. To 
flush off the column and collect the CD28 positively labelled population, 1 mL of 
MACS buffer was used. These cells were CD27- CD28+ CD4+ T cells. Cell viability 
was assessed by tripan bue exlusion test. A representative purity profile depicting 
the dichotomy between non-senescent and senescent T cell populations on which 
this work is based is shown in Supplementary Figure 1. These cells were then 
analysed for functional or signalling readouts either directly ex vivo or upon genetic 
modifications, as described below.  
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       Fig. S1: Purity of non-senescent versus senescent CD4+ T cells.          
 
 
2.1.5 Human T cell activation 
Primary human CD4+ and CD8+ T lymphocytes were cultured in RPMI 1640 
medium supplemented with 10% heat-inactivated FCS, 100 U/ml penicillin, 100 
mg/ml streptomycin, 50 μg/ml gentamicin, and 2 mM L-glutamine (all from 
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Invitrogen) at 37°C in a humidified 5% CO2 incubator. Cell culturing was set up in 
24, 48 or 96 well-plates (according to cell numbers) that were previously ‘coated’ 
for 2 hours at 37° C, using a solution of anti-CD3 antibody (αCD3, purified OKT3 
clone; 86022706; Sigma-Aldrich) diluted in D-PBS at the concentration of 0.5 
µg/mL, followed by gentle washing in D-PBS to remove the unbound antibody 
fraction. Human CD4+ and CD8+ T cell populations, counted and resuspended in 
complete medium at 106/mL, were seeded in the so-coated plates with the addition 
of either rh-IL2 (R&D Systems, 10 νg/mL) or anti-CD28 antibody (αCD28; 37407; 
MAB342; R&D Systems; 0.5 µg/mL), as indicated.  
 
For activation of human CD8+ T cells in the presence of IFN-α (R&D Systems), the 
cytokine was added at the beginning of the culture at the concentration of either 
500 U/mL or 100 U/mL for either short-term (up to 72 hours) or long-term cultures, 
respectively. In long-term experiments, human CD8+ T cells were re-activated 
every 10 days, at which time IFN-α (100 U/mL) was added back in culture. 
 
For lentiviral vector transduction, primary human highly differentiated CD27− 
CD28− CD4+ T cells were activated in the presence of plate-bound αCD3 (0.5 
μg/ml) plus recombinant human IL-2 (10 ng/ml) and then, at 48 and 72 h after 
activation, were transduced with pHIV1-Siren lentiviral particles using a 10 
multiplicity of infection (MOI, described below). Fresh medium was replaced every 
2-3 days; and transduced cells were maintained in activation medium and 
analysed for functional readouts four days post-transduction (day 7). For long-term 
cultures, transduced cells were reactivated every 10 days in a new αCD3-coated 
plate and analysed up to 4 weeks later. Relatively undifferentiated CD27+ CD28+ 
	 64	
CD4+ T cells were cultured and transduced as their CD27−CD28− counterparts 
were, but cells were activated by plate-bound αCD3 plus αCD28, both at 0.5 
μg/ml.  
 
2.1.6 Phenotypic Analysis 
Isolated human CD8+ and CD4+ T Cells (between 105 to 106 cells) were 
resuspended in D-PBS additionated with 2% fetal calf serum (FCS) and then 
surface stained with anti-CD27 (337169; BD Biosciences) and anti-CD28 (348040; 
BD Biosciences), dilution 1:100. Cells were incubated 15’ at room temperature in 
the dark. Next, cells were washed twice in D-PBS by centrifuging at 1600 rpm for 
4’, resuspended in 200 µl FACS buffer and immediately run using an LSR 
Fortessa (BD Biosciences).  
 
2.1.7 Proliferation Assays 
Proliferation of transduced highly differentiated CD27- CD28- CD4+ T cells was 
assessed four days post-transduction (day 7) by either radioactive or non-
radioactive based methods.  
 
For radioactive measurement, cells were activated in 96-well plates and 
transduced as above described followed by over-night probing with the nucleotide 
analogue 3H thymidine (Perkin Elmer 201112) diluted 1:400 in culture (= 0.5 µCi). 
The next day, cells were harvested onto a printed filtermat A (Perkin Elmer 1205-
401) using a 96-well plate harvester (TOMTEC). Proliferation was determined as 
proportional to scintillation emission countering. Short-term proliferative activity is 
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presented as incorporation of 3H thymidine (as count per minutes, c.p.m.) and 
results are means +/- standard error of triplicate means. 
 
For non-radioactive measurement, a Cell-Trace Violet dye dilution assay, which 
binds to protein ammines, was used (C34557, Invitrogen). Dye dilution stock (5 
mM) were made by re-suspending an anhydrous aliquot of dye in 18 µl of DMSO 
and used in culture at the final concentration of 5 µM. The working dye solution 
was added to freshly isolated cells prior to activation by incubation 20’ at 37°C, 
protected from light. To remove any unbound dye, cells were then washed in 5 
times the incubation volume with fresh medium containing 1% of proteins. Cells 
were washed by centrifugation, resuspended in fresh pre-warmed complete RPMI 
1640 medium and incubated for additional 10’ before stimulation, to allow 
intracellular acetate dye hydrolysis. Rate of proliferation of transduced cells was 
evaluated 96 hours post-transduction by flow-cytometry based analysis of the 
emission peaks of the diluted dye (between 405-450 nm) using an LSR Fortessa.   
 
Alternatively, non-radioactive measurement of T cell proliferation was assessed by 
analysis of the cell cycle related Ki67 nuclear antigen, using the nuclear FoxP3 
staining buffer (130-093-142, Miltenyi Biotec). Cells were fixed at room 
temperature for 15’ using Fix/Perm Solution 1 diluted 1:4 in Fix/Perm Solution 2 
(both provided with the kit). Cells were then washed twice by centrifugation in 
Stain Buffer (BD Biosciences) at 1800 rpm followed by permeabilization for 30’ on 
ice using the kit-provided Permeabilization Buffer diluted 1:10 in ddH2O. During 
the permeabilization phase, cells were directly stained with fluorochrome-labeled 
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anti-Ki67 antibody (1:20, BD Bioscience). Next, cells were washed and 
immediately analyzed by flow-cytometry using a LSR Fortessa.  
 
For long-term expansion rate, population doublings of transduced CD27- CD28- 
CD4+ T cells were calculated as follows: log10 (number of cells counted after 
population expansion) − log10 (number of cells seeded) / log10 2. 
 
2.2 Molecular Biology 
2.2.1 Phospho Flow Analysis 
After surface staining, cells (between 105 to 106 cells) were resuspended in Stain 
Buffer (BD Pharmingen) using 96 round well-plates and fixed for 10 min at 37 °C 
with warm Cytofix Buffer, diluted 1:1 (BD Biosciences). Cells were then washed by 
centrifuging at 1600 rpm for 4’ and permeabilized for 30 min at 4 °C with 100 µl 
ice-cold Perm Buffer III (BD Biosciences). Next, cells were washed twice in Stain 
Buffer by centrifugation at 1600 rpm for 4’ and then incubated for 30’ at room 
temperature with phycoerythrin-conjugated antibody to p38 phosphorylated at 
Thr180 and Tyr182 (612565), phycoerythrin-conjugated antibody to γ-H2AX 
phosphorylated at Ser139 (562377), phycoerythrin-conjugated antibody to under-
phosphorylated Rb (550502) and antibody to Rb phosphorylated at Ser807 and 
Ser811 (558549; all from BD Biosciences); and antibody to AMPKα 
phosphorylated at Thr172 (40H9), antibody to ATM phosphorylated at Ser1921 
(D25E5), antibody to ATF2 phosphorylated at Thr71 (9221), antibody to p53 
phosphorylated at Ser46 (2521), anti-cyclin D1 (DCS6) and anti-p27 (D69C12; all 
from Cell Signalling). Primary unconjugated antibodies were subsequently probed 
for 30 min at room temperature in the dark with a secondary antibody, either 
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phycoerythrin-conjugated goat anti–rabbit IgG (P-2771MP; Life Technologies) or 
fluorescein isothiocyanate-conjugated goat anti–rabbit IgG (65-6111; Life 
Technologies). Cells were finally washed in Stain Buffer and immediately analysed 
with a LSR Fortessa (BD Biosciences). In some experiments, cells were pre-
incubated for 60 min with the AMPK agonist A-769662 (150 μM; Tocris 
Bioscience), the ATM inhibitor KU-55933 (10 μM; Calbiochem) or PMA (phorbol 
12-myristate 13-acetate; 20 ng/ml; Sigma) before being fixed. Data were analysed 
with FlowJo software (TreeStar). For signalling studies with transduced cells, 
events were gated on the GFP+ compartment. 
 
2.2.2 Western Blot 
For Western blot analysis of whole-cell extracts, purified primary human CD8+ T 
cells were activated as abode described. Primary human CD4+ T cells were sorted 
ex vivo immediately after separation into subsets defined by expression of CD27 
and CD28. Alternatively, purified human highly differentiated CD27- CD28- CD4+ T 
cells were harvested 4 days after transduction. 
 
Cells were normalized by equal cell number enumeration and harvested by 
centrifuging 2 times at 1800 rpm for 15’ followed by ultra-centrifugation at 13000 
rpm for 2’, at 4° C. Pellets from 2 x 106 cells were then dried and stored at -80°C. 
Lysates were obtained by incubating samples in 40 µl of RIPA buffer (Sigma 
Aldrich) followed by incubation on ice for 20’. Lysates were then cleared by ultra-
centrifuging at 13000 rpm for 20’ at which time supernatants containing protein 
extract were collected in fresh eppendorf tubes and either stored at -80° C (for not 
immediate use) or immediately stained with 10 µl of Protein Loading Buffer (0,25 
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M Tris-HCl, pH 6.8; 10% (p/v) SDS; 50% (p/v) glycerol; 0,05% (p/v) BBF; 0,5 M 
DTT), and samples were then boiled for 5’ at 95°C to allow protein denaturation. 
Lysates were separated by protein electrophoresis at 120 V for 2 hours on 10% 
SDS-PAGE pre-cast gels (Invitrogen) using MOPS-SDS 1X running buffer (0,05 M 
MOPS; 0,05 M Tris; 0,1% (p/v) SDS; 1,025 mM EDTA); a ‘rainbow’ pre-stained 
protein marker (LC5800, Invitrogen) was loaded alongside to gel samples for 
molecular weight analysis. Next, proteins were transferred to Hybond-P 
membranes (Amersham Pharmacia Biotech, Piscataway, NJ) activated by rinsing 
30’’ in Methanol followed by 30’’ in ddH2O. Protein transfer was done overnight in 
the cold room, using transfer protein buffer (25 mM Tris; 200 mM glycine; 20% 
(v/v) methanol) and assembling the so-displaced following elements (all soaked in 
transfer buffer) in the Western transfer machine (X-Cell II Blot Module from 
Invitrogen): 3 Whatman filter papers (Bio-Rad 170-39-32), 2 foams, the gel, the 
activated membrane and 3 Whatman filter papers plus 2 foams on top of this 
‘transfer sandwich’. The next day, membranes were pre-blocked using a blocking 
solution of 5% (p/v) Blocking Agent (Amersham Biosciences) in Tris/Tween-20 
buffer (Tween/Tris buffered saline, T/TBS; 25 mM Tris; 0,15 M NaCl; 0,1% (v/v) 
Tween-20; pH 7.2). Membranes were then incubated over night in the cold room 
with the indicated western blotting antibodies (please see Table 1 below) diluted in 
blocking solution, followed by 3 washes of 15’ each in T/TBS and incubation with 
secondary anti-mouse or anti-rabbit antibody (diluted 1:3000) in blocking solution 
for 1 hour at room temperature. Membranes were then rinsed 3 times 15’ in 
T/TBS, incubated for 5’ at room temperature with ECL Plus Western detection 
reagents (Amersham Pharmacia Biotech) and transferred into an autoradiography 
cassette. Time course exposures with x-ray films were executed followed by 
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automatic development. Prior to re-probing with different antibodies, membranes 
were stripped at 37°C in agitation using Restore™ Western Blot Stripping Buffer 
(Thermo Scientific), followed by extensive washing in T/TBS buffer for 60’. Table 2 
shows primary antibodies used for Western Blot analysis.  
 
 
Table 2: Signalling antibodies used in Western Blot applications  
 
Protein 
Target 
Molecular 
Weight 
Origin and 
Isotype 
Dilutio
n Producer 
p-
Akt1/2/3  
(Ser 473) 
p-Akt 1: 60 
kDa 
p-Akt 2: 56 
kDa 
p-Akt 3: 60 
kDa 
Rabbit 
Polyclonal 
Antibody – IgG 
1:200 
Santa Cruz 
Biotechnology, 
inc. 
p-
Akt1/2/3   
(Thr 308) 
p-Akt 1: 60 
kDa 
p-Akt 2: 56 
kDa 
p-Akt 3: 60 
kDa 
Rabbit 
Polyclonal 
Antibody – IgG 
1:200 
Santa Cruz 
Biotechnology, 
inc. 
Akt 1 62 kDa 
Mouse 
Monoclonal 
Antibody – IgG1 
1:200 
Santa Cruz 
Biotechnology, 
inc. 
p-AMPK-
α 
(Thr172) 
62 kDa 
Rabbit 
Polyclonal 
Antibody – IgG 
1:1000 Cell Signaling Tech. 
AMPK-α  62 kDa 
Rabbit 
Polyclonal 
Antibody – IgG  
1:1000 Cell Signaling Tech. 
β-actin 42 kDa 
Rabbit 
Polyclonal 
Antibody – IgG 
1:200 
Santa Cruz 
Biotechnology, 
inc. 
        
DLG1  110 kDa 
Rabbit 
Monoclonal 
Antibody – IgG 
1:200 
Santa Cruz 
Biotechnology, 
inc. 
GAPDH 38 kDa 
Rabbit 
Polyclonal 
Antibody – IgG 
1:200 Cell Signaling Tech. 
Histone 
H1      33 kDa 
Mouse 
Monoclonal 
Antibody – IgG2a 
1:200 Abcam 
GAPDH 38 kDa 
Rabbit 
Polyclonal 
Antibody – IgG 
1:200 Cell Signaling Tech. 
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LAT 38 kDa 
Rabbit 
Polyclonal 
Antibody – IgG 
1:1000 Cell Signaling Tech. 
Lck 56 kDa 
Rabbit 
Polyclonal 
Antibody – IgG 
1:1000 Cell Signaling Tech. 
MKK3 40 kDa 
Rabbit 
Polyclonal 
Antibody – IgG 
1:1000 Cell Signaling Tech. 
MKK6 36 kDa 
Rabbit 
Polyclonal 
Antibody – IgG 
1:1000 Cell Signaling Tech. 
  p-MKK3/6 
(Ser189/ 
Ser207) 
p-MKK3: 
40 kDa 
p-MKK6: 
41 kDa 
Rabbit 
Polyclonal 
Antibody – IgG 
1:1000 Cell Signaling Tech. 
p-p38 
(Thr180/ 
Tyr182) 
38 kDa Rabbit Polyclonal Antibody – IgG 1:1000 
Cell Signaling 
Tech. 
 
Total p38-α 
 
38 kDa Rabbit Polyclonal Antibody – IgG 1:1000 
Cell Signaling 
Tech. 
 
p-p38 (Tyr 
323) 
 
38 kDa Rabbit Polyclonal Antibody – IgG 1:1000 
ECM-
Biosciences 
      PP2A-
α/β 36 kDa 
Rabbit Polyclonal 
Antibody – IgG 1:200 
Santa Cruz 
Biotechnology, 
inc. 
p-PP2A 
(Thr307) 36 kDa 
Rabbit Polyclonal 
Antibody – IgG 1:200 
Santa Cruz 
Biotechnology, 
inc. 
PLC-γ1 155 kDa Rabbit Polyclonal Antibody – IgG 1:1000 
Cell Signaling 
Tech. 
SLP-76 76 kDa Rabbit Polyclonal Antibody – IgG 1:1000 
Cell Signaling 
Tech. 
TAB1 
TAB1-α: 60 
kDa 
TAB1-β: 50 
kDa 
Mouse Monoclonal 
Antibody – IgG1 1:1000 
Cell Signaling 
Tech. 
TAK1 78-82 kDa Rabbit Polyclonal Antibody – IgG 1:1000 
Cell Signaling 
Tech. 
TERT 120 kDa Rabbit Polyclonal Antibody – IgG 1:200 
Santa Cruz 
Biotechnology, 
inc. 
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TRAF6 60 kDa Rabbit Polyclonal Antibody – IgG 1:1000 
Cell Signaling 
Tech. 
Zap70 70 kDa Rabbit Polyclonal Antibody – IgG 1:1000 
Cell Signaling 
Tech. 
 
 
2.2.3 Immunoprecipitation  
For co-immunoprecipitation analysis, cell lysates were prepared by incubating 
samples 30’ on ice with 200 µl of ice-cold HNGT buffer (50 mM HEPES, pH 7.5, 
150 mM EDTA, 10 mM sodium pyrophosphate, 100 mM sodium orthovanadate, 
100 mM sodium fluoride, 10 mg/mL aprotinin, 10 mg/mL leupeptin and 1 mM 
phenylmethylsulfonyl fluoride), followed by ultra-centrifugation (13000 rpm, 20’) to 
collect protein content in fresh eppendorf tubes. Lysates from 20 × 106 primary 
human relatively undifferentiated CD27+CD28+ CD4+ T cells were then incubated 
overnight at 4 °C on a rotary shaker with 10 µl of antibody to either TAB1 or p38 
(both from Cell Signaling); for the minor CD28−CD27− CD4+ T cell subset, cells 
from two separate donors were pooled to obtain sufficient cells for analysis.  
Extracts were incubated for 3 h at 4 °C with 10 µl of protein A–protein G–
conjugated agarose beads (Santa Cruz Biotechnology) that were previously 
washed by ultra-centrifuging at 7000 rpm 5’ in 200 µl of HNGT buffer (plus 1x 
protein and phosphatase inhibitor cocktails) and resuspended 1:1 in HNGT buffer. 
Next, samples were washed 3 times in HNGT buffer plus 1x protein and 
phosphatase inhibitor cocktails (both from Millipore) and were then analyzed by 
immunoblotting as per Western Blot analysis. Co-immunoprecipitated proteins 
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were detected with mouse anti-rabbit IgG (conformation-specific antibody; L27A9; 
Cell Signaling) or mouse antibody to rabbit IgG light chain (L57A3; Cell Signaling), 
followed by a secondary anti-mouse IgG antibody (7076; Cell Signaling) and ECL 
Prime Western detection kit (GE Healthcare). 
 
2.2.4 In vitro kinase Assay 
Proteins were immunoprecipitated with anti-TAB1 or anti-p38 as described above. 
Samples were washed by ultra-centrifugation (8000 rpm, 7’), twice in lysis buffer 
and twice in kinase buffer (both from Cell Signaling) supplemented with 1x protein 
and phosphatase inhibitor cocktails (both from Millipore). Kinase reactions were 
performed in 50 µl final volume and incubated for 30 min at 30 °C in the presence 
or absence of 200 μM ATP (Cell Signaling). In some experiments, the ATP 
competitor and allosteric p38 inhibitor SB-203580 (10 μM) was added directly to 
the in vitro kinase reaction. Total p38 and p38 phosphorylated at Thr180 and 
Tyr182 were detected by enzyme-linked immune-absorbent assay with a 
Phospho-Tracer ELISA Kit (Abcam), described below. In vitro kinase assays are 
presented as proportional to the absorbance at 450 nm. 
 
2.2.5 Phospho-Tracer ELISA-based analysis of p38 MAPK 
An antibody mix was prepared by adding Capture Antibody Reagent to p-p38 
(Thr180/Tyr182) and Detection Antibody Reagent (both provided with the Phospho 
Tracer kit by Abcam), in a 1:1 ratio, and 50 µl of this antibody mix were added to 
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the in vitro kinase reaction product (50 µl), loaded in the Phospho Tracer micro-
plates. Antibody binding was then allowed for 1 hour at room temperature on a 
micro-plate shaker. Wells were rinsed three times with 200 µl of 1 X washing 
buffer (provided with the kit). Meanwhile, a substrate mix was prepared, 
immediately before use by diluting 1:100 the HR-substrate 10-Acetyl-3, 7- 
dihydroxyphenoxazine (ADHP) with ADHP Dilution Buffer (both provided with the 
kit), a stabilized H2O2 solution. Next, 100 µl of this substrate mix were added to 
each well, and incubated 10’ at room temperature on a micro-plate shaker for 
colour development. The reaction of conversion of ADHP into the fluorescent 
molecule Resorufin was then stopped by adding 10 µl of stop solution to each well. 
Signal was read using an Elisa reader micro-plate. 
2.2.6 Rapid Extraction of DNA-binding proteins 
Pellets from 5 x 106 T cells were used for separation of cytosolic and nuclear 
protein contents. The lysis was performed for 10’ on ice in 200 µl of buffer A (10 
mM Hepes-KOH, pH 7.9; 1,5 mM MgCl2; 10 mM KCl; 0,5 mM (DTT); 0,2 mM 
Phenilmethanesulphonylfluoruride (PMSF)) plus 1X protease (Amersham 
Biosciences) and 1X phosphatase inhibitors (Pierce, Rockford, IL). Samples were 
then ultra-centrifuged for 10’’ at 13000 rpm at 4°C, followed by collection of the 
(cytosolic) supernatant fraction in fresh eppendorf tubes. The pellet was then 
resuspended in 100 µl of buffer C (20 mM Hepes-KOH, pH 7.9; 420 mM NaCl; 1,5 
mM MgCl2; 0,2 mM EDTA; 0,5 mM DTT; 0,2 mM PMSF; 25% (v/v) glycerol) plus 
inhibitors (as above). Samples were incubated for 20’ on ice followed by ultra-
centrifuging at 13000 rpm for 2’. Supernatants (purified nuclear extracts) were then 
collected in fresh eppendorf tubes. The purity of nuclear extracts was assessed by 
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immunoblotting with anti-H1 histone.  
2.2.7 Telomeric Repeat Amplification Protocol (TRAP) Assay 
Telomerase activity was measured using either a radioactive-based TRAPeze 
telomerase detection kit (Chemicon Europe) or the non-radioactive TeloTAGGG 
telomerase ELISA kit (Roche). Lysates from 2 x 103 cells were prepared in 200 µl 
of CHAPS buffer (10 mM Tris-HCl, pH 7.5; 1 mM EGTA; 150 mM NaCl; 1 mM 
MgCl2; 0,25 mM Sodium deoxycholate; 10% (v/v) glycerol; 5 mM β-mercapto-
ethanol; 1% (v/v) Nonidet P-40 (NP-40); 0,5% (p/v) 3-(3-cloro-amminopropil) 
dimethylammonio-1-propanesulfonate (CHAPS); 0,1 mM [4-(2-aminoetil)-benzene 
sulfonyl fluoride hydrochloride] (AEBSF)). Extracts were incubated 30’ on ice, 
followed by ultracentrifugation at 13000 rpm for 20’ at 4°C. Cleared supernatants 
were then either stored at -80°C (for non immediate use) or immediately used as 
described below. For detection of nucleus/cytosol telomerase activity, 
nucleus/cytosol extracts prepared as above described were used. 
For radioactive measurement of telomerase activity, 4 µl of cell extracts were 
mixed to 100 ng of TS - primer, 50 μM of dNTPs and TRAP buffer (20 mM Tris-
HCl, pH 8.3; 68 mM KCl; 1,5 mM MgCl2; 1 mM EGTA). This first reaction was 
incubated at 22° C for 30’ (extension phase) to allow the telomerase-dependent 
extension of the telomeric-like TS primer (5’ - AAT CCG TCG AGC AGA GTT - 3’). 
Next, a PCR mix was made by adding 100 ng of CX-primer, 2 μCi of [α-32P] dCTP 
(DuPont NEN Research Products, Boston, Ma, USA) and 2 units of Taq-
polymerases (DyNAzyme II, Finnzymes) to each sample reaction. Table 3 shows 
the PCR amplification settings applied to the radioactive mix. 
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           Table 3: PCR Settings used in TRAP Assay (radioactive) 
 
This PCR product (40 µl) was mixed to 8μl of 6X DNA loading buffer  (0,25% (p/v) 
bromophenol blue; 0,25% (p/v) xylene cyanol FF; 40% (p/v) sacarose in ddH2O) 
and resolved by electrophoresis on non-denaturing 12% (p/v) poly-acrylamide gels 
(19:1 (p/p) acrylamide: bis-acrylamide). Samples were run for 2 hours at 290 V in 
1X TBE buffer (90 mM Tris-Borate; 2 mM EDTA). Gels were fixed using a solution 
of 0,5 M NaCl, 50% (v/v) ethanol and 40 mM Sodium acetate (pH 4.2) and then 
transferred and incubated with X-ray films (Kodak Rochester, NY) into an 
autoradiography cassette for 72 hours at -80°C. 
For non-radioactive measurements of telomerase activity, 4 µl of cell extracts were 
mixed to 25 µl of ready-to use PCR Reaction mixture (provided with the kit), and 
sterile water was added up to 50 µl final volume. Tubes were then transferred to a 
thermal cycler to perform combined primer elongation/amplification PCR reactions 
by the following protocol (Table 4): 
 
Denaturation Annealing Synthesis  
94°C 50°C 72°C 4°C 
30’’ 30’’ 1’ ∞ 
× 30 cycles  
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Table 4: PCR Settings used in TRAP Assay (non-radioactive) 
 
Next 5 µl of the amplification product were added to 20 µl of kit-provided 
Denaturation reagent and incubated for 10’ at 20°C. This denaturated biotynilated 
telomere-amplicons were then hybridized to digoxigenin (DIG)-labeled, telomeric 
repeat-specific detection probes by adding 225 µl of Hybridization Buffer and 
transferring 100 µl of this reaction mixture to streptavidin coated micro-plates (both 
provided with the kit). The biotin-streptavidin binding was allowed for 2 hours on a 
micro-plate shaker at 37°C. Next, micro-plates were extensively washed 3 times 
using 250 µl of 1X-washing solution per well (provided with the kit). The 
abundance of DIG-labeled telomere-amplicons bound to micro-plates was 
detected by adding to micro-plates 100 µl of (ddH2O-reconstituted) anti 
digoxigenin-antibody conjugated to peroxidase, followed by micro-plate shaking for 
30’ at 20°C. Plates were rinsed by washing 5 times with 250 µl of 1X-washing 
solution and coloured-substrate development was then allowed by adding 100 µl 
    
Time 
 
Temperature 
  
Cycles 
Primer 
elongation 10-30’ 25°C 1 
Telomerase 
inactivation 5’ 94°C 1 
Amplification: 
Denaturation 
Annealing 
Polymerization 
 
30’’ 
30’’ 
90’’ 
 
94°C 
50°C              
72°C 
30 
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of TMB substrate per well and incubating for 10-20’. Reactions were terminated by 
adding 100 µl stop solution (provided with the kit) per well and read on an ELISA 
reader as absorbance emission at 450 nM.  
 
2.2.8 Electrophoretic Mobility Shift Assay (EMSA) 
Nuclear extracts were obtained as above described. Five (5) µl of extracts were 
incubated with 30,000 cpm [32P]γ-ATP (Amersham Biosciences) end-labeled 
oligonucleotides. The radioactive labelling reaction was performed in T4 kinase 
buffer (10 mM MgCl2; 70 mM Tris-HCl, pH 7.6; 5 mM DTT) in the presence of 5 
units of T4 kinase, 3,5 pmol of oligonucleotide and 10 μCi of [γ-32P] ATP (DuPont 
NEN Research Products, Boston, Ma, USA). The reaction was incubated for 1 
hour at 37°C and then terminated by adding 50 mM EDTA and the so-labelled 
oligonucleotide was resuspended in TE buffer (10 mM Tris HCl, pH 8.0; 1 mM 
EDTA).  
Extracts were incubated with 1,75 pmol of radioactive labeled oligonucleotide 
(either the sequence corresponding to 2184 to 2161 bp of the hTERT promoter 
containing the putative E2F site (59–CGCCCAG- GACCGCGCTCCCCACGT–39) 
or with a commercially available oligonucleotide containing a NF-kB consensus 
sequence (obtained from Promega). Reactions were performed in a 10 mL volume 
for 20 min at room temperature in a buffer consisting of 5 mg/ml poly 
(deoxyinosinic-deoxycytidylic) acid, 10 mM Tris–HCl, 50 mM NaCl, 0.5 mM DDT, 
0.5 mM EDTA, 1 mM MgCl2, and 4% glycerol (pH 7.5; Promega). Samples were 
stained using 10X-gel loading buffer (250 mM Tris HCl, pH 7.5; 0,2% (p/v) 
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bromophenol blue (BBF); 40% (v/v) glycerol), and Protein–DNA complexes were 
resolved by electrophoresis on non-denaturing 5% (p/v) poly-acrylamide gels. Gels 
were run at 350 V for 20’ in 0,5 X TBE buffer, dried by vacuum-pumping and 
transferred and incubated with X-ray films (Kodak Rochester, NY) into an 
autoradiography cassette for 18 hours at -80°C. 
 
2.2.9 Cloning 
Dr. David Escors kindly provided the p-SIREN/HIV-1 lentivector for gene 
knockdown. The following shRNA sequences that were previously described (Ge 
et al., 2003; Tangeman et al., 2012) were introduced into this vector: 
CCTAAGGTTAAGTCGCCCTCG (shCtrl), GGCGGTCCTTCTCAACAACAAG 
(shTAB1) and ATGATGTCAGATGGTGAATTT (shAMPK-α).  
First, 10 µg of p-SIREN/HIV-1 vector were digested with 10 units of both BaMH1 
and EcoR1 restriction enzymes (Promega) in 1X-buffer D (Promega), in a final 
reaction volume of 40 µl. The reaction was incubated at 37° C for 2 hours, then 
stained with 10 µl of DNA loading buffer and run (20’, 90 mV) by electrophoresis 
for purification (1% agarose gel in 1X Tris/Borate/EDTA (TBE) buffer and 1:1000 
ethidium bromide). A Hyper Ladder was also loaded for size analysis (Bioline 
33025). The digestion product was then visualized using a UV-trans-illuminator 
(Amersham Biosciences) and excised from the gel. The DNA in gel was 
solubilized in 500µl of Buffer QC (Quiagen) at 55°C and purified by 
chromatography (DNA purification kit, Quiagen). The column was ultra-centrifuged 
at 13000 rpm for 1’ and then rinsed with 500 µl Washing Buffer PE (Quiagen). 
Next, the column was ultra-centrifuged twice as above. DNA was eluted from the 
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column using 30 µl pre-warm Elution Buffer EB.  
To insert the shRNA sequences in digested p-SIREN/HIV-1 lentivector, 2 parallel 
reactions were set up. In the ligation reaction, 4 µl of digested vector were mixed 
to 4 µl of shRNA nucleotide (bearing specific flanking sequences for integration in 
BaMH1/EcoR1 digested DNA) and 1 µl of T4 kinase. In the control reaction, 4 µl of 
ddH20 was added instead of any insert. Reactions were left for 60’ at room 
temperature or overnight at 16°C.  
 
2.2.10 Transformation 
Tubes containing HB101 competent bacteria (MCLAB) were thawed on ice for 20’. 
Next, either control or ligation reactions were added to bacteria. Bacteria were 
transformed by thermic shock, incubating 2’ at 37°C followed by 2’ on ice. Bacteria 
were grown over night at 37° C on LP-Ampicillin agar plates (0,1 mg/mL, Sigma 
Aldrich). The day after, any bacteria grown in the control plate was considered as 
a background (as the lentivector bearing an ampicillin resistant gene is not 
functional upon digestion, control transformed bacteria should not grow on 
ampicillin treatment). 
2.2.11 Mini-Prep 
For bacterial clone analysis, between 5-10 individual clones (depending on control 
background) were expanded by mini prep and then sent for sequencing. For mini 
prep a standard protocol was used, provided with the Quiagen mini-prep kit. 
Briefly, bacteria were grown overnight at 37°C in agitation in 15 mL falcon tubes 
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containing 4 mL of LB-medium plus Ampicillin (1:1000). The next day, samples 
were centrifuged for 30’ at 3000 rpm and the bacterial pellets were resuspended in 
250 µl of Buffer P1 (additionated with RNaseA). After addition of 250 µl Lysis 
Buffer P2, tubes were gently mixed by inversion, to avoid genomic DNA 
contamination, and incubated for 5’ at room temperature. Next, DNA was 
precipitated by adding 350 µl of Buffer N3. Samples were centrifuged at 13000 
rpm for 10’. Supernatants containing non-genomic DNA were filtered on Whatman 
paper through DNA chromatography columns. Columns were rinsed with 750 µl of 
Buffer PE (with Ethanol), centrifuged twice, and DNA was eluted by adding 50 µl 
pre-warm Buffer EB. DNA purity was assessed by nano-drop; DNA preparations 
were considered pure when A260/A280 was equal or above 1.8. The purified 
lentiviral vector preparations were then sent to the UCL sequencing facility to 
assess presence of the desired shRNA.  
 
2.2.12 Transfection and Lentiviral Titration 
HEK 293 cells were seeded in T75 tissue culture flasks using 10 mL Dulbecco’s 
Modified Eagle Medium (DMEM) additionated with 10% FCS, 100 U/ml penicillin 
and 2mM L-glutamine (all from Invitrogen), and then cultured at 37°C in a 
humidified 5% CO2 incubator. When cells were 80% confluent, old medium was 
replaced with 10 mL fresh medium and cells were transfected by Fugene-6 
(Promega). 
For transfection, 1.5 µg of 8.91 plasmid DNA (encoding for gag/pol structural HIV-
1 proteins), 1.5 µg of pMDG construct (encoding for VSV-g envelope proteins) and 
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2.3 µg of lentiviral transfer vector (encoding for both GFP fluorescent protein and 
the above-cloned specific shRNA) were added in an eppendorf tube along with 
ddH2O water in a final volume of 50 µl. In a separate eppendorf tube, 27 µl of 
Fugene 6 liposome transfection reagent were slowly added to 200 µl OPTIMEM 
medium (Lonza). Next, the DNA mix was added to OPTIMEM/Fugene 6, incubated 
for 15’ at room temperature, and then added drop-wise to HEK 293 cells. Cells 
were left growing at 37° C and lentiviral supernatants were collected and stored at 
4° C 24 hours later, when fresh medium was added back on cells. This operation 
was repeated twice until 72 hours post-transfection, at which time supernatants 
were filtered, mixed together and ultra-centrifuged (25000 rpm at 4°C) by layering 
on 5 mL of a 20% sucrose cushion in D-PBS in centrifuge tubes (Beckman 
Coulter), followed by re-suspension in 100 µl D-PBS lentiviral stocks and storage 
at -80° C for future use. 
To titrate the lentiviral vector preparations, HEK 293 cells (5 x 105) were 
resuspended in DMEM medium and seeded in 6 well plates. The next day, cells 
were transduced with 1, 2 or 4 µl of 100-fold concentrated viral preparations and 
left growing at 37° C. Three days post-transduction, GFP expression was analyzed 
by flow cytometry using the following formula: 
                       
(%GFP+ cells) x (transduced cells)/volume of virus (mL) 
 
Assuming that there is a linear correlation between infecting viral units and 
transduced cells up to 30% transduction (that is, 1 cell infected by only an 
individual viral particle), it was possible to estimate the multiplicity of infection 
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(MOI) as the amount of viral units required to infect a cell population (for instance, 
an MOI of 10 indicates that 10 viral particles are required to infect a single cell in 
culture). Titres obtained were elevated, comprised between 108-109 lentiviral 
units/mL. 
 
2.2.13 RNA isolation 
Pellets from 5 x 105 cells were resuspended using 750 µl of TRIzol (Invitrogen). 
Lysates were obtained by gently pipetting up and down several times, followed by 
ultracentrifugation at 12,000 rpm at 4°C for 10’. Supernatants were transferred to 
fresh tubes for the following Phase Separation. Briefly, 200 µl of chloroform were 
added to the samples, shaked for 15’’ and then incubated 10’ at room temperature. 
Samples were then centrifuged at 12,000 rpm for 15’ at 4°C. This allowed 
separation of the RNA content within the aqueous phase solution on the top layer, 
which was then placed in a new tube for the next RNA Isolation Procedure. Next, 
500 µl of Isopropanol were added to the aqueous RNA phase and incubated for 
10’ at room temperature. Samples were centrifuged at 12,000 rpm for 10’ at room 
temperature. The RNA pellet was then washed using 1 mL of 75% Ethanol, then 
centrifuged at 7,500 rpm for 5’ at 4°C. The pellet was air-dried for 10’, followed by 
resuspension in RNAase-free water (100 ng/mL) and incubated in a heat block set 
at 55°C for 10’ to allow full resuspension.  
 
2.2.14 Real Time PCR 
RNA extracts (1 µg/sample) were analysed by Real Time PCR using Taqman 
probe technology. For cDNA synthesis, 1 µl of either random primers (100 µg/mL) 
or oligo dTs and 1 µl of dNTPs (10 mM)	were added to each RNA sample. Total 
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RNA was then heated at 70°C for 6’ (to allow annealing of the random primers to 
the RNA) then quickly incubated on ice for additional 10’. Next, the reaction mix 
was prepared using the following reagents for each RNA sample: 4 µl of 5 x 
reaction buffer, 2 µl of DTT, 1 µl of Recombinant RNAse inhibitor and 1 µl MMLV 
Reverse Trancriptase. The cDNA synthesis reaction was then allowed for 1h at 
42°C. To stop the process, samples were then incubated for 5’ at 65°C. Finally, 
DEPC-treated water was added to a final volume of 100 µl. For gene target 
analysis, a master mix for each sample was prepared as it follows: 10 µl of 
Taqman universal PCR mix, 0.2 µl of Forward/Reverse Primers (900 nM), 0.05 µl 
of Taqman probes (250 nM) and 4.1 µl of H2O. This Master solution was 
transferred to a 96 well-plate then incubated with 5 µl of cDNA samples to be 
analysed (in triplicate). The following probes were used: p38 (Hs00176247_m1), 
AMPKα_(Hs01562315_m1), TAB1 (Hs00196143_m1) and hTERT 
(Hs00972656_m1) (all from Applied Biosystems). GAPDH was used as a 
housekeeping control. The reaction was read using an AbiPrism 7700 sequence 
detector, set as in Table 5. 
 
   Table 5: Settings used in Real Time PCR applications 
 
Incubation 
 
2’ 
 
25°C 
 
1 x 
Ampli Taq Gold 
activation 
 
10’ 
 
95°C 
1 x 
 
PCR 
15’’ 
 
1’ 
          92°C 
      (denature) 
60°C 
(anneal/extend) 
 
 
40 x 
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After amplification, relative target expression among samples (normalized to that 
of the housekeeping GAPDH) was quantified using the ΔΔCT method, where CT 
(threshold cycle) is the cycle at which there is a statistically significant 
fluorescence emission of the Taqman probe over the background.  
 
2.2.15 Measurement of telomere length  
Telomere length of senescent human CD27- CD28- CD4+ T cells was measured 
using a fluorescence in situ flow-cytometry method, four weeks after transduction. 
First a 2 mM BS3 solution was made immediately before use by resuspending a 
BS3 powder aliquot into 1750 µl of PBS final volume. Cell were resuspended in 
100 µl of PBS and 100 µl of BS3 solution, to obtain a final concentration of 1 mM, 
vortexed and then incubated for 30’ in the fridge. This fixation step was then 
quenched by adding 1 ml of 50 mM PBS Tris (pH7.2) solution directly to the 
samples, followed by incubation in the dark at RT for 20’, and final wash in PBS. 
For the hybridization reaction, samples were vortexed in the presence of 1 ml 
hybridization solution, centrifuged at 2000 rpm for 7’ and then resuspended in 300 
µl of hybridization solution. Samples were then splitted into 3 different tubes, used 
as replicates. Next, 5 µl of telomere-Cy5 conjugated probe was diluted by adding 
45 µl of sterile water and 3 µl of the diluted probe were further diluted with 97 µl 
hybridisation solution per tube. (Make in bulk and then distribute 100 µl to each 
tube). Samples were vortexed, incubated for 10’ at 82 degrees in the water bath 
and then refrigerated on ice water. Finally, samples were incubated for 60’ in the 
dark, washed twice in 1 ml post-hybridization solution and twice in PBS, then 
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immediately analzyed by flow-cytometry. The tables below summarizes recipes for 
both hybridization (Table 6) and post-hybridization (Table 7) solutions used: 
 
Table 6: Hybridization solution  
Formamide 7ml 10.5ml 14ml 
Tris. HCl 0.2ml of 1M stock 0.3ml of 1M stock 0.4ml of 1M stock 
BSA 2.5ml of 4% stock 3.75ml of 4% 
stock 
5ml of 4% stock 
NaCl 0.3ml of 5M stock 0.45ml of 5M 
stock 
0.6ml of 5M stock 
TOTAL VOL 10ml 15ml 20ml 
 
Table 7: Post-Hybridization solution 
Formamide 7ml 14ml 28ml 
Tris. HCl 0.1ml of 1M 
pH7.2 
0.2ml of 1M 
pH7.2 
0.4ml of 1M 
pH7.2 
BSA 0.25ml of 4% 
stock 
0.5ml of 4% stock 1ml of 4% stock 
Tween20 0.1ml of 10% 
stock 
0.2ml of 10% 
stock 
0.4ml of 10% 
stock 
NaCl 0.3ml of 5M stock 0.6ml of 5M stock 1.2ml of 5M stock 
H2O 2.25ml 4.5ml 9ml 
 
 
2.3 Statistical analysis  
Graphpad Prism was used for statistical analysis. For pairwise comparisons, a 
paired Student’s t-test was used. For three matched groups, a one-way ANOVA 
for repeated measures using a Bonferroni post-test correction. Differences with a 
P value of <0.05 were considered significant. 
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Chapter III: IFN-α inhibits telomerase in human CD8+ T cells by both 
hTERT down-modulation and induction of p38 MAPK signalling 
 
3.1 Background and rationale 
Telomerase activity confers antigen-specific T cells the ability of long-term 
proliferation. Thus, lack of telomerase activity in human highly differentiated 
(senescent) T cells is associated with very short telomeres and low proliferative 
rates (Akbar and Vukmanovic-Stejic, 2007). As discussed, loss of telomerase 
activity may be due to both transcriptional and post translational mechanisms, 
including reduced expression of the catalytic sub-unit hTERT, reduced hTERT 
phosphorylation by the signalling kinase AKT and changes in NFkB activity 
affecting both telomerase expression and nuclear import (Figure 8). IFN-α is a 
type I interferon that is an anti-viral and immune-modulatory cytokine that inhibits 
telomerase activity in T cells (Reed et al., 2004) but the mechanisms for this 
inhibition are not known. IFN-α  also induces loss of both CD27 and CD28 co-
stimulatory receptors (Fletcher et al., 2005), hallmark of human highly 
differentiated T cells that exhibit features of replicative senescence. Because type I 
IFN has been described to activate senescence related signalling pathways in 
human fibroblasts (Campisi and d’Adda di Fagagna, 2007), the mechanisms of T 
cell telomerase down-regulation by IFN-α may resemble those spontaneously 
occurring in human senescent T cells. In support of this idea, p38 MAP kinase, a 
key molecule downstream of IFN-α receptor signalling, was recently shown to 
inhibit telomerase activity and proliferation in both senescent human CD4+ and 
CD8+ T cells (Henson et al., 2014; Di Mitri et al., 2011). However, it is not known if 
IFN-α inhibits telomerase activity by one or more of these pathways. Thus, I 
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sought to investigate the mechanisms of T cell telomerase down-regulation by 
IFN-α. Figure 10 illustrates potential mechanisms of hTERT down-modulation by 
IFN-α in T cells that are herein investigated.  
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Figure 10: IFN-α mediated telomerase down-regulation. IFN-α may inhibit 
telomerase activity in T cells by both inactivating activatory pathways (red arrows) 
or activating inhibitory pathways (green arrows). The role of each individual 
pathway in telomerase regulation is further discussed in the text. This may offer a 
prototype model for understanding the mechanistic bases of hTERT modulation in 
lymphocytes.  
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3.2 IFN-α down-regulates telomerase activity of human CD8+ T cells 
Telomerase activity can be measured using an assay known as TRAP assay 
(Cong et al., 2002). To confirm that IFN-α inhibited telomerase activity in primary 
human T lymphocytes, CD8+ T cells were isolated from peripheral blood and then 
activated by αCD3 and rhIL-2, either in the presence or absence of increasing 
doses of IFN-α (50 or 500 U/mL). After 72 hours of activation, CD8+ T cells were 
counted, washed and lysed to extract total protein content. Figure 11 a shows that 
although telomerase activity is increased in activated primary human CD8+ T cells, 
IFN-α down-regulates this activity in a dose dependent manner in these cells.  
Results from 3 different donors corroborated these findings (Figure 11 b). 
Importantly, telomerase down-regulation by IFN-α was not due to cytotoxic effects 
because CD8+ T cell survival was not affected by IFN-α even at the highest 
concentration tested (Figure 11 c). Therefore, 500IU of IFN-α was used for further 
experiments. 
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Figure 11: IFN-α inhibits telomerase activity in human CD8+ T cells.  
(a) Measurement of CD8+ T cell telomerase activity by TRAP assay. Human CD8+ T cells were 
isolated from peripheral blood by immunomagnetic beads and then activated by αCD3/rh-IL2 for 72 
hours either in the absence or in the presence of increasing doses (50 or 500 U/mL) of IFN-α. 
Extracts from 2 x 103 cells were analysed by a radioactive based TRAP assay to assess 
telomerase activity in samples. The multi-ladder profile shown was resolved on a non-denaturing 
polyacrylamide gel. (b) Pooled results of band intensity from 3 separate experiments performed as 
in (a) quantified by bi-dimensional densitometry and presented as arbitrary units. (c) Survival of 
human CD8+ T cells cultured as in (a) assessed by trypan blue exclusion test assay, presented 
relative to that un-stimulated cells, set as 1. Error bars indicate SEM throughout; in (b) a one-way 
analysis of variance (ANOVA) for repeated-measures with a Bonferroni post-test correction. *p< 
0,05,   
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3.3 IFN-α down-regulates both hTERT transcription and translation   
The control of the expression of the catalytic sub-unit hTERT is the main 
mechanism for molecular tuning of telomerase (Cong et al., 2002). To investigate if 
IFN-α inhibits T cell telomerase activity by hTERT down-regulation, both hTERT 
transcription and translation were assessed in human CD8+ T cells activated by 
αCD3 and rh-IL2 for 24 hours, either in the presence or absence of IFN-α. To 
measure hTERT transcripts, activated human CD8+ T cells were analysed by RT-
PCR using a specific TaqMan probe to hTERT. The housekeeping beta actin gene 
was used as an internal control. IFN-α was found to inhibit hTERT transcription, 
normalized to that of the housekeeping beta-actin gene (Figure 12 a).  
To study if reduced hTERT transcription by IFN-α resulted in reduced hTERT 
translation, human CD8+ T cells cultured in identical conditions were analysed by 
Western Blot. Immunoblotting analysis showed that IFN-α (500 U/mL) inhibited 
hTERT protein expression in activated human CD8+ T cells (Figure 12 b). The 
densitometric ratio of band intensity of hTERT versus that of the housekeeping 
control beta-actin from 3 different donors confirmed these findings (Figure 12 c). 
Thus, the inhibition of telomerase activity by IFN-α in activated human CD8+ T 
cells is associated with down-regulation of both hTERT transcription and 
translation.  
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Figure 12: IFN-α  down-regulates hTERT expression in human CD8+ T cells. 
(a) Measurement of hTERT mRNA expression by Real-time PCR in human CD8+ T cells activated 
by αCD3 and rh-IL2 for 24 hours, either in the presence or absence of IFN-α (500IU). mRNA from 
activated T cells were retro-transcribed to cDNA and amplified with TaqMan probes to either 
hTERT or beta-actin as an housekeeping control; hTERT levels were normalized using the ΔΔ−CT 
algorithm working out the differential expression between hTERT and the housekeeping beta-actin 
gene as described in Material and Methods. Samples for quantitative PCR were analyzed from 3 
different donors. (b) Representative immunoblots of hTERT and beta-actin expression (as a 
loading control) from CD8+ T cells activated as in (a) for 36 hours. (c) The relative protein 
expression of hTERT normalized to that of housekeeping beta-actin from 3 different experiments 
performed as in (b). Band intensity calculated by bi-dimensional densitometry and presented 
relative to that of un-stimulated control, set as 1, is shown. Error bars indicate SEM throughout; in 
(a) a Student’s t test for paired measurement was used; in (c) a one-way analysis of variance 
(ANOVA) for repeated-measures with a Bonferroni post-test correction. **p< 0,01 
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3.4 IFN-α  inhibits telomerase in both cytosol and nucleus of CD8+ T cells 
I next sought to determine in which subcellular compartment IFN-α negatively 
regulated CD8+ T cell telomerase. CD8+ T cells were activated as described above 
either in the presence or absence of IFN-α for 72 hours, then lysed and 
fractionated to separate either cytosolic or nuclear protein content (see Materials 
and Methods). Cell extracts were then assessed by TRAP assay, which showed 
that IFN-α down-regulated telomerase activity in both the cytosol and nucleus of 
activated CD8+ T cells (Figure 13 a). Results from 3 independent experiments 
corroborated these findings (Figure 13 b). To determine if reduced cytosolic and 
nuclear telomerase activity in activated CD8+ T cells was linked to reduced hTERT 
protein expression in both cell compartments, Western Blot-based experiments 
were run. Immunoblotting analysis demonstrated reduced hTERT protein 
expression in both cytosol and nucleus of activated human CD8+ T cells (Figure 
13 c). For densitometric analysis, the housekeeping genes beta-actin and histone 
H1 were used for measurement of either cysolic or nuclear hTERT protein content 
respectively; this resulted in a strong reduction of hTERT expression in both 
subcellular compartments (Figure 14 d).  
Thus, IFN-α inhibits telomerase activity in both the cytosol and nucleus of 
activated CD8+ T cells and this is associated with reduced hTERT expression in 
both subcellular compartments.  
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Figure 13: IFN-α  inhibits telomerase in cytosol and nuclei of CD8+ T cells. (a) 
Measurement of CD8+ T cell telomerase activity by TRAP assay. Human CD8+ T cells were 
activated by αCD3 and rh-IL2 for 72 hours, either in the presence or absence of IFN-α (500IU). 
Cytosolic and nuclear extracts from 2 x 103 cells were purified as described in Materials and 
Methods and telomerase activity in samples was assessed as in Figure 11 a. (b) Pooled results of 
either (left) cytosolic or (right) nuclear telomerase related activity band intensity from 3 separate 
experiments performed as in (a) quantified by bi-dimensional densitometry and presented as 
relative to un-stimulated control, set as 1. (c) Immunoblots of hTERT expression in cytosolic and 
nuclear protein extracts from activated human CD8+ T cells cultured as in (a) for 36 hours (top); 
(bottom) beta-actin and histone h1 expression from the same gel as cytosol or nuclear protein 
control, respectively. (d) The relative protein expression of either cytosolic or nuclear hTERT 
normalized to that of beta-actin and histone h1 respectively. Band intensity data from 3 different 
experiments performed as in (c) and presented relative to that of unstimulated control, set as 1, are 
shown. Error bars indicate SEM throughout; in (b) a one-way analysis of variance (ANOVA) for 
repeated-measures with a Bonferroni post-test correction; in (d) a paired Student’s t test. *p< 0,05,  
**p< 0,01 
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3.5 IFN-α inhibits hTERT transcription in part by tuning NF-kB and E2F 
activity 
To explore potential transcriptional mechanisms of hTERT down-regulation by 
IFN-α,  EMSA-based experiments were performed to assess the DNA-binding 
activity of CD8+ T cell E2F1 and NFkB transcription factors that regulate hTERT 
transcription (Akiyama et al., 2003; Crowe, 2001). Nuclear protein extracts from 
human CD8+ T cells, activated in the presence or absence of IFN-α for 24 
hours, were incubated with consensus DNA-binding sequences for either the 
transcriptional hTERT repressor E2F1 or the hTERT activator NFkB, that were 
previously labelled in the presence of radioactive [32P]γ-ATP. The resulting DNA-
protein complexes were run on non-denaturing SDS-page gels, which showed that 
IFN-α enhanced the binding of proteins from nuclei of activated CD8+ T cells 
(presumably E2F1) to the specific E2F1-interacting consensus sequence 
extrapolated from the hTERT promoter (Figure 14 a, top line). At the same time, 
IFN-α inhibited the binding of proteins from nuclei of activated CD8+ T cells 
(presumably NFkB) to the specific NFkB consensus sequence (Figure 14 a, 
bottom line); however although NFkB activity is important to induce hTERT 
transcription, the exact NFkB binding site on the hTERT promoter has not been 
identified, suggesting that the interaction may be indirect. These results were 
confirmed in 3 separate experiments (Figure 14 b). Overall these data suggest 
that the documented inhibition of hTERT transcription by IFN-α may be related to 
changes in the activity of both the transcriptional hTERT repressor E2F1 and 
activator NFkB. 
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Figure 14:  IFN-α  modulates E2F1 and NFkB-DNA binding activity. (a) 
Assessment of E2F1 and NFkB DNA binding activity by EMSA assay in nuclei of human CD8+ T 
cells left either untreated or activated by αCD3 and rh-IL2 for 24 hours, in the presence or absence 
of IFN-α (500IU). CD8+ T cell nuclear extracts were incubated with a sequence corresponding to –
184 to –161 bp of the hTERT promoter containing the putative E2F site (5′-
CGCCCAGGACCGCGCTCCCCACGT-3′, top) or a commercially available NF-kB consensus 
oligonucleotide (bottom), both radioactively labelled as described in Materials and Methods. DNA-
protein complexes were then resolved by gel electrophoresis, followed by autoradiography. (b) 
Pooled results of (left) E2F1 and (right) NFkB binding activity from 3 separate experiments 
performed as in (a). Error bars indicate SEM throughout. In (b) a one-way analysis of variance 
(ANOVA) for repeated-measures with a Bonferroni post-test correction. *p< 0,05,  ***p< 0,001 
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3.6 IFN-α  inhibits AKT signalling  
The kinase AKT directly phosphorylates hTERT that is essential for enhancing 
telomerase stability and activity in T cells (Kang et al., 1999). Optimal AKT 
activation requires phosphorylation at Ser473 and Thr308 however defective AKT 
phosphorylation at the Ser473 site is a feature of human highly differentiated T 
cells in which is associated with lack of telomerase activity (Plunkett et al., 2007). 
To study if telomerase down-regulation by IFN-α was also related to impaired T 
cell AKT activity, Western Blot-based experiments using specific antibodies to both 
phosphorylated AKT at Ser473 and Thr308 were performed. Also, an antibody to 
total AKT was used to measure total AKT expression throughout. To measure 
changes in AKT activity by IFN-α, human CD8+ T cells were activated in the 
presence or absence of IFN-α for 24 hours, lysed and analysed by Western Blot 
and the ratio of band intensity of phosphorylated AKT to total AKT was determined 
by densitometric analysis. These experiments showed a strong inhibition of AKT 
phosphorylation at both Ser473 and Thr308 regulatory sites, while total AKT 
expression was not affected,  indicating potent kinase inactivation by IFN-
α (Figure 15 a). Cumulative data from 3 different donors confirmed these results 
(Figure 15 b).  
To explore biochemical mechanisms that may be related to reduced AKT 
signalling, the activation of the phosphatase PP2A that has been shown to inhibit 
AKT activity by inducing de-phosphorylation of the regulatory sites (Li et al., 1997) 
was determined in Western Blot-based experiments. Human CD8+ T cells 
activated and cultured in the presence or absence of IFN-α were lysed and PP2A 
activation was measured using antibodies to both phosphorylated PP2A at Thr307 
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and total PP2A. After 24 hours, IFN-α treatment resulted in both induction of PP2A 
synthesis and reduced PP2A phosphorylation (Figure 15 a). Cumulative data from 
3 separate experiments confirmed these observations (Figure 15 b). Because 
phosphorylated PP2A accounts for the inactive form of the enzyme, the 
densitometric analysis showing reduced ratio of phosphorylated PP2A to total 
PP2A indicated increased PP2A activation by IFN-α. These data suggest that AKT 
that is essential for telomerase activity in T cells may be in part inhibited by IFN-
α via PP2A activation.  
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Figure 15: IFN-α  inhibits AKT and induce PP2A activity in CD8 T cells. (a) 
Immunoblots of p-AKT (Ser473), p-AKT (Thr308), total AKT, p-PP2A (Thr307), total PP2A and beta 
actin (as a housekeeping control gene) assessed from whole extracts of human CD8+ T cells 
activated by αCD3 and rh-IL2 for 24 hours, in the presence or absence of IFN-α (500IU). (b) The 
relative AKT kinase inactivation (top) and the relative PP2A phosphatase inactivation (bottom) 
assessed as ratio of AKT phosphorylation at both Ser473 and Thr308 versus total AKT and 
phosphorylation of PP2A versus total PP2A, respectively. Pooled data of band intensity from 3 
separate experiments performed as in (a) and quantified by densitometric analysis are presented 
as relative to stimulated controls, set as 1. Error bars indicate SEM throughout. In (b) a paired 
Student’s T test was used. *p< 0,05,  **p< 0,01. 
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3.7 IFN-α  inhibits telomerase activity in part via p38 MAPK signaling 
The data so far suggested that IFN-α inhibited telomerase by multiple mechanisms 
but direct evidence linking biochemical changes in signalling pathways and 
inhibition of telomerase activity in T cells required a more direct assessment. Thus, 
the potential involvement of p38 MAPK that is important for IFN-α signaling was 
examined. In Western Blot-based experiments, the addition of IFN-α to activated 
human CD8+ T cells potently induced p38 MAPK phosphorylation at 
Thr180/Tyr182 sites within the p38 activation loop while total p38 expression was 
not affected by IFN-α (Figure 16 a); re-probing membranes with anti beta actin 
confirmed equal protein loading throughout (Figure 16 a). Densitometric analysis 
of phosphorylated p38 to total p38 showed indeed strong p38 MAPK activation by 
IFN-α (Figure 16 b). To directly assess the involvement of p38 MAPK signalling in 
T cell telomerase down-regulation by IFN-α, blocking experiments using the pan-
p38 inhibitor BIRB-796 were performed. Purified human CD8+ T cells were 
incubated with either BIRB 796 at the concentration of 500 nM at which the drug 
does not inhibit other related kinases e.g. JNK (Di Mitri et al., 2011), or DMSO, as 
a vehicle control. The cells were then activated in the presence or absence of IFN-
α for 72 hours. The cells were normalized by counting total cell numbers, lysed 
and analysed by TRAP assay to measure changes in T cell telomerase activity, 
using a non-radioactive variant of the TRAP assay (described in Materials and 
Methods). Using this method that is equivalent to the radioactive version of the 
TRAP assay, p38 MAPK blockade was found to restore telomerase activity in IFN-
α treated human CD8+ T cell extracts (Figure 16 c). Thus, p38 MAPK activation is 
directly involved in the inhibition of telomerase by IFN-α. 
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Figure 16: IFN-α  inhibits telomerase activity via p38 MAPK in CD8+ T  cells 
(a) Immunoblots of p-p38 (Thr180/Tyr182), total p38 and beta actin (as a loading control) assessed 
from whole extracts of human CD8+ T cells activated by αCD3 and rh-IL2 for 24 hours, in the 
presence or absence of IFN-α (500IU). (b) The relative activation of p38 MAPK assessed by ratio 
of phosphorylated p38 to total p38 in 3 separate experiments performed as in (a), and presented as 
relative to that of the stimulated control, set as 1. (c) Assessment of telomerase activity by an 
ELISA-based non-radioactive TRAP assay in human CD8+ T cells activated by αCD3 and rh-IL2 for 
72 hours, in the presence or absence of IFN-α (500IU); p38 kinase activity was directly blocked by 
adding in culture the pan-p38 inhibitor BIRB 796 (500nM) as indicated. Extracts from 2 x 103 cells 
were analysed as described in Materials and Methods. Telomerase activity generated a colour 
metabolite detected at 450 nM by an ELISA reader; pooled data from 3 separate experiments are 
expressed as fold change over stimulated control, set as 1. Error bars indicate SEM throughout. In 
(b) a paired Student’s T test was used; in (c) a one-way analysis of variance (ANOVA) for 
repeated-measures with a Bonferroni post-test correction.  *p< 0,05, **p< 0,001,  ***p< 0,001. 
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3.8 IFN-α  accelerates human T cell differentiation 
CMV infection is an important driver for the release of IFN-α by plasmacitoid 
dendritic cells in humans (Fletcher et al., 2005; Libri et al., 2011). To delineate our 
biochemical findings in a more physiological context, we evaluated the impact of 
CMV infection on human CD8+ T cell differentiation in vivo and whether IFN-α 
accelerates this process in vitro. As shown in Figure 17 a, human CD8+ T cells 
can be divided in three separate subsets on the basis of their relative CD27/CD28 
expression profile and old humans have a substantial increase in highly 
differentiated CD27- CD28- CD8+ T cells, as compared to young or middle-age 
individuals. These cells also showed very little telomerase activity after activation 
(Figure 17 b), which confirmed previous findings from our group (Henson et al, 
2009). This suggested that the documented inhibitory effect of IFN-α on human 
CD8+ T cell telomerase in unfractionated populations (Figure 11), is unlikely to 
reflect a direct modulation on the CD27- CD28- cells that already exhibit very little – 
if any- telomerase activity. 
To study the role of chronic CMV infection in human CD8+ T cell differentiation, 
buffy coats from age-matched either CMV+ or CMV- individuals were collected (the 
sierological state was assessed by the diagnostic laboratory of University College 
London Hospital) and the frequency of relatively undifferentiated CD27+ CD28+, 
intermediate differentiated CD27+ CD28- and highly differentiated CD27- CD28- 
CD8+ T cells was determined by flow-cytometry. There was a linear correlation 
between ageing and progressive loss of CD27 and CD28 receptor expression in 
human CD8+ T lymphocytes, in agreement with the notion that repeated episodes 
of antigen activation throughout life induces CD27 and CD28 down-modulation 
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(Figure 17 c left, right and bottom graphs, respectively). The CMV status also 
affected human T cell differentiation in that highly differentiated CD27- CD28- CD8+ 
T cells accumulated in CMV-chronically infected individuals (Figure 17 c, bottom 
graph). However, when these results were stratified by age, no correlation was 
found between CMV status and age, indicating that both ageing and CMV infection 
can drive human T cell differentiation independently (Figure 17 c). Because blood 
IFN-α levels are higher in chronic viral infected individuals (including those who 
are CMV+), one prediction would be that the addition of IFN-α would reproduce the 
down-modulation of CD28 and CD27 receptors in cultured T cells. To explore this 
possibility, human CD8+ T cells were activated by αCD3 and rhIL2 and cultured for 
up to 4 weeks either in the presence or absence of low levels of IFN-α  (100 
U/mL). Every week cells were washed, reactivated and IFN-α added back in 
culture; and every 2 weeks the relative expression of CD27 and CD28 receptors 
was assessed by flow-cytometry. Figure 17 d shows a representative CD27/CD28 
expression profile depicting an increase proportion of highly differentiated CD27- 
CD28- CD8+ T cells in IFN-α treated cells versus control cells. The cumulative data 
from 2 independent donors are shown in Figure 17 e. Taken together, these data 
indicate that inflammatory and anti-viral signals may promote the loss of 
telomerase activity and phenotypic differentiation of human T cells towards 
replicative senescence, and that p38 MAPK signalling may be directly involved in 
this process.  
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Figure 17: IFN-α  accellerates loss of CD27 and CD28 on activated CD8 T 
cells (a) The relative co-expression of CD27 and CD28 receptors in human CD8+ T cells from 
young (< 35 years), middle (40-60 years) and old individuals (> 65 years), representative staining. 
CD8+ T cells were isolated from peripheral blood by positive selection and then stained with 
antibodies to CD27 and CD28, directly ex vivo. Cells were washed and immediately analyzed by 
flow-cytometry. (b) Measurement of telomerase activity by an ELISA-based non radioactive TRAP 
assay in relatively undifferentiated CD28+ CD27+, intermediate differentiated CD28- CD27+ or highly 
differentiated CD27- CD28- CD8+ T cells activated by αCD3 and rh-IL2 for 72 hours. Pooled results 
from 3 different experiments performed as in Figure 16 c and presented as relative to that of the 
relatively undifferentiated CD28+ CD27+ population, set as 1. (c) Pooled data of immune-
phenotyping of human CD8+ T cells defined by relative CD27/CD28 expression from either CMV 
positive (+ve) or CMV negative (-ve) individuals, as assessed by the Royal Free Hospital in 
London, and stratified by age (x axis). (d) The relative co-expression of CD27 and CD28 receptors 
in human CD8+ T cells activated by αCD3 and rh-IL2 either in the presence or absence of low-
doses of IFN-α (100 IU). CD8+ T cells were > 98% CD28+ CD27+ before culture, and were 
maintained in activation medium for 4 weeks; every 10 days cells were re-activated at which time 
IFN-α was addeded back in culture. At 2 and 4 weeks of culture, cells were immune-phenotyped 
for CD27 and CD28 expression by flow-cytometry as in (a-b). Error bars indicate SEM throughout. 
In (b) a one-way analysis of variance (ANOVA) for repeated-measures with a Bonferroni post-test 
correction was used; results in (d) and (e) are represented of two representative experiments.  *p< 
0,05,  ***p< 0,01. 
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3.9 Summary and conclusion  
Previous studies highlighted that the inflammatory cytokine IFN-α was involved in 
T cell telomerase down-regulation both in vitro and in vivo (Fletcher et al., 2005; 
Reed et al., 2004). However, the mechanism by which IFN-α inhibited telomerase 
activity in T cells was not clear. Here I have shown that multiple pathways are 
engaged by IFN-α to negatively regulate telomerase activity in human CD8+ T 
cells. Both transcriptional and post-translational mechanisms may be involved in 
this process. The transcription factors NFkB and E2F1 have been previously 
shown to either induce or inhibit the expression of the catalytic subunit of 
telomerase hTERT gene (Akiyama et al., 2003; Crowe, 2001). Correspondigly, I 
have shown that the reduced hTERT transcription in human CD8+ T cells treated 
with IFN-α is associated with reduced NFkB and enhanced E2F1 DNA-binding 
activity at the hTERT promoter. These results suggest that changes in the activity 
of key hTERT transcriptional regulators may directly inhibit hTERT gene 
expression in T cells activated in the presence of IFN-α.  
The down-regulation of telomerase activity induced by IFN-α in activated CD8+ T 
cells is also likely to occur at the post-translational level. Previous work highlighted 
a role for the kinase AKT in direct hTERT protein phosphorylation (Kang et al., 
1999), that is important to enhance telomerase stability and nuclear import. I have 
shown here that IFN-α can potently inhibit AKT phosphorylation at both Ser473 and 
Thr308 regulatory sites in activated human CD8+ T cells, indicating potent AKT 
kinase inactivation. It is possible that the ability of IFN-α to inhibit AKT in T cells is 
mediated by the phosphatase PP2A, whose activity is strongly induced by IFN-
α (Figure 15 b). Because PP2A is able to de-phosphorylate (thus inactivating) 
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both AKT and hTERT proteins (Li et al., 1997), this might explain the exact 
mechanism linking AKT and hTERT downregulation to IFN-α signalling.  
Of note, this study has provided direct evidence showing that the inhibition of 
telomerase activity by IFN-α is in part due to its ability to strongly activate p38 
MAPK signalling. The addition of the specific p38 inhibitor BIRB can significantly 
rescue telomerase activity in activated human CD8+ T cells treated with IFN-α. 
However the mechanism by which p38 activation is linked to down-stream 
telomerase inhibition and whether this occurs at the transcriptional or post-
translational level remains to be determined.  
Many signalling events described here (reduced AKT phosphorylation, reduced 
hTERT expression, increased p38 activity) have also been reported to regulate 
loss of telomerase and proliferative potential in natural occurring human senescent 
T cells (Henson et al., 2009, 2014; Di Mitri et al., 2011; Plunkett et al., 2007). This 
raises the intriguing possibility that common mechanisms exist in T cells for 
telomerase down-regulation that are either endogenously active during 
senescence or that can be induced by the inflammatory cytokine IFN-α. It would 
therefore appear that IFN-α is able to reproduce the main biochemical features of 
human T cell senescence in vitro. 
Of note, IFN-α can significantly promote human CD8+ T cell differentiation in vitro 
(Figure 17 d), a process that was already described for human CD4+ T cells and 
that might explain the reason why CMV chronic infection, a potent natural trigger of 
IFN-α in vivo (Fletcher et al., 2005), can accelerate CD27/CD28 loss from human 
CD8+ T cells, independently of age. Our study therefore reinforces the role of IFN-
	 107	
α in regulating end-stage human T cell differentiation. Other inflammatory 
cytokines such as TNF-α have also been shown to induce telomerase down-
regulation and activate p38 signalling (Akiyama et al., 2003) and it is therefore 
possible that there is a unique molecular signature that drives the differentiation of 
human T cells towards senescence. In turn, this suggests a link between 
inflammation, senescence and the tuning of T cell function.  
As discussed, it is likely that the mechanisms described here in unfractionated 
human CD8+ T cell populations activated in the presence of IFN-α are due to the 
modulation of signalling pathways in non-senescent T cells, rather than the highly 
differentiated populations that already exhibit very low telomerase activity. 
Although some key signalling events appear to be conserved in both senescent 
and IFN-α primed T cells, the underlying biochemical mechanisms may not be 
identical in these cells, as different upstream trigger may be involved (senescent 
and inflammatory signals, respectively). 
In conclusion, understanding the molecular tuning of telomerase may identify 
interventional targets to enhance T cell proliferative responses during ageing and I 
have shown here a role for IFN-α in T cell telomerase down-regulation through 
direct inhibition of the expression of the telomerase catalytic sub-unit hTERT and 
activation of the key signalling molecule p38 MAPK. It is possible that interfering 
with any of the mechanism reported here may reveal of therapeutic interest to 
boost T cell proliferative responses in chronic viral infections, by restoring 
telomerase activity and the related capacity of expansion of antigen-specific T 
cells (Akbar and Fletcher, 2005). The fact that multiple mechanisms are engaged 
by IFN-α in the inhibition of telomerase in T cells underscores the importance of 
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this process in the regulation of T cell function in vivo. Future work is required to 
establish potential mechanistic links among the various signaling pathways 
orchestrated by IFN-α to inhibit telomerase in T cells.  
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Chapter IV: p38 activation in T cells: Challenging the paradigm 
 
4.1 Background and rationale 
The finding that IFN-α  inhibited T cell telomerase via p38 signalling was 
supported by recent data from our group indicating a spontaneous yet unexplained 
activation of p38 that directly inhibited telomerase and proliferative potential in both 
senescent human CD4+ and CD8+ T cells (Henson et al., 2014, 2015; Di Mitri et 
al., 2011). Conversely, others reported that p38 activation promoted T cell 
proliferation (Zhang et al., 1999) that could be explained by either differences in 
downstream substrate-specificity or different activation pathways upstream of p38, 
or both. Thus a more selective intervention (that is, to block p38 signalling only in 
senescent T cells) may represent a better strategy for boosting T cell function 
during ageing than indiscriminate p38 inhibition in all T cells.  
 
As discussed, there are two (canonical and alternative) independent pathways in T 
cells that can activate p38 in response to various events (Ashwell, 2006). Because 
inflammatory signalling can activate p38 by the canonical MAPK cascade (Chang 
and Karin, 2001) and because the inflammatory cytokine IFN-α accelerates human 
T cell differentiation towards senescence in part through p38 activation, one 
prediction would be that p38 is potently activated by the canonical MAPK cascade 
in senescent T cells. However inflammation also induces loss of co-stimulatory 
receptor expression in T cells (Libri et al., 2011) that are important for canonical 
MAPK activation (Rincón and Davis, 2007), raising the question of whether this 
pathway was actually inactive in senescent T cells that lose both CD27 and CD28 
receptors as a result of differentiation related events. Nevertheless because 
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continuous episodes of T cell activation drive human T cell differentiation (Weng et 
al., 2009), it was possible that p38, activated by the alternative TCR-related 
activation pathway, occurred in senescent T cells. To determine the mechanism of 
spontaneous p38 activation in senescent T cells, both canonical and alternative 
pathways were studied in primary populations of human CD4+ T cells at the 
different stages of relative CD27/CD28 differentiation, directly ex vivo. 
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4.2 Spontaneous p38 activation in senescent CD27- CD28- CD4+ T cells. 
To study p38 signalling and related upstream events in highly differentiated T 
cells, the relative expression of CD27 and CD28 receptors was used as a gating 
strategy for cells at different stages of differentiation. By flow cytometry, the 
proportion of highly differentiated/senescent CD27- CD28- CD4+ T cells ranged 
between 0.5-5 % of total human CD4+ T cells (Figure 18 a, representative 
staining). Flow-cytometry enabled signaling studies in very small populations of 
cells directly ex vivo. To confirm increased p38 phosphorylation in human 
senescent CD4+ T cells, total CD4+ T cells were isolated from blood by positive 
selection and immediately surface stained for CD27 and CD28 receptors, then 
fixed, permabilized and incubated with a fluorocrome labeled antibody to 
phosphorylated p38 at Thr180-Tyr182 that are the sites phosphorylated within the 
activation loop of the molecule. Figure 18 b shows that p38 MAPK signalling is 
spontaneously increased in CD27- CD28- CD4+ T cells, by 2-2.5 fold versus the 
less differentiated CD27+ CD28+ CD4+ T cells and CD27- CD28+ CD4+ T cells. 
These data are derived from 9 separate individuals.   
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Figure 18. Spontaneous p38 activation in human senescent CD4+ T cells. (a) 
The relative expression of CD27 and CD28 receptors in primary human CD4+ T 
cells, directly ex vivo, representative of 9 separated donors. (b) Phospho-flow data 
(n = 9) showing endogenous activation of p38 MAPK in subsets of human CD4+ T 
cells gated as in (a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 113	
4.3 p38 activation without canonical pathway in senescent human CD4+ T 
cells 
As all other MAP kinases, p38 is mainly activated by the canonical MAPK cascade 
in all cell types, including T cells (Ashwell, 2006). To assess if the endogenous 
activation of p38 in human senescent CD4+ T cells was linked with upstream 
signalling by the canonical MAPK cascade, both expression and activation of 
MKK3 and MKK6 that directly phosphorylate p38 in this signalling pathway (Chang 
and Karin, 2001) were assessed by Western Blot. The subsets of human CD4+ T 
cells defined by relative CD27/CD28 expression were isolated as described, 
immediately lysed and endogenous MKK expression and activation were 
measured using antibodies to total MKK3 and MKK6 and to phosphorylated 
MKK3/MKK6 at Ser189/Ser206, respectively. GAPDH expression was measured 
to assess equal protein loading throughout and to determine the relative ratio of 
MKK activation. Figure 19 a shows that progressive CD27/CD28 differentiation in 
human CD4+ T cells is associated with the down-regulation of MKK3/6 expression 
and activation until a maximum extent at which highly differentiated CD27- CD28- 
CD4+ T cells do not synthetize or activate MKK molecules. These result were 
confirmed in 4 independent experiments (Figure 19 b). Thus the spontaneous 
activation of p38 in senescent human CD4+ T cells occurs in the absence of 
upstream MKK3/6 signalling. This raised the question of whether p38 in senescent 
T cells would be unresponsive to canonical MAPK re-activation by a specific 
agonist. Thus human CD4+ T cells were isolated, labelled for CD27/CD28 
expression, activated for 1 hour by the canonical MAPK cascade agonist phorbol 
ester PMA (Alam et al., 2014), and p38 activation was measured by phospho-flow. 
Despite higher basal p38 activity, PMA treatment did not further increase p38 
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(T180/Y182) phosphorylation in highly differentiated CD4+ T cells (Figure 19 c); 
conversely p38 was potently phosphorylated in response to PMA in relatively 
undifferentiated CD4+ T cells that express MKK molecules (Figure 19 c). The 
cumulative data from 3 different experiments are shown in Figure 19 d. These 
data show that despite the constitutive increase in p38 activity, human senescent 
CD27− CD28− CD4+ T cells did not regulate p38 signalling by the canonical MAPK 
cascade. Of note, since the representative shift depicting increased p38 activity in 
CD27− CD28− CD4+ T cells is not absolute (for instance, as compared with the 
PMA-induced activation of p38 in the non-senescent population), it suggests that 
only  part of this senescent population exhibits endogenous activity of the kinase. 
This does not alter the conclusion that endogenous p38 activity in senescent 
human CD4+ T cells occurs independently of canonical MAPK signaling.  
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Figure 19: Loss of canonical p38 activation pathway in human senescent CD4+ T cells.  (a) 
Immunoblots of MKK3, MKK6 or phosphorylated MKK3/6 (Ser189/Ser206) in the CD27/28 related 
populations of human CD4+ T cells. Untouched CD4+ T cell were isolated by an immunomagnetic 
based ‘negative’ selection followed by further purification in CD27+ CD28+, CD27- CD28+ and CD27- 
CD28- T cells directly ex vivo. Cell populations were immediately harvested without activation and 
endogenous signalling responses are shown. (b) The pooled results of band intensity from 3 
different donors showing endogenous activation of MKK3/6 assessed by ratio of MKK3/6 versus 
total GAPDH, presented as relative to MKK activation in relatively undifferentiated CD27+ CD28+ 
CD4+ T cells, set as 1. (c) Measurement of p38 activity by phospho-flow in relatively 
undifferentiated (as a positive control) or highly differentiated T cells either before or after short 
activation with the canonical MAPK agonist PMA (20 ng/mL) for 1 hour. (d) The pooled results of 3 
separate experiments performed as in (c) and presented as relative to that of unstimulated CD27+ 
CD28+, set as 1. In (b, d) a one-way analysis of variance (ANOVA) for repeated-measures with a 
Bonferroni post-test correction. ***p< 0,01. Error bars indicate s.e.m. 
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4.4 p38 activation without alternative pathway in senescent human CD4+ T 
cells 
T cells possess an alternative pathway downstream of TCR activation in which 
p38 is phosphorylated on Tyr323 by the TCR related kinases LCK and ZAP70 
(Salvador et al., 2005), followed by p38 auto-phosphorylation on Thr180-Tyr182 
(Salvador et al., 2005). The scaffold molecule DLG1 coordinates this process 
(Round et al., 2007). Because this pathway does not require co-stimulatory 
signalling and because human T cell differentiation occurs in response to repeated 
episodes of TCR activation, I studied the potential involvement of the alternative 
pathway in the constitutive activation of p38 found in senescent human CD4+ T 
cells. To determine if alternative p38 signalling can occur in senescent human 
CD4+ T cells, p38 (Y323) phosphorylation was measured by Western Blot both 
before and after αCD3 activation in either senescent CD27− CD28− CD4+ T cells or 
nonsenescent CD27+ CD28+ CD4+ T cells (as a control). These experiments 
showed that unlike relatively undifferentiated CD4+ T cells in which p38 was 
abundantly phosphorylated on Tyr323 upon TCR activation (Figure 20 a), 
senescent human CD4+ T cells did not phosphorylate p38 on Tyr323 either before 
or after TCR ligation (Figure 20 a), suggesting that the alternative pathway was 
inactive in this sub-population of human T cells. In fact, Western Blot-based 
experiments revealed that CD27− CD28− CD4+ T cells lacked LCK, ZAP70 and 
DLG1, essential TCR signalosome components that mediate alternative p38 
activation (Ashwell, 2006) (Figure 20 b). Conversely, both CD27+ CD28+ and 
CD27- CD28+ CD4+ T cells expressed high levels of TCR signalling molecules 
(Figure 20 b). This loss of TCR signalosome components was confirmed in four 
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different donors (Figure 20 c). Together, these data show that the alternative TCR 
dependent pathway does not activate p38 in senescent human CD4+ T cells. 
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Figure 20: Loss of alternative p38 activation pathway in human senescent CD4+ T cells.  (a) 
Immunoblots of phosphorylated p38 at Tyr323 and total p38 in relatively undifferentiated CD27- 
CD28- or highly differentiated CD27- CD28- CD4+ T cells either before or after short-term activation 
(30’, 10 µg/mL) with antibody to invariant CD3 chain. (b) Immunoblots of total LCK, ZAP70, DLG1 
and GAPDH (as a loading control) in purified subsets of human CD27+ CD28+, CD27- CD28+ and 
CD27- CD28- CD4+ T cells directly ex vivo. (c) Pooled data of band intensity for 3 separate 
experiments performed as in (b) and presented as relative to relatively undifferentiated CD27+ 
CD28+ CD4+ T cells, set as 1. In (c) a one-way analysis of variance (ANOVA) for repeated-
measures with a Bonferroni post-test correction. **p< 0,01,  ***p< 0,01. Error bars indicate s.e.m. 
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4.5 The loss of TCR signalosome is associated with defective Calcium 
signalling 
The loss of TCR signalling components in highly differentiated, senescent human 
CD4+ T cells was unexpected. To further characterize this process, the expression 
of other molecules that are essential for optimal TCR signalling was assessed. 
Human CD4+ T cells were purified by relative CD27/CD28 expression, immediately 
lysed and then immune-blotted for LAT, SLP76 and PLC-γ1 expression using 
specific signalling antibodies; GAPDH was used to assess equal protein loading 
and to measure relative expression of LAT, SLP76 and PLC-γ1 throughout. Figure 
21 a shows that CD27− CD28− CD4+ T cells do not express LAT and SLP76 
molecules and show very low expression of PLC-γ1 that are important to trigger 
calcium dependent signalling cascades upon TCR stimulation. The cumulative 
data from 3 different donors are shown in Figure 21 b. Because intracellular 
calcium-flux is essential for optimal T cell activation and proliferation, loss of TCR 
signalling machinery and proliferative potential in senescent T cells might be 
related to defective calcium signalling (in addition to lack of telomerase activity). To 
explore this possibility, human CD4+ T cell subsets were isolated and activated by 
αCD3 for 5’ and intracellular calcium abundance was measured by flow-cytometry 
using Fluo-4 AM dye. This probe that emits fluorescence excitation proportional to 
intracellular calcium concentration showed that levels of calcium in activated 
senescent CD27− CD28− CD4+ T cells were much lower than those in relatively 
undifferentiated CD27+ CD28+ CD4+ T cells upon activation (Figure 21 c). These 
observations were confirmed in 3 independent experiments (Figure 21 d). Thus, 
the loss of TCR signalosome is a novel feature of human T cell differentiation that 
is associated with defective intracellular calcium signals.  
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Figure 21: Loss of TCR signalosome in senescent CD4+ T cells.  
(a) Immunoblot of total LAT, SLP-76 and PLC-γ 1 expression in freshly isolated human CD4+ 
CD27/CD28 defined subsets. GAPDH was used as a loading control. (b) The relative expression of 
LAT, SLP-76 and PLC-γ 1 vs. total GAPDH in the CD4+ CD27/CD28 defined subsets from 3 
different individuals. (c) Representative overlay and (d) pooled Fluo-4 AM data from 3 independent 
experiments showing intracellular calcium influx after αCD3 activation (10 µg/mL, 5’) in CD27+ 
CD28+ and CD27- CD28-  CD4+ T cells, as measured by flow-cytometry. In (b) a one-way analysis 
of variance (ANOVA) for repeated-measures with a Bonferroni post-test correction. In (d) a paired 
Student’s t test. *p< 0,05, **p<0.01, and ***p< 0.001. Error bars depict SEM throughout. 
 
 
 
 
 
 
 
 
 
 
	 121	
4.6 Summary and conclusions 
In T cells, P38 can be activated by either the canonical or alternative pathway in 
response to either environmental stress or TCR activation, respectively (Rincón 
and Davis, 2007). Here I provide evidence to challenge this paradigm and to imply 
the existence of a third, unrecognized mode for the activation of p38 in senescent 
T cells that potently activate the kinase in the absence of both canonical and 
alternative related pathways.  
 
Although inflammation can activate p38 through the canonical MAPK cascade 
(Chang and Karin, 2001) (Chapter 3), resulting in loss of telomerase and 
accelerated T cell differentiation, it was unlikely that the canonical MAPK cascade, 
that requires co-stimulatory receptor engagement, would be active in senescent T 
cells that are CD27- CD28- lymphocytes. Indeed there was a progressive loss of 
upstream (canonical) MKK signalling during human CD4+ T cell differentiation. The 
loss of canonical MAPK activation of p38 was not compensated by alternative 
TCR mediated p38 activation and instead there was an unexpected loss of TCR 
signalosome components in senescent human CD4+ T cells, leaving the activation 
of p38 in these cells unexplained.  
Because human senescent CD4+ T cells also had defective calcium influx upon 
TCR activation, it suggests that loss of TCR signalling machinery in CD27- CD28- 
CD4+ T cells may cause TCR hypo-responsiveness resulting in loss of TCR driven 
proliferation. Reduced capacity for TCR activation has been already described in 
aged naïve T cells from both mice and humans but it was linked with defective 
tuning of TCR calibration due to reduced ERK signalling and altered microRNA 
signature (Li et al., 2012). Together with loss of co-stimulatory receptor expression 
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and down-regulation of telomerase and proliferative potential (Akbar and Henson, 
2011), the loss of TCR signalling machinery represents a novel feature of human T 
cell differentiation. Whether it is reversible is not clear at present.  
 
In conclusion the results presented here challenge the current paradigm for 
activation of p38 in T cell populations and introduce an unrecognized characteristic 
of human T cell senescence. However the proximal signals that activate p38 in 
senescent human T cells remained to be identified. In the next chapter of this work 
the mechanism that spontaneously activates p38 in these cells will be unveiled. 
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Chapter V: p38 is activated by AMPK/TAB1 in senescent human 
CD4+ T cells 
 
5.1 Background and rationale 
Another MKK independent mechanism for p38 activation was described in 
HEK293 cells using a yeast two hybrid screening assay to identify p38 binding-
partners. The mechanism relied on the scaffold molecule TAB1 that was 
previously found to constitutively bind to and activate the MAPKK kinase TAK1 
activated in turn by various cytokine receptors (Ge et al., 2002). Thus TAB1 was 
initially thought to provide a link between cytokine signalling and downstream p38 
activation through the canonical MAPK cascade. However sub-sequent findings 
that both TAK1 and MKK-negative mutants did not prevent activation of the p38 
bound to TAB1 revealed that the process occurred independently of the canonical 
MAPK pathway (Ge et al., 2002). Instead it relied on the intrinsic kinase activity of 
p38 itself because inactivating mutations within the p38 kinase catalytic domain or 
addition of the ATP competitive p38 inhibitor SB-203580 prevented the 
phosphorylation of p38 mediated by TAB1 (Ge et al., 2002)  (that is, auto-
phosphorylation of p38). The fact that TAB1 activates p38 independently of TAK1 
was further corroborated by the discovery of a naturally occurring splicing variant 
of TAB1 (namely TAB1-β) that lack the C-term domain for interaction with TAK1 
but that still potently activates p38 through the same auto-phosphorylation 
dependent mechanism (Ge et al., 2003).  
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The physiological relevance for TAB1 mediated activation of p38 has remained 
elusive as the pathway responded in HEK293 cells to stimuli such as 
inflammation, sorbitol and UV radiation that generally activate p38 via the 
canonical MAPK cascade (Ashwell, 2006). Among the upstream regulators of 
TAB1 dependent auto-phosphorylation of p38, the ubiquitin ligase TRAF6 was 
found to co-immunoprecipitate with both TAB1 and p38 in response to TNF-α 
activation in HEK293 (Ge et al., 2002) and also in monocyte-derived immature 
dendritic cells in response to discoidin domain receptor 1 (DDR1) engagement 
(Matsuyama et al., 2003), indicating that the mechanism could have important yet 
still poorly characterized physiological implications for tuning of immune cell 
function.  
 
TAB1 dependent activation of p38 was also proposed to be important for p38 auto-
phosphorylation in mouse ischemic cardiomyocytes. Li et al. reported that the 
process occurred in both wild type and MKK3 knockout ischemic hearts indicating 
that the process met the MKK-independence requirement for alternative TAB1 
mediated p38 activation (Li et al., 2005). Importantly the mechanism was defective 
in AMPK knockout hearts, indicating involvement of the energy sensor AMPK (Li 
et al., 2005). However two sub-sequent studies rejected these conclusions by 
showing that perturbation of AMPK signalling by either gene knockdown or 
negative dominant mutant overexpression failed to prevent TAB1 dependent 
activation of p38 in the same experimental conditions and proposed instead that 
AMPK lay downstream of TAB1-p38 (Jacquet et al., 2007; Jaswal et al., 2007).  
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Here I tested the hypothesis that TAB1 dependent p38 signalling could 
compensate for the loss of both canonical and alternative p38 activation pathways 
observed in senescent human CD4+ T cells.  
 
5.2 Alternative TAB1 expression in senescent human CD4+ T cells is 
associated with spontaneous AMPK activation 
There are two splicing variants of TAB1 (of 60 and 50 kDA, respectively) that bind 
to and activate p38 through the same mechanism that is based on auto-
phosphorylation (Ge et al., 2002, 2003). To begin to evaluate if TAB1 was involved 
in the spontaneous activation of p38 observed in senescent T cells, TAB1 
expression was studied in the subsets of human CD4+ T cells defined by relative 
CD27 and CD28 expression as above described, directly ex vivo. Western Blot 
based experiments showed that TAB1 was expressed in human CD4+ T cells at all 
stages of differentiation however only senescent CD27- CD28- CD4+ T cells 
expressed the alternative splicing 50 kDA-variant of TAB1 that does not bind nor 
activate the kinase TAK1 (Ge et al., 2003), its binding partner (Figure 22 a). 
Indeed these cells also did not express TAK1 itself (Figure 22 a). Because TAB1 
signalling has been shown to require upstream activation by the ubiquitin ligase 
TRAF6 to in turn down-stream activate p38 (Ge et al., 2002), the expression of 
TRAF6 was investigated in the same experiments. Membranes were stripped and 
re-probed with anti-TRAF6, which showed that this molecule was lost in CD27- 
CD28- CD4+ T cells (Figure 22 a). Conversely, non-senescent CD27+ CD28- or 
CD27+ CD28+ CD4+ T cells expressed abundant TRAF6 protein (Figure 22 a). 
Thus, if TAB1 was involved in the activation of p38 in senescent CD4+ T cells, it 
	 126	
would have to be activated by a different upstream mechanism, independently of 
the TRAF6-TAK1 axis. 
AMPK is a low energy sensor that is a TAB1 binding partner (Li et al., 2005). 
Activated AMPK is phosphorylated on its catalytic α sub-unit in response to either 
catabolic conditions (that is, when AMP levels increase over those of ATP) or 
oxidative stress (Cardaci et al., 2012; Hardie et al., 2012). Although it was shown 
that AMPK activation blocks anabolic mTOR dependent signalling in T cells (Rolf 
et al., 2013), it is not known if AMPK can activate p38 in these or other immune 
cells. To study if AMPK was involved in p38 activation via TAB1 in senescent T 
cells, both AMPK expression and activation were evaluated in Western Blot-based 
experiments. Human CD4+ T cells defined by relative CD27 and CD28 expression 
were isolated, immediately lysed and immunoblotted with antibodies to AMPK-α 
and phosphorylated AMPK-α at Thr172. These experiments showed that although 
all human CD4+ T cells had abundant AMPK-α expression only the senescent 
CD27- CD28- population spontaneously activated the kinase (Figure 22 b). To 
begin to probe if AMPK could act upstream of T cell p38, AMPK was 
pharmacologically activated by A-769662, a selective AMPK agonist (Goransson 
et al., 2007). CD27+ CD28+ CD4+ T cells that normally exhibit very low 
spontaneous p38 phosphorylation in the absence of AMPK activity were activated 
either by DMSO vehicle control or A-769662 for 1 hour, followed immediately by 
analysis of p38 phosphorylation by phospho-flow. The representative overlay in 
Figure 22 c shows that agonist driven activation of AMPK induces p38 
phosphorylation on T180/Y182, which indicates that AMPK acts upstream of p38 
in T cells. The results from 3 separate experiments confirmed these findings 
(Figure 22 d). However the potential link with TAB1 remained to be determined.  
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Figure 22: Senescent CD4+ T cells spontaneously activate AMPK and 
express an alternative TAB1 variant. (a) Immunoblots from 2 separate donors (A and B) 
of TAB1, TAK1 and TRAF6 in freshly isolated human CD4+ CD27/CD28 defined T cell subsets. 
Alternative TAB1 variants (60 and 50 k-DA respectively) are indicated by black arrows. (b) 
Endogenous phosphorylation of AMPK-α at Thr172 and expression of total AMPK-α assessed by 
western blotting in subsets of human CD4 T cells gated as in (a). (c) Phosphorylation of T cell p38 
at Thr180/Tyr182 assessed by phospho-flow after incubation with either the AMPK agonist A-
769662 (150 µM) for 1 hour or DMSO as vehicle control. Human CD4+ T cells were isolated from 
peripheral blood by ‘positive’ selection, and, after pharmacological AMPK activation, surface-
stained with antibody to CD27 and CD28 receptors; p38 activity was then studied in the CD27+ 
CD28+ population. (d) Pooled phospho-flow data of p38 activity from 3 separate experiments 
performed as in (c) and presented as relative to that of DMSO vehicle control, set as 1. In (d) a 
paired Student’s t test was used. **p<0.01. Error bars depict sem. 
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5.3 Silencing AMPK and TAB1 in senescent human CD4+ T cells by lentiviral 
vectors 
Lentiviral vectors are HIV-1 derived systems used to manipulate gene expression 
of both dividing and non dividing target cells by permanent integration of a gene 
cassette into the host genome, a process known as gene transduction (Vigna and 
Naldini). The delivered gene cassette may encode for either a transgene, to 
enforce gene expression, or a short-hairpin RNA (shRNA), for gene knockdown 
studies based on activation of the RNA interference pathway (RNAi) (Wilson and 
Doudna, 2013). We used lentiviral vectors enconding shRNAs to either AMPK 
(shAMPK-α) or TAB1 (shTAB1) genes and studied the role of AMPK-TAB1 
signaling in primary human senescent CD4+ T cells. An irrelevant (nonsilencing) 
shRNA was used as control (shCTRL). These specific shRNAs were cloned (as 
described in Materials and Methods) into a p-SIREN HIV-1 derived lentiviral vector 
backbone, kindly provided by Dr. David Escors (a schematic representation of the 
vector is provided in Figure 23 a). These vectors were co-transfected in HEK293 
cells by liposomes (Fugene 6) together with env and gag-pol plasmids to generate 
specific lentiviral particles (the procedure is described in Materials and Methods). 
These particles were then titrated in HEK293 cells (described in Materials and 
Methods) and finally transduced (with an MOI of 10) into purified human CD27- 
CD28- CD4+ T cells, after activation for 48 hours by αCD3 and rh-IL2. Using this 
strategy of gene manipulation of primary human senescent CD4+ T cells, potent 
knockdown (about 60-80% protein down-regulation) of either T cell AMPK-
α (Figure 23 b) or TAB1 (Figure 23 c) in comparison to scrambled control 
transduced cells was achieved, as assessed by either RT-PCR or Western Blot 
analysis, 96 hours after transduction. 
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Figure 23: Validation of lentiviral vector knockdown of AMPK-α and TAB1 in 
senescent human CD4+ T cells. (a) Schematic representation of the p-Siren HIV lentiviral 
vector system used for gene knock-down. The vector encodes a shRNA for interference studies 
that is coupled to a GFP reporter gene (under control of a PGK promoter). LTR, long terminal 
repeats. Measurement of (b) AMPK-α or (c) TAB1 expression in human CD27- CD28- CD4+ T cells 
by either immunoblot (top) or RT-PCR (bottom). Human CD4+ T cells were purified by ‘negative 
selection’ followed by CD27 and CD28 sorting; and highly differentiated CD27- CD28- CD4+ T cells 
were activated by αCD3 plus rh-IL2 for 48 hours. Cells were then transduced with lentiviral 
particles encoding shRNAs to either AMPK-α or TAB1. A scrambled shRNA was used as internal 
control. Four days post-transduction AMPK-α or TAB1 expression was assessed in shAMPK-α or 
shTAB1 transduced populations as above described by comparison to that of shCTRL transduced 
cells. Immunoblots are representative of 3 independent experiments. Samples for quantitative PCR 
were analyzed from 4 different donors and normalized against housekeeping GAPDH. Knockdown 
efficiency was evaluated 96 hours post-transduction (day 7).  **p<0.01 and ***p< 0.001 values 
were assessed by a paired Student’s t test. Errors bars depict s.e.m. 
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5.4 Both AMPK and TAB1 act upstream of p38 in human senescent CD4+ T 
cells 
In addition to shRNA expression, the lentiviral vectors used for gene knockdown 
also encode for a green fluorescent protein (GFP) reporter gene. Thus detection of 
GFP+ expression by flow-cytometry enabled the identification of effectively 
transduced cells in which gene knockdown was active. To study signalling events 
at the single cell level in the reporter GFP+ populations, phospho-flow analysis was 
used. Human CD27- CD28- CD4+ T cells were purified from peripheral blood of 
healthy volunteers, activated for 48 hours by αCD3 and rh-IL2, transduced with 
lentiviral particles using an MOI of 10, and the effect of either AMPK-α or TAB1 
knockdown on p38 activity was studied in the GFP+ compartments (Figure 24 a) 
using APC-labelled antibody to p-p38 (T180/Y182), 96 hours post-transduction. 
These experiments showed that under-steady state conditions both AMPK-α and 
TAB1 silenced cells showed a significant reduction of p38 activity versus 
scrambled control cells (by 40-50% kinase activity down-regulation; Figure 24 b). 
The pooled data from 3 independent experiments are shown in Figure 24 c. Thus 
both AMPK and TAB1 act upstream of p38 activation in senescent human CD4+ T 
cells. 
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Figure 24: Both AMPK and TAB1 act upstream of p38. (a) Measurement of the 
reporter GFP gene expression in transduced purified CD27- CD28-  CD4+ T cells (staining of 
shCTRL lentivector is shown; this is representative of shTAB1 and shAMPK-α vectors too). Cells 
were purified, activated and transduced as in figure 23 and analyzed by flow-cytometry 96 hours 
post-transduction. (b) Overlay from the same experiment and (c) pooled phospho-flow data from 3 
separate experiments showing steady-state p38 (Thr180,Tyr182) phosphorylation within the reporter 
GFP+ populations of CD27- CD28- CD4+  T cells transduced with lentiviral vectors encoding either 
shAMPKa, shTAB1 or shCtrl. Cells were fixed immediately ex-culture without further activation, 
permeabilized and incubated with APC-conjugated antibody to p38 phosphorylated at (Thr180-
Tyr182), followed by analysis by flow-cytometry. Data are presented as relative to the transduced 
control population, set as 1. In (c) a one-way analysis of variance (ANOVA) for repeated-measures 
with a Bonferroni post-test correction was used. *p< 0,05, **p<0.01, and ***p< 0.001. Error bars 
depict SEM throughout. 
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5.5 AMPK activates p38 via TAB1 in senescent human CD4+ T cells 
To study the reliance of AMPK on TAB1 to induce p38 signalling, senescent 
human CD4+ T cells were isolated, activated and transduced as above described 
and p38 signalling was studied in response to AMPK activation by A-769662 for 1 
hour using APC-labelled antibody to p-p38 (T180/Y182). Phospho-flow analysis of 
GFP+ cells showed that agonist driven activation of AMPK elevated p38 signalling 
in shCTRL transduced CD27- CD28- CD4+ T cells but not in those transduced with 
shAMPK-α (Figure 25 a), confirming that the process was AMPK dependent. 
Importantly, the AMPK-agonist mediated activation of p38 was also impaired in 
shTAB1 transduced CD27- CD28- CD4+ T cells (Figure 25 a), indicating that 
AMPK activation required TAB1 expression for optimal downstream activation of 
p38. I confirmed these observations in 3 separate experiments (Figure 25 b). To 
corroborate these data, the activity of a downstream target of p38, namely 
transcription factor ATF-2 phosphorylated at Thr71, was assessed by phospho-
flow in the same experimental conditions. ATF2 activation driven by A-769662 was 
impaired in both shAMPK-α and shTAB1 transduced CD27- CD28- CD4+ T cells, 
compared to scrambled control cells (Figure 25 c). The cumulative data are 
shown in Figure 25 d. Thus upon activation, AMPK induces p38 signalling in a 
TAB1 dependent way in senescent human CD4+ T cells. 
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Figure 25: AMPK activates p38 via TAB1. (a) Phospho flow analysis and (b) pooled 
data from 3 separate experiments of purified human CD27- CD28-  CD4+ T cells activated and 
transduced as in figure 24. Cells were treated using the AMPK agonist (150 µM) for 1 hour 
followed by immediate analysis of p38 activity in the GFP+ by intracellular-flow citometry. (c) Upon 
pharmacological AMPK activation (as in (a)), transduced CD27- CD28-  CD4+ T cells were analyzed 
by phospho-flow using anti-p-ATF2 (Thr71). (d) Pooled data from 3 separate experiments 
performed as in (c) and presented as relative to ATF2 phosphorylation in shCTRL transduced cells, 
set as 1. In (c), (d) a one-way analysis of variance (ANOVA) for repeated-measures with a 
Bonferroni post-test correction was used. ***p< 0.001. Error bars depict SEM throughout. 
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5.6 AMPK is activated in response to endogenous DNA damage in 
senescent human CD4+ T cells 
 
The spontaneous activity of AMPK in senescent human CD4+ T cells was 
unexplained and understanding the signals that regulate AMPK activity in 
senescent T cells would be important to determine the physiological significance of 
this pathway. AMPK is activated generally in response to low nutrient sensing in 
the cell, when the AMP levels rise over those of ATP (Hardie, 2007). However, 
there was not a significant reduction of ATP levels in CD4+ T cells at all stages of 
differentiation (Supplementary Figure 2).  
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Figure S2: Endogenous ATP levels in CD27/CD28 subsets of CD4+ T cells. 
(a) ATP levels from 2 donors were measured by ELISA directly ex vivo. 
 
We therefore tested whether spontaneous AMPK activation in CD27- CD28- CD4+ 
T cells was a biochemical manifestation of senescence. When CD27- CD28- CD4+ 
T cells were analysed by either phospho-flow or western blotting, evidence of 
endogenous, active DNA damage related signalling was found (Campisi and 
d’Adda di Fagagna, 2007), such as spontaneous phosphorylation of the apical 
kinase ATM at S1961 (representative overlay in Figure 26 a and pooled data from 
3 separate experiments in Figure 26 b) and of its downstream target H2A-X at 
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T169 (representative overlay, Figure 26 c and pooled data in Figure 26 d). These 
features were previously used to probe active DNA damage foci. Conversely non-
senescent CD27- CD28+ or CD27+ CD28+ CD4+ T cells did not spontaneously 
activate either ATM (Figure 26 a) or H2AX (Figure 26 b), confirming that the 
process occurred in a T cell compartment specific way. To investigate if ATM 
could in turn downstream activate both AMPK and p38, CD27- CD28- CD4+ T cells 
were isolated from peripheral blood and immediately treated for 1 hour with the 
selective ATM inhibitor Ku-55933 (Hickson et al., 2004), to block endogenous ATM 
kinase activity directly ex vivo, followed by measurement of both AMPK and p38 
phosphorylation by intracellular specific flow-cytometry. Treatment with Ku-55933 
impaired activation of both AMPK (Figure 26 e) and p38 (Figure 26 g). These 
findings were confirmed in 3 separate experiments for both AMPK (Figure 26 f)  
and p38 (Figure 26 h). Together these data showed that ATM endogenously 
acted upstream of both AMPK and p38 in vivo. Thus endogenous AMPK-p38 
activity in senescent human CD4+ T cells occurred in response to ATM dependent, 
DNA damage related signalling. 
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Figure 26: AMPK-p38 signalling is activated downstream of ATM. (a) 
Phosphorylation of ATM at Ser1981 by phospho-flow analysis and (b) pooled results from 3 
separate experiments performed as in (a) in  CD27- CD28- and CD27+ CD28+ CD4+ T cells, directly 
ex vivo. Human CD4+ T cells were purified by ‘positive selection’ and then immediately surface-
stained for CD27 and CD28 expression, followed by intracellular staining for p-ATM. (c) 
Immunoblots of γ-H2A-x phosphorylated at Ser139 in CD27/CD28 defined CD4+ T cell subsets 
directly ex vivo. GAPDH, loading control. (d) Endogenous phosphorylation of γ-H2AX at Ser139 in 
CD27/CD28 defined CD4+ T cell subsets assessed by phospho-flow. (e) Representative overlay 
and (f) pooled phospho-flow data showing the effect of the selective ATM inhibitor KU-55933 (60’, 
10 µM) on constitutive AMPK-α (Thr172) phosphorylation in CD27- CD28-  CD4+ T cells. Highly 
differentiated CD4+ T cells were isolated by ‘negative selection’ and immediately treated with the 
ATM inhibitor KU-55933, followed by incubation with anti p-AMPK-α. A DMSO vehicle solution was 
used as a control. (g) Representative overlay and (h) pooled phospho-flow data of p38 
(Thr180,Tyr182) phosphorylation from 3 separate experiments performed as described in (e,f). 
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5.7 Elevated oxidative stress endogenously activates ATM, AMPK and p38  
 
Because DNA damage by reactive oxidative species (ROS) is associated with cell 
senescence (Passos et al., 2013) and because ROS are known activator of AMPK 
(Cardaci et al., 2012), it was possible that oxidative stress (hence a telomere-
independent pathway of senescence) was linked with activation of ATM, AMPK 
and p38 signalling in CD27- CD28- CD4+ T cells. Indeed intracellular (cytosolic) 
ROS levels were elevated in these cells as compared to relatively undifferentiated 
CD27+ CD28+ CD4+ T cells (measured by the dye indicator Dihydroethidium, DHE; 
Figure 27 a). To evaluate the effect of ROS signalling, CD27- CD28- CD4+ T cells 
were isolated directly ex vivo and either left untreated or treated for 1 hour with the 
ROS scavenger Super-oxide dismutase (SOD) that catalyses the permutation of 
superoxide into oxygen and peroxide hydrogen and is therefore involved in anti-
oxidant defence. This treatment reduced ATM, AMPK and p38 activity in CD27- 
CD28- CD4+ T cells (about 50% of kinase activity down-regulation; Figure 27 b). 
The pooled data from 3 separate experiments are shown in Figure 27 c. These 
results indicate that oxidative stress by ROS can endogenously activate ATM, 
AMPK and p38 in senescent human CD4+ T cells. 
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Figure 27: ROS endogenously activate ATM, AMPK and p38 in senescent 
CD27- CD28- CD4+ T cells. (a) Intracellular ROS levels by Dihydroethidium (DHE) in CD27+ 
CD28+ and CD27- CD28- CD4+ T cells directly ex vivo, as measured by flow cytometry. Data are 
pooled from 4 independent experiments. (b) Representative overlays and (c) pooled phospho-flow 
data from 3 different donors showing the effect of the ROS scavenger superoxide-dismutase (SOD; 
100 U, 60’) on AMPKa (Thr172), p38 (Thr180,Tyr182) and ATM (Ser1921) phosphorylation in senescent 
CD27- CD28- CD4+ T cells. All *p< 0,05, **p<0.01, and ***p< 0.001 values were calculated by a 
paired Student’s t test. Error bars depict s.e.m 
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5.8 Evidence for  p38-dependent checkpoint regulated by glucose in T cells 
Because AMPK is a low-glucose sensor that is activated in response to glucose 
withdrawal (Rolf et al., 2013) and because spontaneous AMPK activation induces 
p38 signalling via TAB1 in senescent human CD4+ T cells (Figure 25), it was 
possible that glucose deficiency would trigger p38 activity in non-senescent CD4+ 
T cells that do not spontaneously activate AMPK and have very low endogenous 
phosphorylation of p38. A first clue that this was possible came from culturing non-
senescent CD27+ CD28+ CD4+ T cells, activated by αCD3 plus αCD28 for 48 
hours, either in the presence or absence of glucose (25 mM). Glucose is essential 
for T cell growth (Frauwirth et al., 2002) and in the absence of a valid carbon-
source alternative (for example, galactose) T cells should not become activated 
and die instead (Chang et al., 2013). To link p38 activation to nutrient sensing and 
to study its role in T cell activation, T cells were activated either in the presence or 
absence of the selective p38 inhibitor BIRB-796 in media either with or without 
glucose. Culturing T cells in the presence of glucose resulted in robust T cell 
clusters, hallmark of optimal lymphocyte activation (Figure 28, top left panel). 
This process was impaired by the addition of BIRB-796 (Figure 28, top right 
panel), indicating that p38 signalling supports T cell activation in the presence of 
glucose. In the absence of glucose, T cell clustering was completely abrogated 
(Figure 28, bottom left panel). However the addition of BIRB-796 to glucose-
deprived T cells partially enforced T cell clustering (Figure 28, bottom right 
panel), suggesting that when p38 is activated in response to glucose withdrawal, it 
negatively regulates T cell activation instead. These data are consistent with p38 
being activated in non-senescent T cells in response to glucose deprivation, a 
well-recognized condition leading to AMPK activation (Rolf et al., 2013). 
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Figure 28: Evidence for a p38-dependent T cell activation checkpoint 
regulated by glucose. Microscopy of relatively undifferentiated human CD27+ CD28+ CD4+ T 
cells activated by αCD3 plus αCD28 and cultured either in the presence or absence of glucose 
(25mM); p38 activity was direclty blocked through the addition of the selective p38 inhibitor BIRB 
796 (500 nM) before activation; and a DMSO vehicle solution was used as a control. 
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5.9 Glucose deficiency activates p38 via AMPK-TAB1 in T cells 
To rigorously validate that p38 was activated in response to glucose deprivation, 
non-senescent CD27+ CD28+ CD4+ T cells were isolated and either rested in full-
glucose or glucose-starved for 18 hours, followed by measurement of p38 activity 
by phospho-flow using APC-labelled antibody to p-p38 (Thr180/Tyr182). These 
experiments showed that glucose deprivation induced p38 phosphorylation by 1.5-
2 folds in T cells (Figure 29 a). The cumulative data from 3 separate experiments 
are shown in Figure 29 b. To investigate if the increase in T cell-p38 activity under 
glucose starvation was dependent on upstream AMPK-TAB1 signalling, CD27+ 
CD28+ CD4+ T cells were isolated, activated by αCD3 plus αCD28 and 48 hours 
later transduced with lentiviral particles to silence either AMPK-α or TAB1 gene 
expression. Four days post-transduction, CD27+ CD28+ CD4+ T cells were 
glucose-starved for 18 hours and p38 activity was measured in the GFP+ T cell 
compartment by phospho-flow, which showed that p38 phosphorylation was 
impaired in CD27+ CD28+ CD4+ T cells transduced with either shAMPK-α or 
shTAB1 versus those transduced with shCTRL lentivector (Figure 29 c). These 
observations were confirmed in 3 independent experiments (Figure 29 d). Thus 
the activation of T cell-p38 in response to glucose starvation relies on AMPK-
TAB1. Together with endogenous DNA damage activating AMPK in senescent T 
cells (Figure 26), these data support a model in which both low nutrient sensing 
and senescence related signalling converge on AMPK to downstream activate p38 
via the scaffold molecule TAB1 in both senescent and non-senescent T cells.  
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Figure 29: Glucose deficiency activates T cell p38 via AMPK-TAB1.  
(a) Measurement and (b) pooled data from 3 separate donors showing p38 phosphorylation at 
Thr180-Tyr182 by phospho-flow in relatively undifferentiated CD27+ CD28+ CD4+ T cells rested in 
the presence or absence of glucose for 18 hours. (c) Phosphorylation of p38 under glucose 
starvation in relatively undifferentiated CD27+ CD28+ CD4+ T cells that have been transduced with 
lentiviral particles expressing either shCTRL, shAMPK-α or TAB1. Cells were activated by αCD3 
plus αCD28 for 48 hours and then transduced 48 hours later. Four days post-transduction, GFP+ 
cells were analysed by phospho-flow for p38 activity. In (b) a Student’s t test was used; in (d) a 
one-way analysis of variance (ANOVA) for repeated-measures with a Bonferroni post-test 
correction.**p<0.05 ***p< 0.001. Error bars depict s.e.m.  
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5.10 AMPK activation induces p38 binding to TAB1 in T cells 
Our data described a system in which there were three components: a sensor 
(AMPK), a scaffold (TAB1) and an effector kinase (p38). To further dissect the 
mechanistic details of the AMPK-TAB1 pathway of p38 activation, 
immunoprecipitation studies were performed in non-senescent CD27+ CD28+ CD4+ 
T cells that were either left untreated or activated for 2 hours using the AMPK 
agonist A-769662. Cells were lysed, immunoprecipitated with antibody to TAB1, 
extensively washed and analysed by western blotting, which showed that agonist 
driven activation of AMPK induced p38 binding to TAB1 (Figure 30 a). The 
densitometric analysis to total TAB1 from 4 separate experiments demonstrated 
an increase in p38 binding to TAB1 in response to AMPK activation up to 3 fold 
(Figure 30 b). Furthermore TAB1 immunoprecipitates from AMPK agonist treated 
CD27+ CD28+ CD4+ T cells were enriched for both phosphorylated AMPK and p38, 
indicating the existence of an active complex (Figure 30 a). These results were 
consistent with p38 being activated in response to AMPK activation through TAB1 
binding.  
It was possible that in senescent CD27- CD28- CD4+ T cells in which the AMPK-
TAB1 pathway for p38 activation is spontaneously active, the p38 binding to TAB1 
was constitutive. To verify this prediction, either CD27- CD28- or CD27+ CD28+ 
CD4+ T cells (as a negative control) were isolated, immediately lysed and 
immunoprecipated with antibody to TAB1, followed by western blotting analysis. 
These experiments showed that indeed both phosphorylated AMPK and p38 were 
bound to the shorter 50-kDa variant of TAB1 expressed senescent human CD4+ T 
cells (Figure 30 c); conversely non-senescent human CD4+ T cells expressed the 
60-kDA variant of TAB1 and did not show constitutive binding of either 
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phosphorylated AMPK or p38 (Figure 30 c). Collectively these data indicate that in 
response to AMPK activation, p38 is phosphorylated and is bound to the scaffold 
TAB1 in both senescent and non-senescent T cells. 
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Figure 30: AMPK activation recruits T cell p38 to TAB1. (a) Immunoblots of total 
p38, phospho-p38 (Thr180/Tyr182), total AMPK-α, phospho-AMPK-α (Thr172) and TAB1 in CD27+ 
CD28+  CD4+ T cells activated with DMSO control or the AMPK agonist A-769662 (150 mM) for 2 
hours, followed by immunoprecipitation with anti-TAB1. Data are representative of 4 separate 
donors. Immunoblot of total p38 from whole cell lysate (WCL) served as input control. (b) The 
relative binding of p38 to TAB1 upon AMPK activation as determined by 4 independent 
experiments performed as described in (a), and presented as relative to control cells (-AMPK act), 
set as 1. (c) Freshly-isolated CD27+ CD28+ or CD27- CD28- CD4+ T cells were immunoprecipitated 
with anti-TAB1 and analysed by immunoblot, as indicated (alternative TAB1 isoforms depicted by 
black arrows). Data are representative of 2 separate experiments (for the minor CD4+ CD27- CD28- 
T cell fraction, cells were pooled together from 2 different donors to achieve sufficient cell number 
to perform the assay). In (b) a Student’s t test was used.**p<0.05 ***p< 0.001. Error bars depict 
s.e.m. 
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5.11 AMPK triggered p38 recruitment to TAB1 causes p38 auto-
phosphorylation.  
The biochemical means by which TAB1 bound p38 became activated was still 
unclear. But because TAB1 was reported to mediate p38 auto-phosphorylation, a 
modification that relies on the intrinsic activity of the kinase (Ge et al., 2002), and 
because p38 is not a direct substrate for AMPK, the data suggested that AMPK 
may have induced p38 auto-phosphorylation via eliciting its binding to TAB1. Thus 
p38 was immunoprecipitated from AMPK agonist-activated CD27+ CD28+ CD4+ T 
cells that had been transduced with either shTAB1 or shAMPKα and the kinase 
activity of p38 was assessed in the absence of an added substrate in vitro as 
described, to determine p38 auto-phosphorylation (Salvador et al., 2005). Using 
this assay, activated p38 was detected in immunoprecipitates from scrambled 
control-transduced CD27+ CD28+ CD4+ T cells, and this activity was enhanced by 
the addition of ATP in vitro (Figure 31 a). Conversely adding ATP to p38 
immunoprecipitates from shTAB1 or shAMPKα-transduced CD27+ CD28+ CD4+ T 
cells did not increase p38 activity in vitro (Figure 31 a). This indicates that p38 
auto-phosphorylation requires both AMPK-TAB1 with which p38 interacts in 
response to AMPK activation. To confirm that the above experiment was indicative 
of p38 auto-phosphorylation (and not an event mediated by an unrelated co-
immunoprecipitated kinase), an inhibitor of p38 that is an ATP-competitor (SB-
203580) was added directly to the in vitro kinase reaction itself. SB-203580 
prevented the enhanced p38 phosphorylation in vitro in response to exogenous 
ATP, but not the baseline kinase activation within the cells, in TAB1 
immunoprecipitates after AMPK activation (Figure 31 b). Similar results were 
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obtained with a different inhibitor of p38 activity (BIRB 796, data not shown). Thus, 
the p38 recruited at the AMPK-TAB1 complex auto-phosphorylates. 
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Figure 31: AMPK-TAB1 bound T cell p38 auto-phosphorylates. (a) Measurement 
of p38 auto-phosphorylation by ELISA-based in vitro kinase assay of p38 immunoprecipitates from 
transduced purified CD27+ CD28+ CD4+ T cells reactivated with the AMPK agonist A-769662 (150 
µM) for 2 hours. Immunoprecipitates were left untreated or incubated for 30 min with ATP (200 
µM). Data are pooled from 3 different donors and are presented as relative to the shCTRL 
transduced populations that was not treated with ATP (-ATP), set as 1. (e) Measurement of p38 
auto-phosphorylation of TAB1 immunoprecipitates from CD4+ CD27+ CD28+ T cells activated with 
the AMPK agonist A-769662 (150 µM) for 2 hours. The assay was performed as described in (a) in 
the presence or absence of the p38 inhibitor SB-203580 (10 µM). Data are pooled from 3 separate 
donors and presented as relative to the control cells without ATP (-ATP). In (a), (b) a one-way 
analysis of variance (ANOVA) for repeated-measures with a Bonferroni post-test correction. 
**p<0.01, and ***p< 0.001. Error bars depict s.e.m.  
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5.12 Summary and Conclusions 
Here a previously unrecognized mode for the activation of T cell p38 is described. 
This relies on upstream activation by the metabolic master regulator AMPK and is 
mediated by the scaffolding molecule TAB1, leading to p38 MAPK auto-
phosphorylation. In senescent CD4+ T cells the pathway is spontaneously active 
because of endogenous activation of the DDR related kinase ATM, in response to 
genotoxic stress. However, glucose starvation can also trigger AMPK and lead to 
p38 activation via the scaffold TAB1 in non-senescent CD4+ T cells that have no 
DNA damage. Thus, signalling through this AMPK-TAB1 pathway for p38 
activation can be induced in undifferentiated T cells by low nutrient availability or in 
senescent T cells by DNA damage. This defines an ‘intra-sensory’ pathway for p38 
activation in T cells that, unlike the canonical or alternative pathways that respond 
to external cues (Ashwell, 2006)(for example, cytokines or TCR activation), senses 
intracellular changes such as nutrient deprivation and genotoxic stress. Thus, 
intra-sensory p38 signalling is characterized by the integration of two very 
separate physiological processes namely low nutrient signalling and senescence 
through activation of the energy sensor AMPK and downstream MAPK activation. 
Whether this mode may also be important for the non-canonical activation of other 
MAP kinases (such as the JNKs or the ERKs) remains to be determined. 
 
Auto-phosphorylation is important for intra-sensory activation of p38. Nevertheless 
auto-phosphorylation of p38 was previously shown to characterize both alternative 
DLG1 (Round et al., 2007) and TAB1 (Ge et al., 2002) mediated activation of the 
kinase, indicating that possibly all non-canonical mechanisms for p38 activation 
rely on the intrinsic activity of the kinase itself. The reason for the evolution of 
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various (canonical, alternative and the newly identified intra-sensory) modes for 
the activation of p38 is not clear, but our findings suggest that they may enable the 
same signalling molecule to exert opposite effects on T cell function. This may 
involve phosphorylation of completely different subsets of transcription factors and 
other effector molecules downstream of p38 as it has been recently suggested for 
the differential regulation of NFAT activity by canonical versus alternative 
phosphorylated T cell p38 (Alam et al., 2014). One possibility is that the binding of 
p38 to TAB1 will direct the kinase towards a different subsets of biochemical 
targets, which would explain the different physiological functions of differentially 
activated p38. In the future, it would be interesting to identify the specific 
downstream targets by which intra-sensory activated p38 acts, using mass 
spectrometry analysis. 
 
The crystal structure of the docking site for TAB1 on p38 has been solved and is 
conserved in both the 60-kDa and 50-kDa variants of TAB1 that activate p38 
through the same mechanism based on auto-phosphorylation (De Nicola et al., 
2013). Targeting this restricted, MKK-independent interaction may reveal useful to 
dampen p38 activity, as it would spare ubiquitous activation by the MAPK 
cascade. TAB1 may be therefore a very promising target for selective tuning of 
p38 activity, in a T cell compartment specific way (that is, to reduce p38 signalling 
only in senescent T cells). In the light of the different roles ascribed to p38 
signalling in T cell biology that are linked with different upstream activation 
pathways, this would offer important pharmacological opportunities to design 
selective strategies for tuning of T cell function. This may be particularly interesting 
in the case of p38 blocking since all the available p38 inhibitors that have been 
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developed for treating disease with inflammatory aetiology exhibited disappointing 
side effects due to the ubiquitous expression of p38 and related unselective p38 
blockade in off-target tissues (Hammaker and Firestein, 2010).  
The cross talk between AMPK and MAPK signalling is an important, so-far 
unrecognized property of immunological networks, showing that the metabolic 
changes that accompany nutrient deprivation and senescence (that is, when T cell 
function has to be constrained) do not just rely on the blocking of anabolic routes 
such as mTOR yet also involve the activation of dedicated downstream signalling 
cascades. However because AMPK is a central regulator of cell metabolism and 
homeostasis in many different tissues, direct intervention to block AMPK signalling 
in order to reduce p38 activity may not be an optimal solution. This further 
reinforces the idea that TAB1 inhibition may be a more interesting interventional 
target for tuning of intra-sensory MAPK signalling.  
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Chapter VI: Consequences of AMPK/TAB1 activated p38 
signalling in T cells 
 
 
 
6.1 Background and rationale 
The activation of p38 regulates pleiotropic functions in T cells (Ashwell, 2006). 
Nevertheless the existence of different activation pathways upstream of p38 that 
regulate its kinase activity in opposite physiological conditions may explain the 
different biochemical and functional properties of the molecule.  
 
Previous studies reported that T cell telomerase and proliferation are actively 
inhibited in senescent T cells by spontaneous p38 activation (Di Mitri et al., 2011). 
Importantly the observation that p38 blockade restores both proliferative potential 
and telomerase activity in senescent T cells raised the question of whether these 
effects could be reproduced in principle via tuning p38 activity by silencing either 
AMPK or TAB1 that are upstream of p38.  
 
Therefore the aim of this chapter was to examine the effects of AMPK and TAB1 
inhibition on T cell function and to link this with the downstream down-regulation of 
p38 activity in senescent human CD4+ T cells.  
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6.2 Silencing AMPK or TAB1 restores telomerase in senescent CD4+ T cells 
 
To investigate the functional outcomes of AMPK or TAB1 inhibition, CD27- CD28- 
CD4+ T cells were isolated from peripheral blood, activated by αCD3 plus rh-IL2 
and 48 hours later transduced with lentiviral particles (using an MOI of 10) 
encoding either shAMPK-α, shTAB1 or shCTRL. Cells were maintained in 
activation medium (replaced every 2-3 days) and examined for functional readouts 
either four days post-transduction, when hTERT expression, telomerase activity 
and short-term proliferation were measured, or after up-to 1 month in culture, when 
long-term proliferation and telomere length were assessed. In case of long-term 
culture, cells were reactivated every 10 days (the procedure is further described in 
Material and Methods; see also Figure 32). 
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Figure 32: Experimental design. The experimental settings to manipulate gene 
expression in primary human senescent CD4+ T cells are shown and further discussed in the text. 
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Firstly, the effect of AMPK-TAB1 signalling on T cell telomerase was examined. As 
discussed, the up-regulation of the catalytic sub-unit of telomerase hTERT is 
essential for telomerase activity and reduced hTERT expression is a feature of 
human senescent T cells that have defective telomerase activity (Akbar and 
Vukmanovic-Stejic, 2007). When activated CD27- CD28- CD4+ T cells were 
transduced with lentiviral particles and then examined by Western Blot using 
antibody to hTERT, the protein was found to be abundantly expressed in both 
TAB1 and AMPK-α silenced cells versus scrambled control cells, one week after 
activation (Figure 33 a, left panel). This was also true when hTERT mRNA was 
examined from transduced cells by RT-PCR under the same experimental 
conditions (Figure 33 a, right panel). Thus, silencing AMPK-α or TAB1 restored 
hTERT expression in senescent human CD4+ T cells.  
To investigate if enhanced hTERT expression in both AMPK-α and TAB1 silenced 
cells would result in telomerase activity up-regulation, activated CD27- CD28- 
CD4+ T cells were analysed by TRAP assay at the same time point. There was a 
significant induction of telomerase activity (by 2-3 fold) one week after 
transduction, upon silencing of either TAB1 or AMPK-α versus scrambled control 
cells (Figure 33 b). These data indicate that AMPK-TAB1 signalling inhibited T 
cell telomerase activity in part through active hTERT down-modulation. 
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Figure 33: Silencing AMPK or TAB1 restores T cell telomerase. (a) 
Measurement of hTERT expression by both immunoblot (left) or RT-PCR (right) in purified human 
CD27- CD28- CD4+ T cells. Cells were activated by αCD3 and rh-IL2 and transduced with the 
indicated lentiviral particles 48 hours later, followed by assessment of hTERT levels 96 hours post-
transduction. Immunoblot is representative of 2 separate experiments; hTERT mRNA were 
measured from 3 different donors, and presented as relative to those of shCTRL transduced cells, 
set as 1. (b) Pooled data from 3 different donors showing measurement of telomerase activity by 
an ELISA-based non radioactive TRAP assay in purified human CD27- CD28- CD4+ T cells 
activated and transduced as in (a). Results are from 3 separate donors and are presented as 
relative to control transduced cells, set as 1. In (a) and (b) a one-way analysis of variance 
(ANOVA) for repeated measures with a Bonferroni post-test correction. **p<0.01, and ***p< 0.001. 
Error bars depict s.e.m. 
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6.3 Silencing AMPK or TAB1 restores telomere length and proliferation in 
senescent CD4+ T cells 
As discussed, loss of telomerase activity in senescent T cells results in telomere 
shortening, leading to proliferative arrest and replicative senescence (Plunkett et 
al., 2007). Thus to explore the in vivo effect of enhanced telomerase activity in 
AMPK and TAB1 silenced cells, telomere length was assessed. Purified CD27- 
CD28- CD4+ T cells were activated and transduced as above described, 
reactivated every 10 days, and after 4 weeks in culture telomere abundance was 
determined using the flow-fish protocol described in Materials and Methods. These 
experiments showed that enhanced telomerase activity in senescent human CD4+ 
T cells was biologically important and led to an effective telomere elongation by 
0.5-0.7 kb in the GFP+ compartments of both AMPK-α and TAB1 silenced cells, 
versus scrambled control cells (Figure 34 a). The pooled data from 3 independent 
experiments are shown in Figure 34 b. 
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Figure 34: Silencing AMPK or TAB1 elongates T cell telomeres. (a) Abundance 
of telomeres in the GFP+ population of CD27−CD28− CD4+ T cells transduced as in a, assessed by 
fluorescent in situ hybridization coupled to flow cytometry with a telomere-specific probe conjugated 
to indodicarbocyanine (Cy5 telomere). (b) Change in telomere length (Δbp) in CD27−CD28− CD4+ T 
cells transduced as in (a) and subjected to two rounds of activation with anti-CD3 and rh-IL2 during 
culture and assessed after 30 d (experimental design, figure 32), as in (a) and presented relative 
to that of cells transduced with shCTRL, set as 0. 
 
 
 
 
 
 
 
	 158	
Next the effects of either AMPK or TAB1 knockdown on both short and long-term 
proliferation of CD27- CD28- CD4+ T cells were assessed. When transduced CD27- 
CD28- CD4+ T cells were labelled using the cell-trace violet dye to determine T cell 
proliferation, multiple cell generations resulting in progressive dye dilution were 
observed in either AMPK-α or TAB1 silenced cells versus scrambled control 
transduced cells, one week after activation (Figure 35 a). This increase in short-
term T cell proliferation was also confirmed by overnight 3H-thymidine 
incorporation (to measure rate of active DNA synthesis) in activated transduced 
CD27- CD28- CD4+ T cells. Silencing either AMPK-α or TAB1 enhanced 3H-
thymidine incorporation rates (by 3-4 fold) versus scrambled control transduced 
cells (Figure 35 b). Collectively these data demonstrate that AMPK-TAB1 
signalling inhibits human T cell proliferation.  
To assess if restored telomerase and proliferative potential in senescent human 
CD4+ T cells may be associated with increased long-term expansion, activated 
transduced CD27- CD28- CD4+ T cells were counted and their population 
doublings (PD) were measured, according to the equation described in Materials 
and Methods. There was a constant growth advantage (by 2-3 fold) for both AMPK 
and TAB1 silenced cells over scrambled control cells that was evident at both 96 
hours post-transduction (Figure 35 c) and also throughout the four weeks of 
culture (Figure 35 d). Altogether these data suggested that active AMPK-TAB1 
signalling enforced a status of replicative senescence in human CD27- CD28- 
CD4+ T cells. However cells could re-elongate their telomeres and re-acquire some 
proliferative activity thus escaping senescence when either molecule was silenced. 
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Figure 35: Silencing AMPK or TAB1 restores T cell proliferation.  
(a) Multi-generation measurement of cell divisions by dye dilution analysis in activated CD27- CD28- 
CD4+ T cells transduced as indicated and analyzed 96 hours later (see also experimental design, 
figure 32). (b) The pooled results from 3 separate experiments performed as in (a), and presented 
as relative to the shCTRL transduced population, set as 1. (c) Pooled data from 3 separate donors 
of rate of DNA synthesis by [3H] thymidine incorporation assay (n=3) in activated CD27- CD28- 
CD4+ T cells transduced as indicated and analyzed 96 hours post-transduction. (d) Replicative 
lifespan by cumulative population doublings (PD) of long-term cultured CD27- CD28-  CD4+ T cells, 
transduced as indicated (see also experimental design, figure 32). Data are from 3 separate 
donors. Cumulative PD were calculated by total cell number enumeration as described in Materials 
and Methods. All *p< 0,05, **p<0.01, and ***p< 0.001 values were calculated using a one-way 
analysis of variance (ANOVA) for repeated-measures with a Bonferroni post-test correction. Error 
bars depict s.e.m. 
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6.4 Silencing p38 reproduces the effects of AMPK-TAB1 knockdown 
Because silencing either AMPK-α or TAB1 that are upstream of p38 restored 
telomerase and proliferative activity in senescent T cells, silencing p38 should 
produce similar effects. Thus CD27- CD28- CD4+ T cells were purified, activated, 
transduced as described with lentiviral particles encoding either shP38 or shCTRL 
and functional outcomes were measured at the indicated time points. To confirm 
p38 knockdown, CD27- CD28- CD4+ T cells were lysed four days post transduction 
and analysed by both RT-PCR and Western blotting to measure p38 levels in both 
shP38 and shCTRL expressing cells. CD27- CD28- CD4+ T cells transduced with 
shP38 vector had much lower p38 mRNA and protein levels than those of shCTRL 
transduced cells (Figure 36 a), which showed that the knockdown was effective. 
To study the effect of reduced p38 expression on telomerase, activated 
transduced CD27- CD28- CD4+ T cells were analysed by TRAP assay, which 
showed that p38 silencing up-regulated telomerase activity more than 2 fold 
(Figure 36 b). This effect was similar to that was similar to that achieved by 
shTAB1 or shAMPK-α transduction in these cells (Figure 33). P38 knockdown 
produced an analogous up-regulation to that induced by either AMPK-α or TAB1 
knockdown, of both short (Figure 36 c) and long-term proliferation of CD27- CD28- 
CD4+ T cells (overlay in Figure 36 d and pooled data in Figure 36 e), as assessed 
by overnight 3H-thymidine incorporation and cell-trace dye violet analysis 
respectively. In line with increased proliferation, senescent T cells depleted of 
either AMPK or TAB1 expanded in culture much more than control cells as 
assessed by population doublings enumeration (Figure 36 f). Together these data 
indicate that the AMPK-TAB1 ‘intra-sensory’ pathway for p38 activation inhibits T 
cell proliferative activity. 
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Figure 36: Silencing p38 restores T cell telomerase and proliferation (a) 
Measurement of p38 expression by both immunoblot (left) and quantitative PCR (right) in 
highly differentiated CD4+ CD27- CD28- T cells, transduced as indicated. Immunoblot is 
representative of 2 independent experiments. Samples for quantitative PCR were 
analyzed in triplicate from 3 different donors and normalized against housekeeping 
GAPDH. Knockdown efficiency was evaluated 96 hours post-transduction (day 7). (b) 
Telomerase activity by TRAP assay in CD4+ CD27- CD28- T cells transduced as indicated. 
Experiments were performed in triplicate from 3 separate donors, 96 hours post-
transduction. Proliferative activity by either (c) 3H thymidine incorporation or (d) dye 
dilution assay in CD4+ CD27- CD28- T cells, transduced as indicated. Experiments were 
performed in triplicate from 3 separate donors, 96 hours after transduction. (e) The pooled 
results of 3 separate experiments performed as in (d). MFI values of a representative 
experiment are shown in (d). (f) Replicative lifespan by cumulative PD of long-term 
cultured CD4+ CD27- CD28- T cells, transduced as indicated. Cumulative PD were 
assessed by absolute cell number enumeration, in triplicate, from 3 separate donors. All 
*p< 0,05, **p<0.01, and ***p< 0.001 values were calculated by a paired Student’s t test. 
Error bars depict s.e.m 
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6.5 p38 mediated modulation of cell cycle machinery in senescent CD4+ T 
cells 
 
To explore biochemical events that may be related to restored telomerase and 
proliferative potential in senescent T cells upon p38 blockade, the effects of p38 
inhibition on the cell-cycle machinery of CD27- CD28- CD4+ T cells were examined.  
In proliferating cells, there are two separate important cell-cycle regulatory 
checkpoints, at both the G1-S and G2-M boundaries (Giacinti and Giordano, 
2006). But because senescent T cells are blocked at the G1-phase to avoid DNA 
replication under persistent DDR signaling (Fumagalli and d’Adda di Fagagna, 
2009) and because p38 inhibition increased S-phase cycling in senescent T cells 
as assessed by increased 3H-thymidine incorporation, only known regulators of the 
G1-S transition were studied. CD27- CD28- CD4+ T cells were purified from 
peripheral blood, activated for 36 hours by αCD3 and rh-IL2 either in the presence 
or absence of the p38 inhibitor BIRB 796, and the levels of D1-cyclins, cell-cycle 
inhibitors p21 and p27, RB phosphorylation and p53 activation were examined by 
intracellular flow-cytometry using specific PE-conjugated antibodies. Blocking p38 
signalling down-modulated the expression of the cell cycle inhibitor p27 (Figure 37 
a), that was confirmed in 3 indepdent experiments (Figure 37 b); and it up-
regulated the levels of D1-cyclin (representative overlay in Figure 37 c, pooled 
data in Figure 37 d). Inhibiton of p38 also lowered the expression of under-
phosphorylated Rb (Figure 37 e), the active variant of the protein that acts as a 
cell cycle suppressor. This observation was confirmed in 3 separate experiments 
(Figure 37 f). The relative levels of phosphorylated RB (the inactive variant of the 
enzyme, associated with cell cycle progression) did not change when blocking p38 
(data not shown) however the ratio to dephosphorylated RB-protein expression, 
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showed enhanced RB inactivation by BIRB-796 (Figure 37 f). Finally, p38 
inhibtion diminished activation of p53 at the regulatory S46 residue that is directly 
phosphorylated by p38 (Figure 37 h). These changes are known to promote the 
G1-S transition (Campisi and d’Adda di Fagagna, 2007), which suggested that 
spontaneous p38 activity in senescent CD4+ T cells enforces G1-phase 
occupancy. 
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Figure 37: Blocking p38 down-regulates G1 inhibitory cell cycle machinery.  
(a, c, e, g) Representative overlays and (b, d, f, h) pooled data from 3 independent experiments 
using purified human highly differentiated CD4+ CD27- CD28- T cells, activated in the presence or 
absence of the selective p38 inhibitor BIRB (500 nM) for 36 hours, then analyzed by flow-citometry 
with the indicated antibodies; Rb inactivation was calculated as fold increase of the inhibitory 
Ser807/811 phosphorylation to the active, under-phosphorylated species; and p53 activation was 
calculated as phosphorylation at Ser46. All **p<0.01 values were calculated by a paired Student’s t 
test. Error bars depict s.e.m. 
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6.6 AMPK inhibits T cell telomerase and proliferation via p38 MAPK 
Thus far the data showed that blocking either AMPK, TAB1 or p38 itself restored 
telomerase and proliferative activity in senescent human CD4+ T cells in which the 
AMPK-TAB1 pathway for p38 activation is spontaneously active but the reliance 
on p38 signalling had to be formally proved. To mechanistically demonstrate that 
changes in p38 activity by upstream AMPK-TAB1 signalling are directly linked with 
the tuning of T cell function, AMPK was pharmacologically activated by A-769662 
in non-senescent CD27+ CD28+ CD4+ T cells either in the presence or absence of 
the p38 inhibitor BIRB 796. Agonist driven activation of AMPK inhibited both the 
short-term proliferation and telomerase activity (96 hours post-activation) and 
completely abrogated the population expansion of CD27+ CD28+ CD4+ T cells (up 
to 4 weeks in culture) activated by αCD3 plus αCD28 while the addition of BIRB 
796 restored these functions (Figure 38 a-b).  
To robustly validate these findings (that is, to exclude off-target effects due to the 
simultaneous addition of two drugs targeting two different kinases in cell), p38 
signalling was also blocked by lentiviral-vector knockdown. Purified CD27+ CD28+ 
CD4+ T cells were activated as above described and transduced 48 hours later 
with lentiviral particles (using an MOI of 10) expressing either shP38 or shCTRL. 
Four days post transduction, either the AMPK agonist A-769662 or DMSO vehicle 
solution control was added in culture and both cell proliferation and telomerase 
activity were assessed by 3H-thymidine incorporation and TRAP assay 
respectively, after additional 36 hours in culture. The AMPK agonist A-769662 (but 
not the DMSO vehicle control) inhibited both proliferation and telomerase activity 
of activated non-senescent human CD4+ T cells in shCTRL expressing cells but 
not in those transduced with shP38 lentiviral vector (Figure 38 c). Silencing p38 
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also slightly inhibited the proliferation (but not the telomerase activity) of activated 
CD27+ CD28+ CD4+ T cells in the presence of DMSO vehicle control, in 
accordance with the published observation that alternative activated p38 
downstream of TCR signalosome promotes the proliferation of non-senescent T 
cells (Salvador et al., 2005) (Figure 38 d). Altogether these data show that AMPK 
activation inhibits the telomerase and proliferation of human T lymphocytes via 
downstream activation of p38 signalling, a process that requires p38 allosteric 
binding to the scaffold molecule TAB1, followed by p38 MAPK auto-
phosphorylation (‘intra-sensory’ p38 activation). 
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Figure 38: AMPK inhibits T cell telomerase and proliferation via p38. (a) 
Measurement of telomerase activity by an ELISA-based non-radioactive TRAP assay in purified 
relatively undifferentiated CD27+ CD28+ CD4+ T cells activated by αCD3 plus αCD28 for 72 hours 
either in the presence or absence of the AMPK activator A-769662 (150 µM) and/or the p38 
inhibitor BIRB 796 (500 nM). A DMSO vehicle solution was used as a control. Data are pooled from 
3 separate experiments and presented as relative to telomerase in the control activated population, 
set as 1. (b) Replicative lifespan by cumulative PD of CD27+ CD28+ CD4+ T cells activated and 
cultured over 4 weeks as in (a). Data are from 3 separate donors. (c) Undifferentiated CD4+ CD27+ 
CD28+ T cells were activated by αCD3/CD28 antibodies and transduced 48 hours later with either 
shCTRL or shP38. Subsequently, cells were maintained in activation medium in the presence of 
the AMPK agonist A-769662 (150 µM) or DMSO vehicle control solution. Four days post-
transduction, telomerase activity was assessed by an ELISA based non radioactive TRAP assay.  
(d) Proliferative activity in CD4+ CD27+ CD28+ T cells activated and transduced as in (c) was 
measured by 3H thymidine incorporation assays. All *p< 0,05, **p<0.01, and ***p< 0.001 values 
were calculated by a one-way analysis of variance (ANOVA) for repeated-measures with a 
Bonferroni post-test correction. Error bars depict s.e.m 
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6.7 Glucose starvation inhibits T cell telomerase and proliferation via p38 
MAPK 
Because glucose withdrawal was found to activate p38 via AMPK-TAB1 signalling, 
the effect of p38 activity in glucose starved T cells was studied. Non-senescent 
human CD27+ CD28+ CD4+ T cells that do not spontaneously activate AMPK were 
activated as above described either in full glucose (as a positive control) or in the 
absence of glucose and any other valid carbon-source alternative (that is, to 
elevate AMPK signalling); either the p38 inhibitor BIRB 796 or vehicle DMSO 
control was added in culture to glucose starved T cells, since day 0. In accordance 
with the T cell activation status observed by cell-microscopy (Figure 28), glucose 
deprivation completely abolished human CD4+ T cell proliferation as assessed by 
strong down-regulation of the nuclear antigen Ki67 that is associated with active 
cell cycling, compared to cells cultured in full-glucose (Figure 39 a). This inhibitory 
effect on cell cycle and related proliferation was in part mediated by p38 activation 
because addition of BIRB 796 enforced Ki67 up-regulation (by 10-12 fold) by 
glucose deprived T cells (Figure 39 a). These observations were confirmed in 3 
separate experiments (Figure 39 b). Importantly the enhanced T cell proliferation 
upon p38 blockade was also associated with increased telomerase activity of 
CD27+ CD28+ CD4+ T cells activated by αCD3 plus αCD28 under glucose 
starvation (Figure 39 c), which indicated that low-energy related activation of p38 
(by AMPK-TAB1) is- at least in part- directly responsible for shutting-off T cell 
function. However cells did not survive the prolonged absence of glucose after 5 
days even when blocking p38 (Figure 39 d) , in agreement with previous studies 
(Chang et al., 2013). 
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Figure 39: Glucose deprivation inhibits T cell proliferation and telomerase 
via p38. (a) Glucose starved CD27+ CD28+ CD4+ T cells were activated and cultured as 
described in (a) for 48 hours and proliferation was assessed by intracellular staining for the nuclear 
antigen Ki67. CD4+ CD27+ CD28+ T cells grown in the presence of glucose [20mM] served as 
positive proliferation control. (b) The pooled data from 3 independent experiments, performed as 
described in (a). (c) Telomerase activity of relatively undifferentiated CD27+ CD28+ CD4+ T cells 
under glucose starvation either in the presence or absence of the small molecule p38 inhibitor 
BIRB 796 (500 nM). Cells were activated by αCD3/CD28, in the absence of glucose. Telomerase 
activity was determined after 48 hours by TRAP assay. (d) Viability of cells as in (c) after 5 days in 
culture. Cells activated in full glucose served as an internal control. In (b, c) *p< 0,05 calculated by 
a paired Student’s t test. Error bars depict s.e.m 
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6.8 AMPK activation mediates loss of TCR signalling molecules via p38. 
The loss of TCR signalling components is a novel feature of human T cell 
senescence. Because AMPK activation was found here to drive other important 
senescence characteristics of T cells such as loss of proliferative and telomerase 
activity, it was possible that AMPK signalling was involved in the down-regulation 
of TCR signalling machinery. To study a potential albeit so-far unrecognized link 
between the metabolic master regulator AMPK and TCR signalling, non-senescent 
human CD27+ CD28+ CD4+ T cells that possess a functional TCR signalosome 
were activated by αCD3 plus αCD28 in the presence of either DMSO vehicle 
control or increasing dosages of the AMPK activator A-769662. Four days post-
activation, cells were counted, lysed and immunoblotted using antibodies to total 
Zap70, LCK and SLP-76 that are all essential components of the TCR signalling 
machinery. Agonist driven activation of AMPK induced a dose-dependent loss of 
TCR signalling molecules (Figure 40 a) that resembles that found in ex-vivo 
isolated senescent human CD4+ T cells in which AMPK is spontaneously active 
(Figure 20). Thus AMPK activation inhibits TCR function. To explore if AMPK 
activation mediated loss of TCR signalosome relied on downstream activation of 
p38 (similarly to the documented loss of T cell proliferative and telomerase 
potential), CD27+ CD28+ CD4+ T cells were activated by αCD3 plus αCD28 either 
in the presence or absence of the AMPK activator A-769662, with or without the 
p38 inhibitor BIRB-796. After four days, cells were analysed by intracellular flow-
cytometry for expression of the TCR signalling molecules LAT and SLP-76. These 
experiments showed that AMPK activation potently down-regulated LAT and SLP-
76 expression however the addition of BIRB-796 partially antagonized this process 
(Figure 40 b). Conversely blocking p38 in DMSO control treated cells did not 
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significantly modulate either LAT or SLP-76 expression (Figure 40 b). These 
observations were confirmed in 3 separate experiments (Figure 40 c). Further 
studies using the glycolysis inhibitor 2DG, that potently activates AMPK (Rolf et 
al., 2013), are in due course. These data show that p38 activation downstream of 
AMPK is in part involved in the loss of the TCR signalosome in glucose-deprived 
lymphocytes discovered here.  
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Figure 40: Loss of TCR machinery regulated by AMPK-p38 signalling. 
(a) Immunoblots of p-AMPK-α at Thr172 (as a pharmacological activation control), LCK, Zap70 and 
SLP76 in relatively undifferentiated CD27+ CD28+ CD4+ T cells activated by αCD3 plus αCD28 for 
4 days either in the absence or presence of increasing concentrations of the AMPK agonist A-
769662 (100 or 150 µM respectively). (b) Pooled MFI data from 3 different experiments of Lat and 
SLP-76 expression in relatively undifferentiated CD27+ CD28+ CD4+ T cells activated as in (a) 
either in the presence or absence of the AMPK activator A-769662 (150 µM) or the p38 inhibitor 
BIRB 796 (500 nM), assessed by intracellular flow-citometry. In (b) a one-way analysis of variance 
(ANOVA) for repeated-measures with a Bonferroni post-test correction. *p< 0,05, **p<0.01, and 
***p< 0.001. Error bars depict s.e.m 
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6.9 Summary and Conclusions 
Here I investigated the consequences of AMPK-TAB1 (‘Intra-sensory’) activated 
p38 signalling and found that this pathway maintains the senescence of human T 
lymphocytes. There are at least three known different senescent features in T 
cells, namely loss of telomerase and proliferative activity and the here-identified 
loss of TCR signalosome components. Here I showed that AMPK, activated in 
response to either glucose deprivation or senescence-associated DNA damage, in 
turn promotes the onset of all these features of T cell senescence in part through 
downstream activation of p38, a process that requires TAB1 expression. This 
provides a mechanistic link between nutrient sensing and senescence signalling 
pathways in human T cells. Indeed, intra-sensory p38 activation was found here to 
inhibit the function of both senescent and non-senescent T cells, regardless of the 
upstream trigger activating AMPK. 
 
Further studies are needed to fully understand how ‘intra-sensory’ activated p38 
constrains human T cell proliferation and telomerase activity however our data 
highlighted an active role for T cell p38 during senescence through the inhibition of 
various elements that promote the G1-S cell cycle transition (Mathon and Lloyd, 
2001). But because previous studies reported instead that p38 activity promoted 
cell proliferation and active cell cycling (Alam et al., 2014), different mechanisms 
downstream of p38 have to be engaged to either promote or inhibit cell 
proliferation.  
 
There is a tremendous number of molecules that lie downstream of p38 (Shi and 
Gaestel, 2002) and different tissue expression profiles for the various p38 
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biological substrates may explain the opposite functional outcomes regulated by 
p38, however our data suggests this not to be the case. Opposite effects were 
indeed observed in non-senescent T cells when blocking p38, activated 
downstream of either AMPK or TCR signalosome, which indicates that even within 
the same cell-type and timing p38 activation differentially regulates T cell function. 
Thus multiple pathways upstream of p38 that activate the molecule under opposite 
physiological conditions provide a more robust answer.  
 
The tuning of T cell function by the metabolic master regulator AMPK indicates 
that there are important yet poorly understood biochemical networks linking T cell 
metabolism and T cell signalling. However whether p38 can directly modulate T 
cell metabolism downstream of AMPK remains elusive. Also, although p38 activity 
is in part involved in the loss of TCR signalosome downstream of AMPK, blocking 
p38 did not restore TCR signalosome expression in senescent T cells (data not 
shown), indicating the existence of other mechanisms. 
 
Enhancing human T cell proliferation through direct inhibition of the AMPK-TAB1 
pathway for p38 activation described here may represent a novel way to boost 
immune cell function in vivo. One caveat is that the enhancement of telomerase 
and proliferation in senescent T cells that have evidence of DNA damage may be 
tumorigenic (Akbar and Henson, 2011). The risk versus possible benefit of 
selective therapeutic ‘tuning’ of telomerase in human T lymphocytes in vivo 
remains to be determined. 
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Chapter VII: General discussion 
The Hayflick limit dictates that the extent at which mammalian cells can proliferate 
is constrained by mechanisms of telomere erosion, which regulate the onset of 
replicative senescence (HAYFLICK and MOORHEAD, 1961). The activation of the 
enzyme telomerase extends mammalian cell life span by telomere elongation 
however in most adult somatic cells telomerase activity is repressed (Hodes et al., 
2002). Conversely cancer cells and stem cells up-regulate the telomerase by virtue 
of their indefinite proliferative potential (Cong et al., 2002).  
 
Unlike other somatic cells, lymphocytes can potently induce telomerase activity 
upon antigenic challenge that is essential to regulate the rapid expansion of 
antigen specific lymphocytes followed by their contraction when the immune 
challenge is cleared (Akbar and Vukmanovic-Stejic, 2007).  
 
The mechanisms regulating telomerase in both immune and non-immune cells are 
poorly characterized and this PhD project investigated mechanisms of telomerase 
down-regulation in primary human T lymphocytes. There is progressive inhibition 
of telomerase activity during the differentiation of T cells towards senescence, 
which limits T cell proliferative potential (Goronzy and Weyand, 2013). Here I set 
up a strategy to restore both telomerase and proliferative activity in naturally 
occurring senescent human T cells. These cells that have lost expression of both 
the co-stimulatory receptors CD27 and CD28 can be found in peripheral blood 
since relatively young age and accumulate during ageing, chronic viral infections 
and auto-immune disease probably because of differentiation related events, when 
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repeated episodes of cell activation occurs, and tissue inflammation (Weng et al., 
2009).  
Boosting T cell proliferation during ageing may be therefore essential to restore 
immune protection towards a ‘healthy ageing’ and to prevent the onset of age-
associated concerns such as elevated cancer incidence and low responsiveness 
to vaccination that is essential to modulate immunity in humans (Boraschi et al., 
2013). However it is presently unknown if the accumulation of low proliferative, 
senescent T cells actively contributes to defective immunity in old humans, neither 
is known if restoring the proliferation of senescent T cells that have evidence of 
irreversibly-damaged DNA by means of telomerase up-regulation may be a safe 
therapeutic intervention. But because very little is known about end-stage specific 
mechanisms that regulate life span in humans, these studies are important to 
understand the biology of human ageing. 
 
There is very little and controversial information about the mechanisms that 
regulate human ageing although the causative link with cell senescence is 
relatively well accepted. In humans, senescence is most studied in fibroblast 
models where it is induced upon modifications in vitro such as aberrant oncogene 
activation, UV radiation, growth factor withdrawal or repeated cell passages 
(Campisi and d’Adda di Fagagna, 2007). Thus although such studies have 
provided important insights into the basic mechanisms regulating senescence, 
whether the same processes might also be active in vivo remains to be 
determined. Also, it is not clear how senescence is regulated in different human 
cell types, nor the in vivo phenotype of most human senescent cells is known.  
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T cell senescence is a relatively unexplored field of study. However the 
identification and isolation of blood highly differentiated CD27- CD28- T 
lymphocytes with very short telomeres, low telomerase activity, loss of proliferative 
potential and the here identified loss of TCR signalosome expression, provide a 
unique model for studying mechanisms of immune-senescence directly ex vivo, in 
humans. This is the first study investigating spontaneous signalling processes in 
primary populations of human highly differentiated (senescent) T cells, followed by 
their in vitro manipulation, thus linking endogenous mechanisms of immune-
senescence to the tuning of human T cell function.  
 
Caution should be taken to evaluate biochemical data generated by in vitro 
manipulation of human samples. Here when human T cells were activated in the 
presence of the inflammatory cytokine IFN-α, this was found to activate p38 MAPK 
signalling resulting in telomerase down-regulation, similarly to what spontaneously 
occurs in senescent T cells (Di Mitri et al., 2011), which raised the question of 
whether the underlying biochemical mechanism of p38 activation was identical. 
However p38 signalling in senescent T cells was then found to be unrelated to 
upstream activation by the canonical MAPK cascade that links inflammation to 
downstream MAPK activation (Chang and Karin, 2001). Instead it relied on an 
unrecognized AMPK-TAB1 dependent mechanism integrating endogenous DNA 
damage and low-nutrient sensing (‘Intra-Sensory’ pathway, Chapter V). Indeed 
inflammatory signals did not even activate AMPK-TAB1 in T cells (data not 
shown). While these data suggest that in vitro and in vivo biochemical processes 
are not necessarily linked, it would be interesting to assess if highly differentiated 
T cells induced in culture by IFN-α would also lose canonical MAPK cascade and 
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activate p38 by AMPK-TAB1 signalling, thus behaving as their endogenously 
generated counter-parts. 
 
The previous link between AMPK and senescence was tenuous. In a study 
conducted on fibroblasts, replicative senescence was shown to be associated with 
spontaneous AMPK activation in vitro (Wang et al., 2003). Subsequently, aberrant 
activation of fibroblast AMPK by either metformin or genetic manipulation was 
shown to enforce cell cycle arrest at the G1-phase via a p53-dependent 
mechanism (Jones et al., 2005). Because both TAB1 and p38 lie downstream of 
AMPK that is important to activate p53 (Jones et al., 2005), it is possible that the 
‘intra-sensory’ AMPK-TAB1 mechanism of p38 activation described here in 
senescent T cells would be also active in fibroblasts. If so, it would be interesting 
to understand whether a conserved signature that regulates senescence in 
multiple cell types may exist, as this would offer a common mechanism to reverse 
the detrimental effects of ageing. Nevertheless there are important biochemical 
clues that this may be the case. Firstly, all senescent cells are characterized by 
the upstream activation of persistent DDR signalling and rely on potent activation 
of p53 to enforce proliferative arrest (Campisi and d’Adda di Fagagna, 2007). 
Secondly, DNA damage is well-recognized trigger of AMPK activity in many 
different cell types (Sanli et al., 2010). Thirdly, it has been recently reported that 
telomere shortening in fibroblasts from TERT knockout mice (a modification 
required to induce replicative senescence in mice whose telomeres are 
significantly longer than humans) triggers spontaneous activation of AMPK leading 
to enhanced energetic demands (Missios et al., 2014). Albeit this would represent 
a provocative scenario- set by a unique signature for mammalian senescence 
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whose manipulation may reveal a potent tool to either attenuate or reverse ageing- 
blocking such a mechanism may bear risks of uncontrolled cell proliferation and 
malignancy. Nevertheless this concern is linked with the pleiotropic antagonistic 
nature of senescence itself (Campisi and d’Adda di Fagagna, 2007). 
 
Because AMPK and mTOR activation are antagonistic processes, these data 
appear incompatible with previous reports indicating a pro-ageing role for active 
mTOR signalling, possibly due to the generation of aberrant oxidative stress (Lee 
et al., 2010). There is indeed robust, evidence-based belief that mTOR inhibition 
extends life span in mammals (Johnson et al., 2013). Furthermore, mTOR 
inhibition has been very recently shown to improve T cell function in old humans 
(Mannick et al., 2014). Paradoxically enough both senescent human CD4+ and 
CD8+ T cells do not even express mTOR (Henson et al., 2014). How can these 
data be re-conciliated together? Most likely the core-question may be due to a 
semantic issue; even among researchers the terms ageing and senescence are 
often used interchangeably. Although senescent cells accumulate during ageing 
and probably accounts for the overall progressive loss of cell function 
characterizing ageing, considering a whole tissue or an unfractionated cell 
population from an aged animal or individual as entirely senescent per se may 
give rise to important misunderstandings. Also, the exact time-point of intervention 
(throughout either age or differentiation) should be homogenous to make different 
studies comparable, because the mechanisms that drive senescence (that is, 
before entering senescence) and those that actively maintain senescence (that is, 
to enforce G1-phase occupancy) do not necessarily overlap. I propose that mTOR 
inhibition would delay human T cell differentiation and the onset of senescence 
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however restoring function in senescent T cells requires inhibition of AMPK 
signalling and down-stream TAB1 dependent activation of p38.  
 
The existence of multiple pathways for the activation of p38 in T cells that respond 
to opposite physiological stimuli indicates that the same effector molecule can 
regulate opposite functions by engaging different downstream mechanisms. It is 
not clear at present if such pathways are also active in other immune or even in 
non-immune cell types, although it seems that alternative activation pathway of 
p38 that was initially ascribed only to activated T cells may also occur in activated 
B cells. Also, we note that end-stage differentiated human NK cells exhibit 
spontaneously activation of AMPK and show elevated p38 phosphorylation 
suggesting that the ‘intra-sensory’ pathway of p38 activation may not be a 
prerogative of T lymphocytes (Durovic Muller B, Lanna A & Akbar AN, unpublished 
findings). If so, it would be important to investigate the effect of blocking AMPK-
TAB1-p38 signalling in these cells. As discussed, one tempting yet unsupportive 
speculation is that the proliferative defects of various senescent cells is maintained 
in part via intra-sensory p38 signalling in response to endogenous DNA damage. 
 
Signal integration is a well-recognized property of biochemical networks identified 
by numerous cross talks among separate signalling cascades. Yet it is not clear 
how the same signalling molecule can respond to contrasting physiological stimuli. 
Why would mammalian cells use convergent mechanisms to tune opposite cellular 
functions rather than completely separate processes? I propose that the 
convergence of opposite physiological inputs on the same effector molecule may 
be important to ensure functional output variability through a limited number of 
	 181	
biochemical processes. In such a model, different scaffolding molecules would be 
important to tune downstream specificity of the same effector kinase towards 
separate subsets of biochemical substrates, which induce in turn robust, non-
ambiguous physiological responses. An integrated biochemical network would be 
of easier regulation rather than a system in which various physiological cues 
downstream activate a multitude of different pathways (Figure 41). In this post-
genomic era of high-throughput screening, logic may therefore reveal a more 
useful tool to understand biochemical complexity.  
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Figure 41: The advantage of upstream signalling convergence over 
divergence. Different stimuli triggering separate pathways (A, B, C) may converge on the same 
effector molecule (X) to induce non-ambiguous physiological responses (α , β , γ ; left). This is the 
case for p38 signalling in T cells. This model allows multiple, non-reduntant responses through a 
limited number of biochemical effectors, hence restricting regulatory checkpoints compared to a 
system in which different upstream triggers signal via separate biochemical effectors (X, Y, Z; 
right). 
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Chapter VIII: Future Perspectives 
 
8.1 How does metabolism regulate TCR signalling? 
One unexpected observation was that several components of the TCR 
signalosome such as LCK, ZAP70, DLG1, LAT and SLP-76 are spontaneously lost 
in senescent human CD4+ T cells that also lose expression of both co-stimulatory 
receptors CD27 and CD28. The collective loss of these signalling molecules will 
exacerbate the inhibition of proliferation in these cells by decreasing their capacity 
for TCR activation. It is not clear if TCR machinery can be restored in senescent T 
cells however our data linking TCR signalosome down-modulation to the upstream 
activation of the energy sensor AMPK suggests the existence of metabolic 
programs within the T cells that directly regulate TCR responsiveness. It is well 
recognized that important metabolic changes occur downstream of TCR activation 
in T cells (Pearce et al., 2013; Sinclair et al., 2013) and these data provide 
evidence that inhibitory feedback mechanisms exist linking changes in T cell 
metabolism to TCR function. Because AMPK activates catabolic metabolism, it is 
tempting to speculate that enforcing anabolic metabolism would restore TCR 
function in senescent T cells, in an antagonistic way. It would be important to 
identify the specific metabolic programs that may exert TCR control and the 
related downstream mechanism, as it may provide interventional targets for 
boosting TCR responsiveness that is impaired during ageing. Importantly, TCR 
down-modulation may also be an unrecognized way by which non-senescent T 
cells become unresponsive during an immune response in vivo, when nutrient 
supply may not be optimal (O’Sullivan and Pearce, 2015). 
 
	 184	
8.2 Towards an Intra-Sensory MAPK cascade? 
Another important standing question is a possible involvement of ERK and JNK, in 
addition to p38, during T cell senescence and whether they may also be activated 
downstream of AMPK. Unlike p38, non-canonical pathways for ERK or JNK 
activation have not been reported. The possible existence of an intra-sensory 
mode for multiple MAPK activation driven by AMPK may unveil MAP kinases as 
important biochemical effectors of unrecognized signalling networks. 
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